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Reactive oxygen species (ROS) are constitutively produced by mitochondria and
represent the major cellular source of oxidative stress. ROS are capable of
attacking molecules such as DNA, proteins and lipids, and of compromising
either the structural and functional integrity or the survival of cells. Mitochondria
also play a key role in apoptosis, the major mechanism of cell death in retinitis
pigmentosa (RP), which is a diverse group of inherited human retinal dystrophies
associated with progressive degeneration of photoreceptor cells. Mutations in
numerous genes have been implicated in RP, which have distinct
pathophysiological mechanisms and lead to retinal degeneration at different rates.
The aim of this thesis was to investigate the role of oxidative stress in disease
progression using mouse models of human RP.
The mouse mutants retinal degeneration 1 (rdl/rdl), atypical retinal
degeneration 1 (atrdl/atrdl), rhodopsin knockout (R/?c/ ~) and peripherin/retinal
degeneration slow (rds/rds) were firstly investigated for evidence of oxidative
damage by analysis of oxidative stress markers. Secondly, the mutants were
crossed to a superoxide dismutase 2 heterozygous mouse (Sod2+/~), with decreased
mitochondrial antioxidant activity, to examine the effect on disease progression.
Thirdly, mutants were treated with a mitochondrially targeted ubiquinone
derivative (MitoQ), which is a powerful antioxidant, to try and slow the rate of
retinal degeneration. MitoQ was administered orally during pregnancy and for an
extended postnatal period and uptake, toxicity, breeding behaviour and survival
were assessed. Rates of photoreceptor degeneration were estimated by
morphometric and apoptosis assays, while the cellular redox status was assessed
by glutathione assays and by measuring the activities of the mitochondrial
enzymes NADH:ubiquinone oxidoreductase (complex I), which is oxidative
stress-sensitive, compared with citrate synthase, which is oxidative stress-
insensitive.
All retinal degeneration mutants were found to show significantly reduced
complex I activities, while citrate synthase was unchanged, indicating
mitochondrial oxidative stress. Rates ofphotoreceptor degeneration were
unchanged either by crossing to a Sod2+' genetic background or by MitoQ
administration. Only the rds/rds mutant, with the slowest rate of degeneration,
showed a significant increase in complex I activity after MitoQ administration.
Although mitochondrial oxidative stress is shown to be present in all of the retinal
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atrdl Atypical retinal degeneration 1 mutant mouse (pde6baXrdl)
BCG Bacillus Calmette-Guerin
BSA Bovine serum albumin
BSO L-buthionine-(S,R)-sulfoximine
cAMP Cyclic adenosine 3' 5' monophosphate
CAT Catalase
CI Complex I (NADH:ubiquinone oxidoreductase)
CoQ Coenzyme Q (Ubiquinone)
COX Cytochrome c oxidase
CS Citrate synthase
DAPI Diamidino-2-phenyl-indol










ETC Electron transport chain
FADH2 Flavin adenine dinucleotide (reduced)











H&E Haematoxylin and Eosin
H202 Hydrogen peroxide
HIF Hypoxia inducible factor
HNE 4-Hydroxynonenal
IBM Inner boundary membrane
IBTP 4-Iodobutyl-triphenylphosphonium
IMS Intermembrane space
INL Inner nuclear layer









MIM Mitochondrial inner membrane
MnTBAP Manganese 5,10,15,20-tetrakis (4-benzoic acid) porphyrin
MOM Mitochondrial outer membrane
MSS Mutant steady state
mtDNA Mitochondrial DNA
NADH Nicotinamide adenine dinucleotide (reduced)
NADPH Nicotinamide adenine dinucleotide phosphate (reduced)
14




q _. Superoxide anion
OAA Oxaloacetate
•qjj Hydroxyl radical
ONH Optic nerve head
ONL Outer nuclear layer
ONOO- Peroxynitrite
OPL Outer plexiform layer
OS Outer segment
OXPHOS Oxidative phosphorylation
PARP Poly (ADP-ribose) polymerase
PBS Phosphate buffered saline
PCR Polymerase chain reaction





PTP Permeability transition pore
PUFAs Polyunsaturated fatty acids
rdl Retinal degeneration 1 mutant mouse (Pde6ba,rdl)
rds Retinal degeneration slow mutant mouse (Prph2rds)
REDOX Reduction/oxidation
Rho Rhodopsin mutant mouse
ROS Reactive oxygen species
RP Retinitis pigmentosa
RPE Retinal pigment epithelium
RT Room temperature




SDS Sodium dodecyl sulfate
SOD Superoxide dismutase
SSC Saline-sodium citrate
TBARS Thiobarbituric acid reactive substances
TBE Tris/Borate/EDTA
TEA Triethanolamine
TNFa Tumour necrosis factor-alpha
TPMP Methyltriphenylphosphonium
TUNEL Terminal deoxynucleotidyl transferase-mediated dUTP-
biotin nick end-labelling
UV Ultraviolet




Figure 1: Reactive Oxygen Species 22
Figure 2: The structure of a mitochondrion 23
Figure 3: The oxidative phosphorylation system 25
Figure 4: ROS production and antioxidant enzymes 28
Figure 5: Ubiquinone structure 41
Figure 6: Uptake of alkyltriphenylphosphonium cations by mitochondria
within cells 43
Figure 7: Mitochondrial^ targeted antioxidant compounds 45
Figure 8: Structure of the eye 53
Figure 9: The structure of the retina 55
Figure 10: The susceptibility of retinal photoreceptors to oxidative stress 69
Figure 11: The intrinsic pathway of apoptosis 72
Figure 12: Schematic representation of the kinetics of cell loss 79
Figure 13: Species differences in rates of neurodegeneration on the
mitochondrial regulation of apoptosis 80
Figure 14: The citrate synthase assay 116
Figure 15: The complex I assay 118
Figure 16: Tissue histology 122
Figure 17: Outer nuclear layer analysis by DAPI 123
Figure 18: Outer nuclear layer analysis by H&E staining 124
Figure 19: Outer nuclear layer analysis on male and female mouse eyes 126
Figure 20: The TUNEL assay 128
Figure 21: The COX/SDH assay 130
Figure 22: Optimisation of the citrate synthase assay 132
Figure 23: Optimisation of the complex I assay 133
Figure 24: Strain comparison for citrate synthase and complex I enzyme
activities 135
Figure 25: Optimisation of the reduced glutathione (GSH) concentration
protocol 136
Figure 26: The reduced glutathione (GSH) standard curve 137
Figure 27: The inhibitory effect of triethalonamine on reduced glutathione
measurements 138
Figure 28: Photoreceptor degeneration in rdl/rdl mutants 151
Figure 29: Photoreceptor degeneration in atrdl/atrdl mutants 153
Figure 30: Photoreceptor degeneration in Rho~'~ mutants 154
Figure 31: Photoreceptor degeneration in rds/rds mutants 155
Figure 32: Immunohistochemical detection of rhodopsin in retinal
degeneration mutants 157
Figure 33: Immunohistochemical detection of rod cGMP phosphodiesterase
6b in retinal degeneration mutants 159
Figure 34: Enzyme activities of citrate synthase and complex I in mouse
tissues from wild-type and retinal degeneration mutants 162
Figure 35: Reduced glutathione concentrations in mouse tissues from wild-
type and retinal degeneration mutants 165
Figure 36: Confirming the genotype of Sod2+'~ mutants 174
Figure 37: Outer nuclear analysis on Sod2+,~ mutants 176
Figure 38: TUNEL analysis on Sod2+l~mutants 177
17
Figure 39: Photoreceptor markers in Sod2+'~ mutants 177
Figure 40: Photoreceptor degeneration in rdl/rdl Sod2+l~ mutants 179
Figure 41: Photoreceptor degeneration in atrdl/atrdl Sod2+ ~ mutants 180
Figure 42: Photoreceptor degeneration in RhoSod2+/~ mutants 181
Figure 43: Enzyme activities of citrate synthase and complex I in mouse
tissues from wild-type and retinal degeneration mutants 184
Figure 44: Reduced glutathione concentrations in mouse tissue from wild-
type and retinal degeneration mutants crossed to Sod2+'
mutant 187
Figure 45: Preliminary study outline 193
Figure 46: Preliminary study assessing the stability of MitoQ and the
effects of its administration on weight gain, food consumption
and water consumption 195
Figure 47: The effect of long-term MitoQ administration on the breeding
capacity of wild-type mice and on neonatal survival 198
Figure 48: Reaction of IBTP with thiol proteins in cell fractions 200
Figure 49: Reaction of IBTP with thiol proteins in isolated mitochondria 201
Figure 50: Reaction of IBTP with thiol proteins in mitochondrial fractions
of various wild-type mouse tissues 203
Figure 51: Reaction of IBTP with thiol proteins in mitochondrial fractions
of various wild-type and mutant mouse tissues 205
Figure 52: Alternative interpretation of Figure 51 206
Figure 53: Uptake of orally-administered 3H-MitoQ by different tissues 208
Figure 54: The effect of long-term MitoQ administration on photoreceptor
survival in wild-type mice 210
Figure 55: Photoreceptor degeneration in rdl/rdl mutants after
administration ofMitoQ 211
Figure 56: Photoreceptor degeneration in atrdl/atrdl mutants after
administration ofMitoQ 212
Figure 57: Photoreceptor degeneration in Rho'1' mutants after
administration ofMitoQ 213
Figure 58: Photoreceptor degeneration in rds/rds mutants after
administration ofMitoQ 214
Figure 59: Enzyme activities in retinal degeneration mutants after
administration ofMitoQ 217
Figure 60: Reduced glutathione concentrations in various tissues from
wild-type and retinal degeneration mutants administerd MitoQ220
Figure 61: Pictorial representation of proposed rate of retinal degeneration 226
Figure 62: Application of the schematic representation of the retinal
degeneration model on the current project 229
Figure 63: Summary results - photoreceptor degeneration in retinal
degeneration mutants 231




Table 1: Genes implicated in non-syndromal forms of retinitis pigmentosa 59
Table 2: Optimisation of the citrate synthase assay 132
Table 3: Optimisation of the complex I assay 133
Table 4: Optimisation of the reduced glutathione (GSH) concentration
protocol 136
Table 5: Volumes for the reduced glutathione standard curve 137
Table 6: Enzyme activities in wild-type and retinal degeneration mutants.161
Table 7: Reduced glutathione (GSH) concentrations in wild-type and retinal
degeneration mutants 164
Table 8: Enzyme activities in wild-type and retinal degeneration mutants
crossed to Sod2 heterozygotes 183
Table 9: Reduced glutathione (GSH) concentrations in wild-type and retinal
degeneration mutants crossed to Sod2+~ mutant 186
Table 10: Enzyme activities in wild-type and retinal degeneration mutants
administered MitoQ 216
Table 11: Reduced glutathione concentrations in wild-type and retinal







Cells aim to achieve a state of chemical equilibrium so that fundamental
processes, such as development, growth, metabolism and death, can be carried out
efficiently. The reduction (= gain of electrons)/oxidation (= removal of electrons)
(REDOX) state of the intracellular environment is crucial for the functioning of
many enzymes and its distortion towards the oxidative state can cause problems
that lead to cellular dysfunction and, ultimately, to cell death. If the relative
amounts of oxidants and antioxidants change in favour of the former, then
oxidative stress is generated. Oxidative stress has been broadly defined as the
imbalance between the rate of formation of reactive oxygen species and their
elimination by antioxidants (Halliwell & Gutteridge, 1999; Koutsilieri et al.,
2002). 'Reactive oxygen species' (ROS) is an umbrella term used to describe
potentially toxic by-products of reduced oxygen. ROS can be either free radicals -
i.e. chemical species capable of independent existence with at least one unpaired
electron in their outer orbit (Beatty et al., 2000) - or molecules with their full
complement of electrons, but in an unstable or reactive state (Winkler et al., 1999;
Beatty et al., 2000; Freitas et al., 2002). Consequently, an antioxidant has been
defined as a mechanism, enzyme or compound that counteracts a defined oxidant.
Most free radicals are very reactive molecules, because of their unstable
electron configuration and their search for stability through the acquisition of
another electron. This electron needs to be 'stolen' from a stable molecule, which
in turn becomes a free radical itself. Therefore, a chain of reactions commences,
in which molecules attack each other. Not all free radicals are oxidants, for
instance molecular oxygen has two unpaired electrons, and also not all oxidants
are free radicals, for example hydrogen peroxide (Winkler et al., 1999).
The most common metabolites of oxygen are superoxide anions (O2"*),
hydrogen peroxide (H2O2) and hydroxyl radicals (*OH), mentioned in order both
of formation, as intermediates during the partial one-electron-at-a-time reduction
of oxygen to water (Figure 1), and of increased reactivity. In brief, superoxide
anion is generated by the univalent reduction ofmolecular oxygen. Although it is
not very reactive and cannot diffuse through cell membranes, it can react with
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nitric oxide (NO) to generate the oxidant peroxynitrite (ONOO ) (Rego et al.,
2000). Addition of one more electron to superoxide anion can give rise to the next
most reactive oxygen species, hydrogen peroxide. Although hydrogen peroxide
has no unpaired electrons, and hence is not very reactive (Lledias et al., 1998), its
oxidising properties can kill bacteria. Its most dangerous property lies in its slow
reactivity in the absence of ferrous ion (Fe2+), which gives it time to diffuse into
more distant cellular compartments (Barbouti et al., 2002). In the presence of
transition metals, however, H2O2 can participate in the Fenton reaction, which
results in the formation of the most reactive of all free radicals, the hydroxyl
radical, (*OH). Hydroxyl radicals can also be formed by the reaction of
superoxide anion and hydrogen peroxide (Haber-Weiss reaction) and it is virtually
impossible to stop them from reacting with the first molecule in their path
(Halliwell & Gutteridge, 1999).
4e
°2— 02- H202 - -OH —-—> H20
Superoxide Hydrogen Hydroxyl
anion peroxide radical
Figure 1: Reactive Oxygen Species
Addition of four electrons to molecular oxygen leads to its full reduction to
water. Sequential addition of single electrons results in the partial reduction
of oxygen and the generation of the reactive oxygen species (ROS)
superoxide anion, hydrogen peroxide and hydroxyl radical.
1.1.2. Generation of oxidative stress
1.1.2.1. Mitochondria
The main source of endogenous ROS is the mitochondrion, although is also
known to occur in other organelles (Esposito et al., 1999; Melov et al., 1999;
Hansen et al., 2006). Mitochondria are intracellular organelles found in all
eukaryotic cells. It is widely accepted that their ancestors are a-proteobacteria that
lived in primitive eukaryotic cells as intracellular parasites (Larsson & Luft, 1999;
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Rivera & Lake, 2004) and were later transformed into organelles that are
dependent on the nucleus for their function and replication.
Figure 2: The structure of a mitochondrion
Mitochondria are typically rod-shaped organelles of about 1-10 pm in length.
They have two specialised membranes, the inner (MIM) and outer membranes
(MOM), which divide the organelle into a narrow inter-membrane space (IMS)
and a much larger internal matrix. The surface of the inner membrane is
increased by a large number of infoldings called cristae. [Image from
http://www.spiralnotebook.org/ingraphicdetail]
The structure ofmitochondria (Figure 2) is well established (reviewed in
Frey & Mannella, 2000). They are bound by two membranes, the mitochondrial
outer (MOM) and inner (MIM) membranes, which are separated by the inter-
membrane space (IMS) that is about 28 nm wide (Perkins et al., 1997). These
membranes enclose the mitochondrial matrix, which includes proteins and DNA.
Pioneering work by Palade (1953) showed that the MIM is itself further divided
into two components whose surfaces are contiguous; the inner boundary
membrane (IBM) and the cristae. Although the latter, which increase the surface
of the MIM several fold, were initially thought to be broad foldings of the MIM
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(Palade, 1953), it is now clear that they have a mean diameter of about 31 nm and
are connected to the IBM via narrow, 28 nm in diameter, tubular openings called
cristae junctions (Perkins et al., 1997). The MOM is the physical barrier,
separating the cytoplasmic from the mitochondrial metabolic processes, and the
flux ofmolecules through it is mediated by the pore-forming protein voltage-
dependent anion channel (VDAC) (Mannella et al., 1992). The MIM is more
selective in its permeability and allows substances to flow through it only via
tightly regulated transporters, complexes and pumps. The shape and copy number
ofmitochondria are determined by ongoing mitochondrial fusion and fission
events, which can vary between different cells and over time (Bleazard et al.,
1999). Even within the same cell, mitochondrial shape can range from spherical
organelles to branched tubular networks (Bereiter-Hahn et al., 1994).
Mitochondria have their own DNA (referred to as mtDNA), which is a
circular double stranded molecule of 16,569 base pairs in length in humans and
can be present in anything from tens to tens of thousands of copies per cell
(Larrson & Luft, 1999; GOBASE at http://gobase.bcm.umontreal.ca/index.php).
MtDNA encodes 37 genes and has a compact structure containing overlapping
genes and no introns (Montoya et al., 1983; Rose et al., 2002). The transcription
products of 13 of these are mRNAs, 22 are tRNAs, and 2 are rRNAs (Anderson et
al., 1981). Therefore, only a small fraction of the -1500 proteins required for
normal mitochondrial functioning is encoded by mtDNA (Wallace, 2005). Most
mitochondrial proteins are synthesised in the cytosol and then targeted to the
mitochondrion by short peptide signal sequences (Chinnery & Turnbull, 2000).
1.1.2.2. The oxidative phosphorylation system
Mitochondria have been called the powerhouses of the cell as they produce
cellular energy, in the form of adenosine 5'-triphosphate (ATP), by oxidative
phosphorylation (OXPHOS) (Kim et al., 2002; Nijtmans et al., 2004). The
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mitochondrial respiratory chain complexes (complexes I-IV) and ATP synthase
(complex V) (Figure 3). They are collectively composed of at least 90 different
polypeptide subunits, 13 of which are mitochondrially encoded (Nijtmans et al.,
2004). Animals release energy from their diet, which includes proteins, lipids and
carbohydrates, by oxidising them to CCT and PbO. The Krebs cycle is responsible
for most of these oxidation reactions and the energy yield is conserved in the form
of the reduced electron-accepting coenzymes nicotinamide adenine dinucleotide
phosphate (NADH) and a reduced form of flavin adenine dinucleotide (FADH2)
(Nijtmans et al., 2004). The electrons of these coenzymes can be used to reduce
molecular oxygen to H2O via the respiratory chain (Beatty et al., 2000). The 4
multi-subunit complexes of the ETC are (Larsson & Luft, 1999; Nijtmans et al.,
2004):
Complex I (CI): NADH: ubiquinone oxidoreductase (EC 1.6.5.3)
Complex II (CII): succinate: ubiquinone oxidoreductase (EC 1.3.5.1)
Complex III (CIII): ubiquinol: cytochrome c reductase (EC 1.10.2.2)
Complex IV (CIV): cytochrome c oxidase (EC 1.9.3.1)
The generation of energy through OXPHOS is a complicated process that
involves electron flow through the respiratory chain (Nijtmans et al., 2004). The
latter is also therefore referred to as electron transport chain (ETC) (Figure 3).
Electrons are donated from NADH to CI or from succinate to CII, and are then
passed on to coenzyme Q (CoQ) to generate ubisemiquinone (CoQH) and then
ubiquinol (C0QH2). Electrons are further donated to CIII, which transfers them
via cytochrome c to CIV. Eventually they are used to reduce O2 to H2O. During
the transport of electrons, protons (H+) are pumped from the matrix out to the IMS
via complexes I, III and IV, giving rise to both a pH and an ionic gradient across
the MIM. This electrochemical gradient (Avpr) has been named the proton-motive
force and is used by the last complex of the OXPHOS system, the ATP synthase,
to generate ATP from ADP and inorganic phosphate (Pi). ADP and Pi can enter
the mitochondrion through ATP Synthase and act as substrates for ATP
generation on the matrix side of the MIM. This ATP is then exchanged for
cytosolic ADP through an adenine nucleotide translocator (ANT) located in the
MIM (Rose et al., 2002; Genova et al., 2003).
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1.1.2.3. Leakage of electrons and free radical formation
About 90% of the oxygen consumed by the cell is used by the ETC for ATP
production, while the remaining 10% is used by reactions involving oxidases and
oxygenases (Beatty et al., 2000; Raza et al., 2002). Of this 90%, about 0.4-4% of
the respired oxygen undergoes incomplete reduction to superoxide anion, the first
ROS to be formed (Melov et al., 2001; Noor et al., 2002). The main sites of
electron leakage, and hence of superoxide anion formation, are CI and CIII
(Herrero & Baija, 1997; Nulton-Persson & Szweda, 2001; Genova et al, 2003).
O2"* is then rapidly converted to H2O2 by superoxide dismutase (SOD). As noted
2+
earlier, H2O2 can readily react with Fe and participate in the Fenton reaction to
generate the most reactive of all ROS, *OH (Bilinski et al., 1985; Nulton-Persson
& Szweda, 2001). This series of reactions is shown in Figure 4.
Leakage of electrons occurs even under normal physiological conditions
and hence ROS production is a constitutive cellular event. However, the low
percentage ofpartially reduced oxygen can be increased if the ETC is inhibited or
cannot counteract the concentration of oxidants present within the cell.
This can be the result of:
a) Inhibition of an ETC complex
Inhibition of one of the complexes of the ETC results in the accumulation of
electrons at complex I and ubiquinone (UQ) pool sites (Nulton-Persson &
Szweda, 2001; Pitkanen & Robinson, 1996). Some specific inhibitors for each of
the complexes are given in Figure 3.
b) Inhibition of a Krebs cycle enzyme
If the progress of the Krebs cycle is disrupted, then there are not enough
substrates (namely, NADH and FADH2) for electron transport to take place along
the ETC. For example, aconitase can be inhibited by fluoroacetate and A-methyl-
D-aspartic acid (NMDA). Oxidative stress can both result from Krebs cycle
inhibition, and it can also be the cause of it. The enzymes implicated in the cycle
have different sensitivities to oxidants. Aconitase, which catalyses the conversion
of citrate to cis-aconitate, is very sensitive to O2"*, but much less so to H2O2. It has
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the inactive [3Fe-4S]+ (Gardner et al., 1994; 1995; Nulton-Persson & Szweda,
2001). The activity of the enzyme is often an indirect measure of the degree of
oxidative stress in the cell.
c) Inhibition of ADP/ATP translocator
IfANT is blocked, it results in a depletion of intra-mitochondrial ADP, which in
turn shuts down ATPase (Esposito et al., 1999). This leads to the depletion of H+
in the mitochondrial matrix and their accumulation in the IMS. As a result, the
ETC is blocked, no electron flow takes place and electrons accumulate at the
matrix-side of complexes I and III. These electrons are then available for
converting molecular oxygen to superoxide radicals.
1.1.3. Damaging actions of reactive oxygen species
The extensive production of free radicals is regarded as a type of cellular stress.
As mentioned earlier, free radicals, whether with complete electronic
configurations or not, are in an unstable, and thus reactive, state. In order to
achieve stability, they extract electrons from other molecules, which are
themselves rendered unstable (Beatty et al., 2000). Therefore, a cytotoxic
oxidative chain reaction begins which can only be terminated either if two
radicals react with each other and their unpaired electrons pair up, or if the new
free radical generated is so poorly reactive that it is virtually harmless (Halliwell
& Gutteridge, 1999). However, unless one of these two events takes place, ROS
initiate a large number of oxidative reactions in cellular systems that lead to the
oxidation ofmacromolecules like DNA, proteins and lipids (Winkler et al., 1999;
Freitas et al., 2002; Koutsilieri et al., 2002; Sverko et al., 2002).
DNA is very sensitive to damage by H2O2 through Fenton-type reactions,
which can result in base modifications, single-strand or double-strand breaks
and/or sister chromatid exchanges (Barbouti et al., 2002). The proximity of the
mtDNA to the source of free radicals, the absence ofprotective histones and the
limited repair mechanisms available make it a primary target for free radicals
(Esposito et al., 1999). As a result, mtDNA has at least a 10-fold higher mutation
rate compared to the nuclear genome (Yakes & Van Houten, 1997). The
identification of oxidant lesions in either nuclear or mtDNA has been performed
by HPLC-electrochemical detection (Yakes & Van Houten, 1997). Such studies
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have suggested that the most important DNA lesion produced during oxidative
stress is the 7,8-dihydro-8-oxoguanine (8-oxoG), which, ifnot repaired, results in
mutagenesis due to G:C to T:A transversions during DNA synthesis (Yakes &
Van Houten, 1997; Soultanakis et al., 2000). In addition, a good marker for
mutations in mtDNA is the frequency of a common 4977bp-deletion (Wallace,
2005).
Proteins are also oxidatively damaged by free radicals, since post-
translational modifications can impair their functions or inhibit them altogether.
Not all proteins are uniformly susceptible to oxidative damage, but those that are
include the Krebs cycle enzyme aconitase and complex I of the ETC, in part due
to their close proximity to oxidative stress sources and to the presence of iron-
sulphur clusters (Nulton-Person & Szweda, 2001; Beal, 2002). The most widely
studied marker ofprotein oxidation is a protein carbonyl group, which is formed
by direct oxidation of the side chains of lysine, arginine, proline and threonine
residues (Levine et al., 1990; Beal, 2002). The reaction of these groups with
carbonyl-specific reagents, such as 2,4-dinitrophenylhydrazine, provides a method
for detecting and quantifying protein oxidation (Frank et al., 2000). Another
marker ofprotein oxidation is a change in the protein's mass, which can be
measured by mass spectrometry. A common example is the targeting of tyrosine
residues by peroxynitrite, converting them to 3-nitrotyrosine and resulting in a 45
Da mass shift (Leeuwenburgh et al., 1998; Nakagawa et al., 2001; Sarver et al.,
2001; Beal, 2002).
Finally, polyunsaturated fatty acids (PUFAs) are particularly susceptible
to oxidative stress (Kuhn & Borchert, 2002), because their conjugated double
bonds are convenient sources of hydrogen atoms, which contain one free electron.
The lipid radical formed then tries to capture an electron from another PUFA, in
order to achieve stability. Thus, a cascade of reactions is initiated which results in
the consumption of valuable PUFAs and the impairment ofmembrane structures.
Each of these damaging effects of ROS at the DNA, protein and lipid
level, will be further discussed in Chapter III, where the methods for detecting




There are different endogenous antioxidant mechanisms, by which the cell is able
to defend itself against free radical production. In general, these include lowering
the steady-state concentration of free radical species, counteracting sources that
generate cellular oxidants and/or limiting the likelihood that oxidative damage
will occur (reviewed in Halliwell & Gutteridge, 1999).
Firstly, there are proteins, like haem oxygenase, that minimise the
availability of pro-oxidants. Haem oxygenase is found in the endoplasmic
reticulum (ER) and catalyses the breakdown of the pro-oxidant, haem. As
2+
haemoglobin undergoes slow oxidation to form biliverdin, ferrous ions (Fe ) and
carbon monoxide are released and superoxide anions and ferric ions (Fe3+) are
also formed. There are also proteins capable ofprotecting against oxidative
damage to proteins, for instance heat shock proteins. Their expression has been
shown to increase in response to protein damage, facilitating rapid repair and
recovery of damaged sites (Calderwood, 2005). In addition, there are low
molecular mass agents, like glutathione and ascorbic acid, which are able to
scavenge ROS and reactive nitrogen species (RNS). Lastly, cells have agents that
catalytically remove free radicals and other reactive molecules. Examples of the
latter are the antioxidant enzymes superoxide dismutase, glutathione peroxidase
and catalase.
It is clear therefore that there is a range ofways in which the cell is able to
cope with the production of ROS. These defence mechanisms are highly tissue-,
cell type- and/or cellular localisation-specific. Depending on the physiology and
metabolism of organelles, cells or tissues, different antioxidant defence
mechanisms prevail, and often work in conjunction with each other. An example
is the cellular compartmentalisation of catalase and glutathione peroxidase,
discussed in section 1.1.4.2.
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1.1.4.2. Antioxidant enzymes
The primary antioxidant enzymes in mammalian cells are superoxide dismutase
(SOD), glutathione peroxidase (GPX) and catalase (CAT) (Yen et al., 1996)
(Figure 4). Glutathione peroxidases are antioxidant enzymes involved in the
primary defence against ROS. There are at least 4 isoforms ofGPX, namely
cytosolic GPX1, intestinal GPX2, plasma GPX3 and mitochondrial phospholipid
hydroperoxide GPX4 (Ursini et al., 1995, Esworthy et al., 1997; Ho et al., 1997;
de Haan et al., 1998; Singh & Shichi, 1998; Brigelius-Flohe, 1999; Esposito et
al., 2000; Melov, 2000). All are selenium-dependent homotetramers, which
catalyse the reaction:
H202 + 2GSH A GSSG + 2H20
Glutathione (GSH) is present in distinct cytoplasmic and mitochondrial
pools (Griffith & Meister, 1985) and is oxidised to its stable oxidised form GSSG.
Reduction of the latter by the enzyme glutathione reductase (GR) replenishes
glutathione, maintaining high cellular levels of this antioxidant (van Remmen et
al., 1999). Gpxl" mice are healthy, fertile, show no histopathological abnormality
for at least 15 months and are in general very similar to wild-type animals in the
absence of oxidative challenge (de Haan et al., 1998; Brigelius-Flohe, 1999).
Similar to GPX, CAT can also detoxify H202 to H20. It is an iron-
dependent enzyme whose activity is regulated by zinc (Beatty et al., 2000) and by
the concentration of H202 (Yang et al., 1998). Homozygous catalase knockout
mice develop normally and show no gross abnormalities (Ho et al., 2004).
As mentioned above, GPX and CAT have different cellular localisations
and a series of studies have been concerned with their relative importance in
detoxifying H202. These two enzymes catalyse the same reaction, namely the
conversion of hydrogen peroxide to water and oxygen. They differ however in
that catalase is found predominantly in peroxisomes and is absent from
mitochondria (with the exception of heart mitochondria), whereas glutathione
peroxidase is more abundant in mitochondria, as well as being present in a
number of different cellular compartments, including the cytoplasm and the
nucleus (Halliwell & Gutteridge, 1999; Melov, 2000). It has been reported that
glutathione peroxidase is the main antioxidant enzyme used for scavenging
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hydrogen peroxide, and its capacity for doing so depends also on the activity of
glutathione reductase, on the rate ofNADPH supply and on the glutathione
content. In cellular compartments where both enzymes are present and active,
glutathione peroxidase has the predominant role (Halliwell & Gutteridge, 1999),
while catalase becomes more important in removing hydrogen peroxide as the
latter's concentration increases. The main difference is that detoxification ofH2O2
by CAT does not represent a stress to the cell, because it is converted to oxygen
and H2O, while detoxification by GPX generates energetic stress, since it is only
accomplished by the oxidation of glutathione (Antunes et al., 2002). The GSH
redox cycle however is the primary means ofprotection against HbCb-induced
damage at low concentrations of H2O2. When H2O2 concentrations rise, the
importance ofCAT in detoxifying this ROS increases (Halliwell & Gutteridge,
1999; Winkler et al., 1999; Reddy et al., 2001) since its efficiency is such that it
cannot be saturated by H2O2 at any concentration (Lledias et al., 1998).
Surprisingly, no change in CAT activity has been detected in gpxl'1' mice
(Forgione et al., 2002).
1.1.4.2.1. Superoxide dismutase
Superoxide dismutase is one of the key antioxidant enzymes as it detoxifies
superoxide anion to generate hydrogen peroxide. This reaction is very fast and is
followed by the detoxification of hydrogen peroxide to water and oxygen by GPX
and/or CAT. There are three isoforms of superoxide dismutase, SOD 1, SOD2 and
SOD3, all of which catalyse the same reaction, but differ in, amongst other things,
their cellular localisation.
The first isoform of superoxide dismutase to be characterised was SOD 1
(Halliwell & Gutteridge, 1999; Zelko et al., 2002). The gene for SOD1 is on
human chromosome 21 and on mouse chromosome 16. The human and mouse
genes each have 5 exons, are 567 and 459 base pairs long respectively and show
81% homology at the DNA level. The translation products of the gene are 155
amino acids in the human and 153 amino acids in the mouse, which are 83%
homologous. SOD1 (CuZnSOD) uses copper and zinc as its co-factors. It is the
predominant SOD in most cells, as it accounts for 70-90% of the total cellular
SOD activity, and is mainly cytosolic (Crapo et al., 1992; van Remmen et al.,
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2001; Matsui et al., 2003). It is a 32 kDa homodimer that can be specifically
inhibited by cyanide. Mutations in SOD1 resulting in decreased SOD1 activity
can cause progressive loss ofmotor neurons in familial amyotrophic lateral
sclerosis (ALS) (Rosen et al., 1993; Rothstein et al., 1994).
The gene for the second isoform of superoxide dismutase, SOD2
(MnSOD), is on human chromosome 6 and on mouse chromosome 17 (Halliwell
& Gutteridge, 1999). It has 5 exons in each species and the transcripts are 1026
and 1179 base pairs long, respectively, which are 78% homologous. The SOD2
protein in both species is 222 amino acids long and they are 90% homologous in
human and mouse. Manganese is required as a co-factor for SOD2 and the
protein, a 25kDa homotetramer, is strictly mitochondrial. SOD2 accounts for 10-
20% of cellular SOD activity (van Remmen et al., 2001) and cannot be inhibited
by cyanide, which is often used to distinguish between the two isoforms.
The third isoform of superoxide dismutase, SOD3, is a homotetrameric
CuZnSOD. The SOD3 gene is on human chromosome 4 and on mouse
chromosome 5 (Halliwell & Gutteridge, 1999). SOD3 has 3 and 2 exons in human
and mouse respectively, with transcripts that are 1816 and 1984 base pairs long,
which are 64% homologous. The SOD3 protein is 240 amino acids in human and
251 amino acids long in the mouse and they are 64% homologous to each other.
Copper and zinc are the cofactors for SOD3, which shows an extracellular
localisation.
The relative importance of the intracellular isoforms SOD 1 and SOD2 is
reflected by the differing severity of the phenotypes in animals that have altered
expression of these genes. Studies on Sod2 null mice, both in vitro (Huang et al.,
1997) and in vivo (Reaume et al., 1996), have shown that lack of the SOD1
isoform of superoxide dismutase does not confer a lethal phenotype. There have
been contradictory results on the effect of decreased Sodl expression on lifespan.
Mutant or knockout mice for Sodl produced by homologous recombination
(Reaume et al., 1996), which are totally devoid ofCuZnSOD activity, are
apparently normal and live into adulthood. More recent studies however, showed
that Sodl~'~ mice do indeed have reduced lifespans, when compared to controls
(Elchuri et al., 2005). Although it is unclear if decreased CuZnSOD affects
lifespan, it is apparent that Sod/"7" animals are more sensitive to different types of
acute oxidative stress (Phillips et al., 1989). For example, increased development
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of neurological phenotypes and occurrence of cancers with increased age have
been observed (Busutti et al., 2005; Elchuri et al., 2005). Homozygous Sodl'1'
animals and cells are significantly more sensitive to different types of oxidative
stress than heterozygotes or wild-type mice, with a clear correlation between the
amount of active Sodl and the sensitivity to the insult.
Mice that are deficient for the extracellular isoform of superoxide
dismutase also develop normally and are healthy for at least 14 months (Carlsson
et al., 1995). This is not surprising since the localisation of Sod3 makes it a minor
defence mechanism against what is primarily intracellularly generated oxidative
stress. This would also explain the relatively limited attention Sod3 has received
in the research field of oxidative stress.
In contrast, however, to both Sodl and Sod3 null mice, mice completely
devoid of Sod2 activity have a severe lethal phenotype (Melov et al., 1999). Two
independent groups have produced MnSOD gene knockout mice. Li et al. (1995)
deleted the third exon of Sod2. Homozygous mutants on a C57BL/6 background
were smaller and paler, and exhibited a hypotonic and hypothermic state
compared with wild-type or heterozygous mice. Although they appeared to
fatigue more rapidly, their behaviour was otherwise normal. By the time of death
at P10, they did not show any motor disturbances, central nervous system injury,
ultrastructural evidence of mitochondrial injury or gross mtDNA re-arrangements.
However, on a CD1 background, Sod2 homozygotes died within 10 days post
birth with dilated cardiomyopathy (enlarged hearts with a dilated left ventricular
cavity and reduced left ventricular wall thickness). Accumulation of lipid, both in
the liver and the skeletal muscle, and metabolic acidosis were also present.
Lebovitz et al. (1996) deleted exons 1 and 2 of the Sod2 gene. At birth, the
homozygous mutants could not be distinguished from their littermate controls, but
had a diminished growth rate and, on a mixed genetic background, survived for
up to 18 days. They also exhibited severe anaemia, degeneration of neurons in the
basal ganglia and brain stem, and progressive motor disturbances characterised by
weakness, rapid fatigue, and circling behavior. Mice surviving for more than 7
days exhibited extensive mitochondrial injury within degenerating neurons and
cardiac myocytes. Only 10% of these mice had dilated cardiomyopathy.
A number of different groups have since phenotypically analysed these
homozygous Sod2 mutants and/or the heterozygotes, in attempts to elucidate the
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role of oxidative stress in a wide variety of physiological and metabolic processes
and diseases. From the phenotypes of the different Sod2 mutants it was apparent
that there was a discrepancy in the survival rates of the mice depending on the
background of the animals. The biochemistry of Sod2~" mice that were on a CD1
background was compared to that of littermate heterozygous and control mice
(Melov et al., 1999). Tissue mitochondrial samples prepared from 4 to 6-day old
homozygous mutants showed decreased succinate dehydrogenase, complex I and
aconitase activities, while fumarase activity, which is insensitive to oxidative
stress, remained unchanged. Organic acid abnormalities, like increased levels of
3-methylglutaconic, 2-hydroxyglutaric acids, and 3-hydroxy-3-methylglutaryl
(HMG)-CoA lyase deficiency were also reported in urine and liver, respectively.
Finally, the genomic DNA was oxidatively damaged in the homozygous mutants,
with over 20 different types ofDNA lesions detected in different tissues,
including a 3-fold increase in 8-oxo-guanine, -adenine and -cytosine, in the heart
and brain.
Huang et al. (2001) investigated the role of the genetic background on the
phenotype conferred by MnSOD deficiency. MnSOD deficient mice on the
outbred CD1 strain background developed severe metabolic acidosis and dilated
cardiomyopathy by 5 days of age and died within 10 days, while another mutant
on a mixed C57BL/6 (B6) and 129/Sv genetic background survived for up to 18
days, with only 10% of the mice developing severe dilated cardiomyopathy.
Huang et al. (2001) generated congenic Sod2lmlC/<? mice on a C57BL/6 (B6),
DBA/2J (D2) and B6D2F1 (= B6 female x D2 male, 1 backcross) background to
achieve genetic uniformity and compared the phenotypic differences among the
Sod2~'~ mice bred on these different genetic backgrounds. They firstly observed
marked differences in lifespan, with mice on a B6, D2 and B6D2F1 background
surviving for increasing lengths of time. Mice on a B6 background were mostly
dying prenatally (between El5 and PI), whereas those on a B6D2F1 background
survived for up to 3 weeks. Dilated cardiomyopathy was evident only in B6 mice.
D2 mutants showed increased signs ofmetabolic acidosis and B6D2F1 mice had
milder metabolic acidosis and developed neurological problems. It was concluded
that lifespan is greatly influenced by as yet unknown genetic modifiers, and that
allowing Sod2 mutants to survive longer, brings to the surface phenotypes that
would not be apparent had the animals died earlier. This latter point was further
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supported by subsequent work in which SOD2 mimetics were administered to
Sod2 null mice (Melov et al., 1998; 2000). Melov et al. (1998) reported that
treatment with the SOD mimetic manganese 5, 10, 15, 20-tetrakis (4-benzoic
acid) porphyrin (MnTBAP) rescued Sod2 ~ ~ mutants from the pathology described
above and significantly prolonged their survival. Surviving animals developed a
pronounced movement disorder, which progressed to complete impairment of
strength by 3 weeks of age. Neuropathologic evaluation showed spongiform
degeneration of the cortex and specific brainstem nuclei, associated with gliosis
and intramyelinic vacuolisation, both ofwhich are phenotypic characteristics
previously observed in disorders associated with inherited mitochondrial
abnormalities such as Leigh disease. Melov et al., (1998) suggested that it was the
failure ofMnTBAP to cross the blood-brain barrier that caused the progressive
neuropathology, as the mimetic failed to prevent excessive mitochondrial
production ofROS within the brain.
Asikainen et al. (2002) investigated the sensitivity, lung histopathology
and biochemistry of Sod2 null mice subjected to hyperoxia. Taking advantage of
their increased survival rate on the mixed genetic background, the mice showed
increased mortality rates and decreased body and lung weights, when compared to
wild-type animals. Also, the plasma glutathione levels were decreased, while the
mRNA levels and activity of glutathione peroxidase were increased, possibly
reflecting a compensatory response to decreased MnSOD activity.
The limited lifespan of Sod2 null mice makes it difficult to study the
importance of the mitochondrial isoform of superoxide dismutase in longer-term
experiments and to analyse in more detail the effects that its absence would have
in phenotypes, such as retinal degeneration, that take longer than 3 weeks to
become apparent. Also, the limited lifespan of these mice means that they do not
reach a fertile age, which in turn prohibits the generation of compound mutants,
for investigating the role of oxidative stress in different diseases. One solution is
the use ofSod2 heterozygous mice that have decreased levels of Sod2, but not to
the extent that this becomes lethal. An increasing number of studies have focused
on analysing Sod2+/" mice and using them to understand the involvement of
oxidative stress, and particularly Sod2,s role in a range of disorders, including
neurodegenerative diseases. Heterozygous Sod2 mice on a C57BL/6 background
and aged 2-4 months were initially analysed (Tsan et al., 1998; Williams et al.,
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1998; van Remmen et al., 1999; 2001). Decreased Sod2 expression and protein
levels were confirmed in all tissues analysed. The animals survived well
following exposure to 100% oxygen and, with some exceptions, the mRNA and
protein levels of Sodl, Cat and Gpx were unchanged (Tsan et al., 1998; van;
Williams et al., 1998). In the heart however, there was an increase of Sodl and
Gpx activities, possibly reflecting a compensatory response to decreased Sod2
levels (Tsan et al., 1998). The mRNA level of Gpx in the muscle also showed a
significant decrease (van Remmen et al., 1999). Moreover, in the heterozygous
animals there was a 30% decrease both in total glutathione levels of liver
mitochondria, and in the specific activities of the mitochondrial and oxidative
stress-sensitive enzymes aconitase and complex I. Increased levels of 8-oxoG
residues in the DNA and of increased protein oxidation, suggested increased
oxidative damage in Sod2+,~ mice (Williams et al., 1998).
Subsequent studies focused on longer-term experiments. Andreassen et al.
(2001) evaluated the susceptibility of Sod2+,~ animals, on a CD1 background, to
exposure to different sources of oxidative stress. Animals were subjected to 1-
methyl-4-phenyl-l, 2, 5, 6-tetrahydropyridine (MPTP), malonate and 3-
nitropropionic acid (3NP) treatments, all of which are neurotoxins commonly
used for generation of animal models of Parkinson's and Huntington's diseases
(Bove et al., 2005; Brouillet et al., 2005). No neuropathological features were
evident for 6 months. Malonate-induced brain lesions were however larger in the
heterozygotes, compared to wild-types, and neuronal loss was increased following
3NP treatment. Finally, van Remmen et al. (2003) studied the Sod2 heterozygotes
for up to 26 months of age. Although their lifespan was identical to that of control
animals, they showed increased 8-oxoG levels in their DNA, as well as a 100%
increased tumour incidence.
1.1.4.3. Antioxidants in disease treatment
In addition to work on genetically modified animals, the importance of Sod2 has
been demonstrated by the exogenous administration of chemical analogues that
serve as potential treatments for diseases in which oxidative stress has been
implicated. Rong et al. (1999) pre-treated rats with EUK-134, a synthetic
superoxide dismutase-catalase (Sod-Cat) mimetic, and showed decreased levels of
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protein nitration and neuronal damage after kainate-induced seizure activity. Also,
Izumi et al. (2002) observed decreased organ injury in haemorrhagic shock
induced in anaesthetised rats, after they were treated with EUK-8, another Sod-
Cat mimetic. Finally, Melov et al. (2000) increased the level of antioxidant
systems in C. elegans by administration of either EUK-8 or EUK-134, and
observed a 44% increase in the worm's life span.
1.1.5. Drug development and mitochondrial targeting
It is therefore an attractive idea to design drugs that are targeted to mitochondria,
which, based on the Sod2 studies, are the principal sites of ROS formation in the
cell. The effectiveness of such a drug depends on a number of points, as discussed
by Murphy & Smith (2000). A bioactive molecule needs to find its way to the
correct intracellular location, in specific cell types of a specific organ. Once there,
the drug should be able to manipulate specific metabolic processes without
compromising neighbouring ones. Also, the drug should be cleared from the
system, to ensure the lack of its accumulation in target tissues, hence avoiding
potential problems such as overdose and overloading. For some drugs, depending
on where they are being targeted to, it is also essential to cross the blood-brain
barrier (BBB). This has been discussed in a recent paper by Pardridge (2005), in
which it was pointed out that 98% and 100% of small and large molecule drugs
respectively do not cross the BBB. For a small-molecule drug to be able to do so
in pharmacologically significant amounts, the molecule must have a molecular
mass of less than 500 Da and a high lipid solubility (Pardridge, 2001). In central
nervous system (CNS) disorders, where the primary phenotype resides in neurons,
this is a major issue that needs to be overcome. Finally, the drug delivery and
role-execution procedure should be done with minimal side effects that do not
compromise the vital functions of the cells or their survival.
1.1.5.1. Candidates for mitochondrial targeting
The beneficial effects of a number of natural antioxidants have been studied and
verified, making them potentially good drug candidates in disorders where
mitochondrial function is impaired. Antioxidants like vitamin E (VitE) (Meydani,
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1995) and SOD mimetics have been shown to offer some protection against
oxidative damage. Extensive work, both in vitro and in vivo, has demonstrated
beneficial effects. The best clinical evidence supporting the protective role of
VitE against ischemia/reperfusion injury comes from VitE pretreatment of
patients undergoing cardiopulmonary bypass surgery (Coghlan et al., 1993;
Meydani, 1995). If not pre-treated with the antioxidant, the decreased levels of the
vitamin observed during bypass surgery lead to increased levels of oxidative
damage. Also, treatment with the SOD mimetic MnTBAP significantly
ameliorated both dilated cardiomyopathy and hepatic lipid accumulation and
increased the mean lifespan of Sod2 null mice (Melov et al., 2001).
1.1.5.1.1. Ubiquinone
Ubiquinol derivatives are also promising antioxidants to target to mitochondria, as
work by both Matthews et al. (1998) and Laas et al. (1999) has demonstrated.
Ubiquinones (UQ) are a group of homologous quinones, all of which contain a 2,
3-dimethoxy-5-methylbenzoquinone nucleus with a phenyl side chain (Clane &
Barr 1971). It is the length of this chain that differs between different quinones
(Figure 5), which are also known as coenzymes Q (CoQ) (Bhagavan & Chopra,
2006). They are the most widely distributed quinones in nature, and are found in
the mitochondria of plants, animals and bacteria. In humans, the most prevalent
isoform is coenzyme Qio (CoQio), with a 10-carbon chain, and is present in all
human tissues in varying amounts (Bhagavan & Chopra, 2006). The distribution
of ubiquinone is usually correlated with energy requirement and metabolic
activity, which agrees well with its involvement as a coenzyme in the
cytochrome-containing terminal respiratory system. As reported by Bhagavan &




Figure 5: Ubiquinone structure
General chemical structure of ubiquinones. They all contain a 2,3-
dimethoxy-5-methylbenzoquinone nucleus with a prenyl side chain in the
6-position, but differ in the length of this side chain.
UQ can exist in different redox forms in the cell. It is buried within the
lipid core of the MIM and can stably exist in either an oxidized form (UQ) or a
reduced form called ubiquinol (UQH2) (Ernster & Dallner, 1995). The conversion
from UQ to UQH2 is catalysed by ubiquinone reductases and the UQH2/UQ ratio
is determined by the electron flow through the ETC, shifting to a reduced state
when the flow is decreased (James et al., 2004). In vivo, the ubiquinone pool is
highly reduced and in humans, about 95% of C0Q10 exists as ubiquinol
(Bhagavan & Chopra, 2006).
Ubiquinone is an essential cofactor in the ETC, where it accepts electron
from CI and CII, becoming reduced to ubiquinol, and donates them to CIII. In
addition to its electron carrier role, ubiquinol is a potent antioxidant, as it has been
shown to reduce lipid peroxidation within the MIM (Beyer & Ernster, 1990,
Ingold et al., 1993, Kelso et al., 2001). Its antioxidant role is exerted by the
donation of a hydrogen atom to a lipid peroxyl radical, and the subsequent
formation of a ubisemiquinone radical (UQH*). The latter can react with oxygen
to form ubiquinone and 0{', which gets detoxified by the antioxidant enzyme
superoxide dismutase (Maguire et al., 1989; Ingold et al., 1993; Kelso et al.
2001).
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1.1.5.2. Targeting antioxidants to mitochondria
There is a drawback, however, in using the previously described antioxidants as
drugs. Only a small proportion of the administered antioxidant manages to reach
the mitochondrion, where it is able to reduce ROS formation. Orally administered
C0Q10 has a poor efficiency of absorption due to its insolubility in water and
relatively large molecular weight (Bhagavan & Chopra, 2006). This has been
confirmed in a study with rats, where only 2-3% of orally administered CoQio
was absorbed (Zhang et al., 1995). As a result, patients need to be treated with
large amounts of these natural antioxidants to be able to obtain a beneficial effect,
at which point undesired side effects attributed to over-dosage become apparent.
It is therefore essential to be able to target these antioxidants directly to
mitochondria, where they can accumulate and exert their beneficial effects.
Extensive work by Murphy, Smith and colleagues has been dedicated to
investigating the development and potential use ofmitochondrially-targeted
antioxidants (Smith et al., 1999, 2003; Kelso et al., 2001; Asin-Cayuela et al.,
2004).
A common way of targeting compounds to mitochondria has been to
attach a specific 25-amino acid signal peptide to the N-terminus of the compound
of interest. This is not always straightforward, as the addition of this peptide can
interfere with the structure and function of the molecule. The structural,
physiological and metabolic characteristics ofmitochondria can be exploited in
drug targeting. The MIM is selective in its permeability and allows substances to
pass through it only via tightly regulated transporters, complexes and pumps. For
example, only complexes I, III and IV of the ETC are able to pump protons out
through the MIM during respiration. Similarly, it is only through the ATP
synthase that protons can re-enter into the mitochondrial matrix. During
respiration, the selective flux of protons generates a concentration gradient, which
in turn constitutes a major part of the proton-motive force driving respiration. In
living, respiring cells, a membrane potential is established across the MIM. In
cultured cells, this is 180-200 mV (negative inside), while in vivo it is 130-150
mV. This drop is attributed to the use of some of the electrochemical potential for
respiration, ATP production and ion translocation. It has been shown that some
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cations are able to use this electrochemical potential to their advantage and to
accumulate within mitochondria against a concentration gradient (Figure 6).
Indeed, 90% of intracellular lipophilic cations are located within mitochondria
(Kauppinen, 1983), as they can easily pass through the lipid bilayer, since their
Figure 6: Uptake of alkyltriphenylphosphonium cations by mitochondria within cells
The lipophilic triphenylphosphonium cation, which is covalently attached to
a biologically active molecule (X), is accumulated 5- to 10-fold into the
cytoplasm from the extracellular space by the plasma membrane potential
(Ayp) and then further accumulated 100- to 500-fold into the mitochondrial
matrix by the mitochondrial membrane potential (Aym) [Image from Smith
etal., 2003]
positive charge is shielded (Murphy & Smith, 2000). This accumulation is
described by the Nernst equation:
Membrane potential (mV) = 61.5 logic {[cation]jn/[cation]out}
according to which every 61.5 mV increase in the membrane potential causes a
10-fold increase in the mitochondrial accumulation of lipophilic cations. This
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property of the lipophilic cations has been successfully used for targeting toxic
substances to cancer cells in order to induce their death (Rideout et al., 1989).
1.1.5.2.1. Mitochondrially targeted antioxidant compounds
Murphy and co-workers developed a number ofmitochondrially-targeted
compounds, by taking advantage of these properties of lipophilic cations.
IBTP (4-iodobutyl-triphenylphosphonium) (Figure 7) is a lipophilic
cation that is able to accumulate one hundred-fold within mitochondria and
specifically to label mitochondrial proteins (Lin et al. 2002). Inside mitochondria,
protein thiolates displace the iodo functional group of IBTP to form stable
phosphonium thioethers. These can in turn be identified by immunoblotting using
anti-triphenylphosphonium antiserum. The selectivity of IBTP for mitochondrial
proteins is high, since the pKa values of protein thiols (about 8-8.5) mean that the
mitochondrial pH of 8 is more appropriate for a fast reaction than the cytosolic pH
of 7.2. Therefore, protein modifications attributed to formation ofmixed
disulfides, .S-nitrosylation, or oxidation can result in an altered recognition pattern
of IBTP.
MitoQ (Figure 7) is a ubiquinone derivative targeted to mitochondria. It is
a mixture ofmitoquinone and mitoquinol, the two charged forms of ubiquinone,
which are covalently attached to a lipophilic triphenylphosphonium cation
through an aliphatic carbon chain. The properties of MitoQ as a targeted
antioxidant are often verified by comparison with idebenone. The latter is a short
chain analogue ofCoQio, which has been shown to decrease oxidative damage in
Friedreich's ataxia (FRDA) patients (Mariotti et al., 2003). It is an artificial
ubiquinone with better bioavailability and pharmacokinetic properties than
exogenous CoQio, and has been shown to have beneficial effects in clinical
studies (Rustin et al., 2002). Other compounds that have been synthesised using
the same principle, and which will be mentioned occasionally in this project, are
3H-MitoQ, a tritium-labelled form ofMitoQ and TPMP
(methyltriphenylphosphonium cation), which is very similar structurally to the
above compounds, but does not have an antioxidant capacity.
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Figure 7: Mitochondrially targeted antioxidant compounds
Chemical structures of mitochondrially targeted compounds. They are all
covalently attached to a lipophilic triphenylphosphonium cation. TPMP has
no antioxidant function, whereas IBTP, MitoVitE and MitoQ do. [Image
from Smith et al., 2003]
1.1.5.2.2. Evaluating mitochondrially targeted antioxidants
Having developed these mitochondrially targeted compounds, the next step was to
assess in vitro their efficiency in mitochondrial accumulation and effectiveness as
antioxidants. Because of their very similar chemical structures, inferences were
often made on results using a single targeted compound.
The efficient targeting of these antioxidants into isolated mitochondria
was verified. Kelso et al. (2001) energised isolated mitochondria by incubating
them with KC1 buffer including succinate and rotenone. Subsequent treatment
with 3H-MitoQ, allowed the uptake of this compound by mitochondria and was
verified by scintillation counting. The specificity of the uptake was confirmed by
the use of the respiration uncoupler carbonyl cyanide p-
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trifluoromethoxyphenylhydrazone (FCCP), which blocked the uptake and
prevented the antioxidant's accumulation in the organelles. Lin et al. (2002)
demonstrated the uptake of IBTP by isolated mitochondria, following a similar
protocol that included detection of the compound by an anti-IBTP antibody.
• 3
Finally, Kelso et al. (2001) showed that once H-MitoQ was taken up by
energised mitochondria, it was largely adsorbed to the matrix side of the MIM.
Having demonstrated the uptake of the targeted antioxidants by isolated
mitochondria, it was important to confirm that this was also the case within
isolated cells. Kelso et al. (2001) treated isolated cells with 3H-MitoQ for 40
minutes prior to cellular fractionation and showed a 50% enrichment of the
tritium-label in the mitochondrial fraction, compared to the cytosolic one. The
specificity of this accumulation was verified by treatment with the uncoupler
FCCP, which disrupts the membrane potential.
The mechanism of action ofMitoQ as an antioxidant was also investigated
by Kelso et al. (2001). MitoQ can be reduced and oxidized by complexes of the
ETC. Depletion of endogenous ubiquinone or use of a yeast strain deficient in
ubiquinone biosynthesis verified that MitoQ redox changes were not attributed to
the endogenous ubiquinone pool. The antioxidant role of MitoQ was clarified by
using parinaric acid, which fluoresces when in lipid bilayers but loses this
fluorescence under lipid peroxidation. Incubation ofmitochondria with ferrous
iron resulted in a decreased membrane potential and increased levels of lipid
peroxidation. Treatment with MitoQ however, prevented oxidation of parinaric
acid by ferrous iron, blocked the accumulation of the lipid peroxidation marker
malondialdehyde (MDA) and restored mitochondrial function. The antioxidant
properties ofMitoQ, which seem to lie in its ubiquinol moiety, were abolished
upon malonate and rotenone treatment. These are inhibitors of complex II and
complex I, respectively, which blocked the reduction of MitoQ and prevented it
from successfully inhibiting lipid peroxidation.
The toxicity of MitoQ in cells was assessed by Kelso et al. (2001). The
authors demonstrated that MitoQ doses of less than 10 juM had little effect on
mitochondrial membrane potential and no effect on cell viability. However when
the concentration was increased to 25-50 pM, a decreased membrane potential
and an increase in cell death was observed.
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As mentioned above, for a drug to be efficient, it should be cleared from
the biological system in which it is introduced. This was confirmed for TPMP and
it was therefore assumed that MitoQ would have a similar clearance rate from
mitochondria (Kelso et al., 2001).
The necessity of targeting antioxidant compounds to mitochondria was
illustrated by a comparison between idebenone and MitoQ. Idebenone is evenly
distributed between intra- and extra-cellular compartments, without being
concentrated in the mitochondria. Jauslin et al. (2003) used fibroblasts that had
been isolated from Friedreich's ataxia (FRDA) patients which were then exposed
to the glutathione synthesis inhibitor L-buthionine-(S,R)-sulfoximine (BSO) to
induce cell death by increased endogenous oxidative stress. Comparing the
treatments with Idebenone and MitoQ, the authors showed that the latter was up
to 800-fold more effective at preventing cell death at a much lower concentration
than the former. This difference was abolished upon treatment with the uncoupler
FCCP.
1.1.5.2.3. In vitro studies ofMitoQ
Since the development ofMitoQ as a targeted antioxidant, a number of studies
have demonstrated its efficiency as an antioxidant. Kelso et al. (2001)
investigated in vitro the role ofMitoQ in apoptosis. Incubating Jurkat cells with
H2O2 activated the caspase cascade and increased cell death within 4-6 hours of
exposure. Pre-incubation of the cells however with lpM MitoQ completely
blocked caspase activation and decreased the number of dying cells following
H2O2 treatment. It is worth noting however that this did not occur when the non-
targeted, but evenly distributed, coenzyme Qi was administered, highlighting the
importance of targeting. Similarly, the level of apoptosis induced by staurosporin
or tumor necrosis factor-alpha (TNFa) were also decreased upon MitoQ treatment
(Kelso et al., 2001).
The effect ofMitoQ on telomere shortening and lifespan has been
examined under mild oxidative stress. Telomere shortening, which is a marker of
ageing, is attributed either to the inability ofDNA polymerases to replicate the
ends of chromosomes or to the specific accumulation of oxidative damage in the
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DNA. Saretzki et al. (2003) observed a 50% decrease in hyperoxia-induced
peroxide formation in human fibroblast cultures treated with MitoQ. They also
showed that the replicative lifespan of fibroblasts, which lack telomerase, was
increased by 40% and that telomere shortening was minimised in the presence of
the antioxidant. Also, Sanjuan-Pla et al. (2005) investigated the role of
mitochondrially-produced ROS in the hypoxic signalling of hypoxia inducible
factor 1 alpha (HIF-la). The latter is a transcription factor which is a key
regulator of the cellular responses to reduced oxygen concentrations. HIF consists
of an oxygen-sensitive a subunit and a constitutively active P subunit. The former
is targeted for ubiquitination and proteasome degradation under normoxic
conditions (21% oxygen), but is stabilised under hypoxia (0-5% oxygen) so that it
can transactivate target genes. In this study, the authors found that mitochondrial
ROS are required for HIF-la stabilisation since addition ofMitoQ led to
disruption ofmitochondrial ROS formation, destabilisation ofHIF la and
subsequent loss of its transcriptional activity. MitoQ was therefore used to
highlight the involvement of ROS and oxidative stress in important cellular
processes like telomere integrity, transcriptional activation and apoptosis.
1.1.5.2.4. In vivo studies ofMitoQ
Based on the results of in vitro studies, MitoQ appeared to be a promising
targeted antioxidant that could potentially be used as a therapeutic drug in
mitochondrial diseases. In order to become clinically useful drugs, targeted
antioxidants should work as efficiently in vivo as they have been shown to do in
vitro. The in vivo studies ofMitoQ have not yet been as extensive, since the
antioxidant has only recently become available, but the results so far have been
promising. Work by Smith et al. (2003) was the first attempt to investigate the
delivery and distribution of TPMP, MitoVitE and MitoQ in vivo. These authors
used Swiss-Webster mice to compare three methods of administering these
compounds; intraperitoneal (i.p.) injection, intravenous (i.v.) injection and orally
through the drinking water. Single injections (i.p. or i.v.) of TPMP orMitoVitE
up to 300 nmol were not toxic for at least 7 days after administration. Toxicity
was however evident at 500 nmol within 12 hours of injection. For MitoQ,
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injections of up to 750 nmol were well tolerated by the animals, but toxic side
effects were evident at doses above 1000 nmol. It was concluded that the
maximum tolerated dose ofMitoQ for administration by injection was 20 mg/kg.
The figures were somewhat different when the substances were
administered to the animals through their drinking water. At concentrations of 500
pM, 1 mM and 5 mM, TPMP showed no toxic effects for at least 43 days, toxic
effects at 26 days and toxic effects at 6 days, respectively. MitoVitE doses of 500
pM caused no side effects for at least 14 days of administration. These data
translate into maximum tolerated doses of 97 ± 13 pmol/kg/day and 105 ± 9.2
pmol/kg/day for TPMP and MitoVitE, respectively. MitoQ concentrations of 500
pM and ImM had no toxic effects for at least 26 days, but doses of 2 or 5 mM
had toxic effects after 10 days of treatment. It was also noted that at these
concentrations, food consumption by the animals was 65-80% and 20-30% that of
control animals. The maximum tolerated dose for MitoQ was concluded to be 346
pmol/kg/day.
It is apparent that the toxicity of these compounds depends on the method
of administration, so that oral administration is less toxic than injection. This may
be because lipophilic cations can be toxic at high concentrations, as their
excessive uptake can result in the disruption ofATP synthesis by mitochondria. It
was also noted that it is the lipophilic cations that are toxic to the cell and not the
side chains of the compounds, as indicated by the similar maximum tolerated
doses observed for TPMP and MitoVitE, whose side chains are very different.
The uptake of these substances into tissues was investigated by the use of
• • 3 3tritium-labelled analogues. H-TPMP and H-MitoVitE, administered to mice by
i.p. injections, were efficiently taken up by the heart, liver and kidney, but not by
the brain, within an hour of injection. All tissues absorbed the substances
following i.v. injection. Similarly, all organs also absorbed TPMP and MitoVitE
after 7-10 and 4 days of oral administration through the drinking water,
respectively. Administration of 500 pm MitoQ for 10 days was sufficient for
uptake by all the organs tested. The tissue concentrations recorded were however
lower than for TPMP or MitoVitE, probably reflecting MitoQ's higher
hydrophobicity.
49
The hydrophobicity of these compounds is a key issue that can greatly
affect their efficiency as drugs. Work by Asin-Cayuela et al. (2004) investigated
this by using alkyltriphenylphosphonium (TPP) cations. TPP cations enter
mitochondria as follows: they first bind the outer surface of the MIM and then
permeate the hydrophobic phospholipid bilayer, which potentially acts as an
energy barrier. They then bind to the matrix side of the MIM, from where they are
distributed throughout the mitochondrial matrix. Eventually, equilibrium is
reached between the cations free in solution and those adsorbed as a monolayer
on the membrane surface. It is conceivable that the more hydrophobic the alkyl
chain of the targeted compound, the higher the proportion of the cation that is
membrane-bound, leaving only a smaller proportion available in the matrix. This
point was illustrated by the same group, who modified the size of the alkyl chain
that joins the TPP and ubiquinol moieties. They compared MitoQ3, MitoQs,
MitoQio andMitoQ 15, (with 3, 5, 10 and 15 carbons in their alkyl chains,
respectively) to find that there was a perfect correlation between the chain length
and adsorption. The antioxidant efficacy of these MitoQ analogues depends both
on their reduction by the ETC and on their accumulation within the mitochondria.
As shown by thiobarbituric acid reactive substances (TBARS) and other lipid
peroxidation markers, the antioxidant efficacy of the MitoQ analogues correlated
positively with the size of the alkyl chain. It is conceivable therefore that a
balance needs to be achieved between the availability of the compound and its
antioxidant efficacy. MitoQ io is the analogue that has been most extensively used
in both in vitro and in vivo experiments.
The key property of these targeted MitoQ analogues is their ability to
accumulate in the mitochondria. It is difficult to confirm this in vivo, using
tritium-labelled sub-analogues, as they are rapidly re-distributed upon loss of
membrane potential. For this reason IBTP, which shows covalent binding to
proteins and for which an antibody has been designed, is used. (Lin et al., 2002).
Within mitochondria, the iodo moiety of IBTP is slowly displaced by protein
thiols, binding the butyltriphenylphosphonium cation to mitochondrial proteins by
a stable thioether linkage. This covalent association is stable even under tissue
homogenisation, making its detection by immunoblotting possible. Therefore,
Kelso et al. (2001) injected IBTP intravenously into mice, and 4 hours later were
able to confirm its accumulation in heart mitochondrial fractions. The integrity of
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the targeted antioxidants within the mitochondria, following uptake, was assessed
by mass spectrometry. It was confirmed that the MitoVitE mass was not altered
upon targeting. The same authors also confirmed the clearance of TPMP at a
reasonable rate, with a half-life of 1.54 days. Inferences therefore were made
regarding the integrity and clearance ofMitoQ following its administration in
vivo.
The effects of administration of these targeted substances on the breeding
capacity of animals were also investigated. In addition, it was necessary to
determine whether the targeted antioxidants reach the embryos and whether they
can accumulate in different embryonic organs. By orally administering 3H-TPMP
to the mouse dam during days 1-17 of pregnancy, Smith et al. (2003) showed
substantial TPMP accumulation in the embryos. Additionally, administration of
H-TPMP throughout pregnancy, up to postnatal day 7 (P7) of the neonate,
confirmed its distribution in all organs of the neonate.
Based on the TPMP results, Smith et al. (2003) suggested the following
pharmacokinetic model. Orally administered TPMP is absorbed by the gut and
enters the bloodstream eventually to be taken up by all tissues. This occurs by
non-mediated movement through the lipid bilayer of the cell plasma membrane
(PM), driven by the PM potential. Once in the cytosol, cations are further
concentrated in mitochondria, this time driven by the membrane potential across
the MIM. After several days of oral administration, the cations reach a steady
state concentration within the mitochondria that is several hundred-fold higher
than the concentration in the bloodstream. At this point, the rate of absorption of
these cations matches that of its clearance into the urine and bile.
In summary, the studies of Smith et al. (2003) established that MitoQ can
be used effectively in vivo. Oral administration ofMitoQ at a maximum tolerated
dose of 346 pmol/kg/day for at least 26 days is safe for the animals. It was
confirmed that MitoQ, driven by membrane potentials, can enter tissues and cells
and accumulate within mitochondria. The delivery of MitoQ from parents to
embryos and fetuses after oral administration is also confirmed. Once it has
entered the mitochondria, MitoQ remains structurally intact and can exert its
antioxidant role, which has since been verified in vivo in a number of different
model systems.
Adlam et al. (2005) used MitoQ in an in vivo model of cardiac ischemia-
reperfusion (IR) injury. During IR, the coronary blood supply to the heart is
temporarily reduced or stopped, preventing oxygen, glucose and fatty acids from
reaching the muscle. OXPHOS is inactivated and a number of different
physiological changes point to the disruption ofmitochondrial function. These
include loss of cytochrome c, build up of phosphates and lactic acid and increased
intracellular Ca2+ concentrations. Upon reperfusion, molecular oxygen interacts
with the now damaged respiratory chain to produce ROS. Rats were administered
MitoQ orally, through their drinking water, at a dose of 74-99 pmol/kg/day for 14
days. Following IR injury Adlam et al. (2005) showed that MitoQ protects cardiac
function, as assayed by heart rate and coronary blood flow, against tissue damage
during IR injury. The extent of IR injuries was measured by transmission electron
microscopy and lactate dehydrogenase leakage into the perfusate. MitoQ also
protected against disruption ofmitochondrial function, as assessed by the
respiratory control ratio.
1.2. Photoreceptor degeneration
1.2.1. The structure of the eye
The mammalian eye is a specialised organ concerned with photoreception. Light
enters the eye from the external environment and generates a series of
physicochemical reactions that result in vision. The structure of the eye is highly
organised and is well conserved among vertebrates (Rodieck, 1973).
The mouse eye (Figure 8) is a sphere a few millimetres in diameter, with
distinct anterior and posterior segments. The anterior segment of the eye includes
the conjuctiva, cornea, anterior chamber, aqueous drainage structures, iris, ciliary
body and lens (Smith et al., 2002b). The posterior segment includes the vitreous
body, posterior uvea (choroid), retina, optic nerve, orbit and extraocular muscles
(Smith et al., 2002a). The eye is composed of three major layers; the scleral layers




Figure 8: Structure of the eye
Diagrammatic version of an eye sectioned at the vertical plane. The distinct
features of the posterior and anterior parts of the eye are indicated, with a focus
on the retinal layer. [Image from http://webvision.med.utah.edu/sretina.html]
1.2.1.1. The retina
The retina (Figure 9) is a thin sheet of interconnected nerve cells that lines the
inner surface of the posterior part of the eye (Smith et al., 2002a). It has two main
components; the neurosensory retina, which contains the photoreceptor cells, and
the retinal pigment epithelium (RPE). The neurosensory retina is organised in
layers, which are, in order from the outside of the eye, the nerve fibre layer, the
ganglion cell layer, the inner plexiform layer, the inner nuclear layer, the outer
plexiform layer, the outer nuclear layer and the outer segments of the
photoreceptor cells (Smith et al., 2002a).
Almost all vertebrate retinas are duplex, in that they contain two types of
photoreceptor cells; cones and rods (Carter-Dawson & La Vail, 1979a). Both are
long cells which contain a nucleus, axon, synaptic terminal, inner segment (IS)
and the outer segment (OS), which are closer to and further away from the centre
of the hemispherical retina, respectively (Rodieck, 1973) (Figure 9). The IS and
OS are connected by a thin structure called the connecting cilium. In the mouse
retina, the IS of the cone is shorter and larger in diameter (3-4 pm) than that of the
rod, whose diameter is about 2 pm. Also, the cone OS is conically shaped and its
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length is about 13.4 jam, whereas the rod OS has a uniform diameter across its
-23.6 jum length (Carter-Dawson & La Vail, 1979a). The outer segments are
densely packed with well-organised stacked disk membranes that contain
abundant photopigments; rhodopsin in rods and short and medium wavelength
cone opsins in cones. The OS, although of constant length, is continually
renewed. This is done by shedding the older portion at the tip as a result of
phagocytosis by retinal pigment epithelium (RPE) cells and by adding new
membranes at the base of the OS (LaVail, 1983).
The nuclei of photoreceptor cells are in the outer nuclear layer. Cone
nuclei are oval shaped, with horizontal and vertical diameters of 4.3 and 7.3 pm
respectively, and have at least one clump of heterochromatin and a large amount
of euchromatin. In contrast, rod nuclei are much smaller -at least half the size of
cone nuclei- and are round with a diameter of about 4.5 pm. They have a single
heterochromatin clump that is surrounded by a small amount of euchromatin.
The distribution of rods and cones in the retina varies at different
developmental stages, but the tissue gradually reaches a more-or-less fixed
composition during early postnatal life. In an extensive study by Carter-Dawson
& La Vail (1979b), the genesis of rod and cone cells in C57BL/6 mouse retinas
was studied by autoradiography using tritiated thymidine. It was shown that in the
posterior retina, all cones are generated during the foetal period, while only a
minority of rods is generated during the same period. The majority of the rods are
formed postnatally. In the peripheral retina, cones are again generated before birth
while rods extend their formation up to postnatal day P8. In the mouse retina, the
total number of photoreceptors decreases slightly from the posterior pole to the
periphery and only about 4% of them are cones (Carter-Dawson et al., 1979a).
This low percentage of cone cells in the retina remains constant with age and their




Figure9:Thestr ctureoftretina (A)Theretinaisorganisedndiff r ntlayer .Sta ting fromtheequatorialretin(b t m)layersare; singlelayerofgan lioncel s(GC),thinpl xiform layer(IPL),thinnnuclearNo t plexiformlayer(OPL),thoutern cl arl N innersegments(IS)andthout rOSf photoreceptorcellsandtretinaligm ntepi h lium (RPE).B)Schematicdiagramofphotoreceptorcell Theout rsegment,whichicompos dftacke membranousdisks,iconnectedthn rs gment bytheconnectingilium.Tinn rsegm n accomodatesdifferentorgan llein lu ing mitochondria.[I agefromhttp://www.chemistry.wustl. edu/~edudev/LabTutorials/Vision/images/Rodcell.jpg]
Cones and rods are also functionally different. Cones are used for the
distinction of spatial details and the detection of colour, while rods detect
brightness, contrast and motion (Baylor, 1987). The underlying mechanism by
which these functions are carried out is common to both rods and cones and
involves phototransduction. Phototransduction is a cascade ofprotein activation
and inactivation, ion channel opening and closure, which together alter the
intracellular ion concentrations and affect the polarisation of the photoreceptor
membrane. In the dark, when photoreceptor cells are not stimulated, there is Na+
influx at the OS and K+ efflux at the IS, which set the inner membrane potential at
—40mV. This depolarising current is known as the dark current. The normal
gradients for these ions are maintained by Na K+ ATPase pumps, which are
located in the PM of the IS (Steinberg, 1987). Upon illumination, a photon of
light is absorbed by rhodopsin and activates it by isomerisation of 11 -cis retinal to
the all-trans form. A single activated rhodopsin molecule can then propagate and
amplify the signal by activating 500 transducin molecules by means ofGDP/GTP
exchange. Transducin in turn activates cGMP phosphodiesterase, which lowers
cGMP concentrations and so controls the open or closed status of cyclic
nucleotide gated ion channels residing in the outer segment plasma membrane. In
the light, cGMP-gated Na+ channels close, while the K+ and Ca2+ effluxes in the
IS continue as normal. As a result, the interior becomes increasingly more
negative until the membrane becomes hyperpolarised.
1.2.2. Retinitis pigmentosa
Defects in components of the phototransduction cascade can lead to a large
number of retinal diseases, mediated by both rod and cone dystrophies, many of
which result from impairment of the visual cycle and/or disruption of
photoreceptor OS maintenance (van Soest et al., 1999; Rivolta et al., 2002). Many
of the defects in genes whose products are involved in photoreceptor-specific
functions result in progressive degeneration of rods and cones, and eventually
impaired vision and blindness. These include retinitis pigmentosa.
Retinitis pigmentosa (RP) is the term used to collectively describe a group
of inherited progressive retinal dystrophies characterised by retinal pigmentary
deposition and diminished rod electroretinograms (Rivolta et al, 2002). RP is the
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most prevalent group of retinopathies in the western world, affecting about 1 in
3000 people, and is both genetically and clinically heterogeneous (Rivolta et al.,
2002). It is typically a monogenic disorder, which may be inherited in an
autosomal dominant, autosomal recessive or X-linked fashion, and for which
there have occasionally been reports of digenic inheritance (Fan et al., 2006).
Regardless of the mode of inheritance of RP, the phenotype is
characterised by, initially, the development of night blindness followed by gradual
loss of peripheral vision -referred to as tunnel vision- and eventually loss of
complete vision in many cases (Humphries et al., 1992; Olson et al., 1992).
Photoreceptors are most commonly the retinal cells primarily affected by the
disease (Berson et al., 1968; Kolb & Gouras, 1974), but RP can also result from a
primary RPE defect, which causes secondary photoreceptor cell death (Mullen &
LaVail, 1976). In RP, rod photoreceptors degenerate first, leading to night
blindness, whereas the cone dysfunction and death follows at a later stage, when
daytime vision becomes noticeably impaired. As RP progresses and pathological
changes develop, the retinal pigment epithelium becomes thinner and deposits of
pigment often accumulate on the retinal surface, a phenomenon that gives RP its
name. Nevertheless, long before these visual problems become apparent,
eletrophysiological changes may be detectable in the retina by electroretinography
(ERG), which measures the electrical activity generated by the retina in response
to flashes of light. Reduced amplitude and/or delayed response to the stimulus are
indications of impaired photoreceptor cell function (Berson et al., 1968, 1969).
1.2.2.1. Genes implicated in retinitis pigmentosa
More than 37 genes have been implicated in RP to date (Table 1) (RetNet at
http://www.sph.uth.tmc.edu/Retnet/home.htm). Some examples of genes in which
mutations lead to RP in humans are shown in Table 1. These genes include rod
cGMP phosphodiesterase 6 beta subunit (PDE6B), rhodopsin (RHO) and
peripherin 2/retinal degeneration slow (.PRPH2/RDS). Mouse models for these
three RP mutations are described below.
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1.2.2.1.1. Rod cGMP phosphodiesterase 6b: the retinal
degeneration 1 mutation (Pde6brAX)
The retinal degeneration 1 (rdl) mutation in the Pde6/3 gene is a naturally
occurring, autosomal recessive mutation first reported by Sidman & Green in the
C3H mouse strain in 1965. In the retina of homozygous rdl mice there is
defective postnatal development ofphotoreceptor cells, leading to their complete
loss, as well as to loss of some bipolar cells, by the 3rd postnatal week (Farber &
Lolley, 1974; Lolley et al., 1974). The morphology of the inner layers of the
retina appears to be unaffected by the disease but biochemical adjustments to the
loss ofphotoreceptor cells, like elevated glucose and glycogen levels, have been
reported (Lolley, 1972). The mutant phenotype has been attributed to the
defective activity of rod cGMP phosphodiesterase (PDE). The latter appears to be
deficient before the onset ofphotoreceptor degeneration and its levels are very
low throughout postnatal life (Schmidt & Lolley, 1973). A number of other
biochemical abnormalities are apparent in rdl/rdl retinas (Lolley et al., 1974).
Retinas in the rdl/rdl mouse were found to accumulate large amounts of cGMP,
attributed to abnormally low cGMP PDE activity, strongly implicating defective
cGMP metabolism in photoreceptor
degeneration. In vitro studies by Lolley et al. (1977) demonstrated the deleterious
effects of increased cGMP levels to retinal photoreceptors. Raised cGMP in toad
cultured cells, caused by addition of the unspecific PDE inhibitor 3-isobutyl-l-
methylxanthine (IBMX) in the culture medium, induced photoreceptor
degeneration. It therefore became necessary to elucidate the role of cGMP in the
visual cycle, in order to understand why photoreceptor cells degenerate in the
rd/rdl mouse.
Although a retinal degeneration mutation was long known to be present in the
C3H mouse strain, it was not until 1990 that Bowes et al. found that the mouse
rdl locus encodes the (3 subunit of the rod photoreceptor 3' 5' cGMP
phosphodiesterase (Pde6b). The product of Pde6b contributes to the rod
heterotetrameric phosphodiesterase complex (PDE a, (3, y, y) (Deterre et al., 1986;
Fung et al., 1990), which regulates cytoplasmic cGMP levels in rod
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Gene symbol Mode of Inheritance Protein Location
CERKL Recessive ceramide kinase-like protein 2q31.3
ABCA4 Recessive ATP-binding cassette transporter - retinal lp22.1
CA4 Dominant carbonic anhydrase IV 17q23.2
CNGA1 Recessive rod cGMP-gated channel alpha subunit 4pl2
CRB1 Recessive crumbs homolog l 1 q31.3
CRX Dominant
cone-rod otx-like photoreceptor homeobox
transcription factor
19q 13.32
GUCA1B Dominant guanylate cyclase activating protein IB 6p21.1
IMPDH1 Dominant inosine monophosphate dehydrogenase 1 7q32.1
LRAT Recessive lecithin retinol acyltransferase 4q32.1
MERTK Recessive c-merprotooncogene receptor tyrosine kinase 2q 13
NRL Dominant, recessive neural retina lucine zipper 14ql 1.2
PDE6A Recessive cGMP phosphodiesterase alpha subunit 5q33.1
PDE6B Recessive rod cGMP phosphodiesterase beta subunit 4pl6.3
PRPF3 Dominant








human homolog of yeast pre-mRNA splicing
factor C8
17p 13.3
RDS Dominant peripherin 2 6p21.2
RGR Recessive RPE-retinal Gprotein-coupled receptor 1Oq23 1
RHO Dominant, recessive rhodopsin 3q22.1
RLBP1 Recessive cellular retinaldehyde-binding protein 15q26.1
ROM1 Dominant rod outer segment membrane protein 1 1 lq 12.3
RP1 Dominant, recessive RP1 protein 8q 12.1
RP2 X-linked RP2 protein similar to human cofactorC Xp 11.23
RP22 Recessive not identified 16pl2.3-pl2.1
RP23 X-linked not identified Xp22
RP24 X-linked not identified Xq26-q27
RP25 Recessive not identified 6cen-ql5
RP28 Recessive not identified 2p 16-p 11
RP29 Recessive not identified 4q32-q34
RP31 Dominant not identified 9p22-pl3
RP32 Recessive not identified lp34.3-p 13.3
RP33 Dominant not identified 2cen-ql2.1
RP6 X-linked not identified Xp21.3-p21.2
RP9 Dominant PIMl-kinase associated protein 1 7pl4.3
RPE65 Recessive pigment epithelium-specific 65 kD protein lp31.2
RPGR X-linked retinitis pigmentosa GTPase regulator Xpll.4
SAG Recessive arrestin (s-antigen) 2q37.1
SEMA4A Dominant semaphorin 4A lq22
TULP1 Recessive tubby-like protein 1 6p21.31
USH2A Recessive usherin lq41
Table 1: Genes implicated in non-syndromal forms of retinitis pigmentosa
photoreceptors in response to light. On light stimulation, PDE is activated by the
removal of the two inhibitory y subunits, resulting in decreased cGMP levels and
the hyperpolarisation of the rod cell. Failure to form a normal PDE complex
compromises the enzyme's activity, reducing cGMP hydrolysis and leading to
increased cGMP concentration and rod degeneration (Hussain et al., 1992). The
destructive effect ofmutated rod cGMP PDE on photoreceptor survival is further
highlighted by the fact that more than 95% of retinal cGMP is present in
photoreceptor cells (Cohen, 1984). An equally high percentage of cGMP in the
cells' outer segments may be bound to the cGMP enzyme PDE (Pugh & Lamb,
1990). Therefore, as discussed by Hussain et al. (1992), defective PDE, which has
a higher Km and, hence, a lower affinity for cGMP, results in an increased free
concentration of cGMP in the outer segments. The cGMP-gated cation channels
therefore remain permanently open, which increases the intracellular levels of
several ions, including calcium. The latter has been implicated in a number of
disease phenotypes, and can influence guanylate cyclase, rhodopsin and/or PDE
activities. It can also potentially modulate both the function and survival of
photoreceptor cells, including the light-response recovery, rod sensitivity and
light adaptation (Pepe et al., 1986; Wagner et al., 1989). Ultimately the ionic
imbalance observed in mutated photoreceptors may lead to their death by
apoptosis.
1.2.2.1.2. Rod cGMP phosphodiesterase 6b: the atypical retinal
degeneration 1 mutation (Pde6batrdl)
As part of the MRC Harwell ENU mutagenesis program, new models of retinal
degeneration were identified. N-ethyl-N-nitrosourea (ENU) is an alkylating agent
that, when injected into mouse spermatogonial stem cells, acts as a powerful
mutagen by creating point mutations at random across the genome (Justice et al.,
1999). Its ethyl group can be transferred to oxygen or nitrogen radicals in DNA
and, if not repaired, result in mispairing or base pair substitutions, inducing many
different types ofmutant alleles (Justice et al., 1999). The mutagenesis
programme involves mating of ENU-mutagenised male BALB/C mice to C3H
females, to produce F1 progeny that are then screened for the phenotype of
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interest, in this case, eye defects (Thaung et al., 2002). Because C3H mice are
homozygous for the Pde6brc" allele, all the F1 mice screened were heterozygous
for the recessive Pde6brdI allele, which enabled Thaung et al. (2002) to identify
seven mutant lines that carried new recessive alleles of Pde6b. The phenotype of
four of these lines was indistinguishable from that of the rdl allele in C3H, and
these were named retinal degeneration 1,1-4 Harwell (Pde6brdI'U4H). On fundus
examination, the remaining three new mutant lines appeared to have a near-
normal retina at 3 weeks of age compared with the degenerated retina observed in
age-matched C3H mice. These lines were named atypical retinal degenerations
(atrd) 1-3 (Pde6batrd'~3). Subsequent work by the same group analysed the
timescale of retinal degeneration in these new models ofRP. Indeed, the atrd
mutants showed slower onset of retinal degeneration as determined by visual
acuity testing (the mice responded well to a rotating drum at 3.5 weeks, but were
effectively blind by 10 weeks), fundus examination (near normal fundus at 3.5
weeks, discolouring of optic disks by 6 weeks and indistinguishable from rdl
homozygotes by 10 weeks) and histology (mild cell loss at 3.5 weeks but rapid
progression thereafter) (Hart et al., 2005).
1.2.2.1.3. Rhodopsin knockout mouse
The involvement of rhodopsin in the process of vision has been postulated from
as early as the 19th century, and a large amount of research has established its
central role in phototransduction.
The structure of the mouse rhodopsin gene (Rho), as well as that of its
transcription and translation products, were analysed by Baehr et al. (1988) and
the protein's function has been reviewed by Garriga & Manyosa (2002). The gene
is found on mouse chromosome 6, is just over 3 kilobases long and has 5 exons.
Despite a difference in the length of the introns, the length of the exons is
identical between the species homologues. At the nucleotide level, the mouse
sequence of rhodopsin is 62% and 59% identical to the human and bovine
sequences, respectively. Rhodopsin consists of the 348-amino-acid protein opsin
and the 11 -cA-retinal chromophore, which are covalently attached. It belongs to
the G-protein coupled receptor superfamily, members of which share a seven-
transmembrane helical structure and activate G-proteins upon ligand binding. In
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the case of the visual system, the G-protein is transducin. Rhodopsin is the main
protein component of the rod OS disks in vertebrate retina, comprising about 70%
of the total protein (Baehr et al., 1988). The amino-terminus of the protein resides
within the lumen of the disk, whereas the carboxy-terminus is in the cytoplasm
(Humphries et al., 1992).
Light activation triggers a cascade of events that result in cell signalling.
Upon exposure to light, the 11-cA-retinal attached to opsin isomerises to all-trans-
retinal, which leads to the activation of transducin, by the exchange ofGDP for
GTP. The signal is considerably amplified during propagation until
hyperpolarisation of the cell occurs and a reduction in the rate of photoreceptor
neurotransmission that is perceived as light (Baehr et al., 1988).
Although initial research focused on understanding the function of
rhodopsin, it was not until after the gene was cloned (Nathans & Hogness, 1984)
and an autosomal dominant RP gene was mapped to this locus (Humphries et al.,
1992) that mutations in its sequence were identified (Dryja et al., 1990a, 1990b,
1991). This subsequently led to the association of rhodopsin with visual
impairment. Indeed mutations in RHO, residing on human chromosome 3,
account for 25-30% of autosomal dominant RP (RetNet at
http://www.sph.uth.tmc.edu/Retnet/home.htm). Experimentally-induced or
genetically-inherited mutations in rhodopsin have thrown light on the importance
of rhodopsin, not only in terms of its biochemical role in visual transduction but
also in maintaining the integrity of the retina. Different laboratories have therefore
produced mouse lines expressing rhodopsin either at different levels or with
different mutations (Olsson et al., 1992; Naash et al., 1993).
Olsson et al. (1992) made a transgenic mouse line that carried a mutant
(P23H) human allele. The animals showed marked photoreceptor degeneration by
P20, although the inner retinal layers appeared normal. Also, Naash et al. (1993)
established a transgenic mouse line that carried a mutated mouse opsin gene in
addition to the endogenous opsin gene. Three amino-acid substitutions were made
(V20G, P23H, P27L) near the N-terminus of rhodopsin in exon 1. The
heterozygous animals appeared initially to develop normal photoreceptors but
these failed to reach full length. The number of both rods and cones decreased
with age, which was reflected also by the gradual decrease in light-evoked ERG
responses.
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Humphries et al. (1997) produced a rhodopsin knockout (KO) mouse by
targeted disruption of the Rho gene by homologous recombination. They
introduced a neomycin resistance cassette within the second exon of the gene,
which resulted in reduced levels of rhodopsin mRNA and protein as detected by
reverse transcription-polymerase chain reaction (RT-PCR) and
immunohistochemistry, respectively. Since this is one of the retinal degeneration
models used in this project, its phenotype will be described in more detail. At
P24, homozygous mutant animals had normal numbers of rod nuclei, normal
ONL thickness but no rod OS. The ONL began to thin at P30 and was absent by
P90. Preliminary ERGs showed that there was no dark-adapted (rod) response at 8
weeks, whereas substantial light-adapted responses were present in younger
animals. The mice otherwise developed normally. The heterozygotes retained the
majority of their photoreceptors but the IS and OS displayed some structural
disorganisation, the OS becoming shorter with age. Analysis of retinal sections at
4 months of age revealed that heterozygotes had thinner ONL and shorter OS.
They appeared otherwise normal, although there was evidence of some
disorganisation. The homozygous mutants showed a declining number of
photoreceptor cells with age. At P48, the ONL was reduced to 4-5 rows of nuclei
and the inner and outer segments were even thinner. Finally by P90, a single layer
of nuclei was left in the ONL, indicating completion of the photoreceptor
degeneration. Degeneration was relatively uniform from the periphery to the
central retina. Electron microscopy on 27-day old rhodopsin mutant eyes revealed
that the region between the outer limiting membrane (between IS and OS) and the
RPE contains material primarily of IS origin, including cilia, basal bodies and
mitochondria. No intact OS material was found. Therefore, even at this young age
there was no evidence of rod OS in animals lacking functional rhodopsin genes.
Immunohistochemical analysis of rhodopsin in 8-week old animals from all three
genotypes showed positive staining in the wild-type and the heterozygote but no
immunoreactivity in the mutant. Evidence of photoreceptor disorganisation was
seen in the heterozygote. Finally, dark-adapted (rod) ERG responses from 10 and
13 week old animals were similar to wild-types and heterozygotes. ERGs were
absent however in the homozygous mutants. The light-adapted (cone) ERG
responses were slightly reduced in the homozygous mutants only.
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Subsequently, different groups generated alternative mouse models with
reduced or absent of rhodopsin expression (Lem et al., 1999; Toda et al., 1999;
Frederick et al., 2001; Liang et al., 2004) and confirmed the early photoreceptor
degeneration described by Humphries et al. (1997). Additionally, Sung et al.
(1994) studied a naturally occurring stop codon mutation that removes the last
five amino acids of rhodopsin (Q334ter). These authors observed an abnormal
accumulation ofmutant rhodopsin in the plasma membrane of photoreceptor
cells, indicating that the C-terminus of rhodopsin is required for transportation to
or retention in the outer segments.
Most of the work mentioned above focused on the effects of decreased or
absent rhodopsin expression on photoreceptor structure or survival. Tan et al.
(2001) however demonstrated that over-expression of wild-type rhodopsin can
also lead to photoreceptor degeneration. A two-fold increase in opsin expression
was accompanied by a 33% increase in 11 -cis retinal levels and resulted in a
reduction of the ERG a-wave amplitudes, which were indistinguishable from the
background. Even a 23% increase in opsin levels was sufficient to induce
degeneration similar to the various retinal degeneration mouse models.
Work on many different rhodopsin mutant models has showed that most
mutations confer similar phenotypes, characterised by photoreceptor degeneration
that is completed within a few months of age. In a review discussing the
molecular genetics of RP, Humphries et al. (1992) raised the question as to how
mutations in rhodopsin cause RP. Does phototransduction have any direct
relevance to the manifestation ofRP? The fact that rhodopsin functions as a light-
absorbing protein might be coincidental. Another possibility is that some mutant
rhodopsin molecules may not be efficiently transported from the ER after
translation, compromising the function and structure ofphotoreceptor cells. If the
mutant proteins do get transferred to the outer segment disks, this may destabilise
the disks. It is therefore still not clear what molecular mechanism underlies the RP
phenotype when rhodopsin is mutated.
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1.2.2.1.4. Peripherin 2: the retinal degeneration slow mutation
(.Prph2rds)
The slowly progressing retinal degeneration associated with a spontaneous
mutation in the peripherin 2 gene (Prph2'ds) was first reported in the inbred mouse
strain 020/A by van Nie et al. (1978) and soon after the same group mapped the
gene to mouse chromosome 17 (Demant et al., 1979). It was over a decade before
a candidate gene was identified (Travis et al., 1989) and another 6 years before
the exact nature of the mutation, which prevented the translation of the gene, was
revealed (Ma et al., 1995). The first evidence as to the nature of the Prph2 gene
came from two papers published in 1991. Firstly, Travis et al. (1991) showed that
Prph2 is a 39 kDa, 346 amino acid, photoreceptor-specific integral membrane
component ofOS discs, which is responsible for the rds mutation. Subsequently,
Connell et al. (1991) found that there was a 92.5% identity at the protein level
between a known bovine protein called peripherin and the candidate Rds protein
identified by Travis et al. (1991). Not much was known about the function of
peripherin at the time, apart from the fact that it is found in rod photoreceptor
cells along the rim region of the OS discs.
During the decade between mapping the gene to chromosome 17 and
identifying its genetic basis, there was extensive phenotypic analysis of the
mutant mice. In a wild-type mouse, the retina takes three weeks to fully develop
(Young, 1984). The photoreceptor cells of 7-day-old retinas have an IS, but no
OS. The latter starts to form at P10 and its development and elongation are
completed by P21. In the homozygous mutant rds retina while P7 retinas are
identical to wild-type (Sanyal et al., 1984), there is a subsequent failure to
develop OS. Loss of photoreceptor cells begins from as early as 2 weeks of age
and thereafter, the ONL, OPL and photoreceptor layers begin to reduce in
thickness (Sanyal et al., 1980, 1984). Photoreceptor degeneration is more rapid up
to the age of 2-3 months (Sanyal et al., 1980; Nir et al., 1990) but the loss is
distributed over many months (Cohen, 1983; Sanyal et al., 1980). The inner
retinal layers and the RPE remain unaffected until after loss of visual cells, when
structural changes begin to involve the entire retina (Sanyal et al., 1980). With the
gradual decline of the photoreceptors in older animals, the IS appear to be reduced
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in length and contained fewer mitochondria and other organelles (Jansen &
Sanyal, 1984).
The expression of some other photoreceptor proteins is also altered in the
mutants. Prph2 is normally detected predominantly in the OS layer of rod-
dominant bovine and mouse photoreceptors, but in the homozygous mutant it is
absent and in the heterozygous mutant there is ectopic labelling in the IS (Molday
et al., 1994). Opsin mRNA and protein levels are also significantly lower in
homozygous mutants (Schalken et al., 1985), due to reduction in the synthesis of
opsin (Nir et al., 1990). At the onset of degeneration, some of the photoreceptor
cells show positive opsin expression (Nir et al., 1990; Jansen et al., 1987), which
in older retina is localised to elongated membranes emanating from a few ciliary
tips (Nir et al., 1990).
Biochemical analysis performed in rds/rds mutants revealed that cGMP
levels are decreased in the mutant (Sanyal et al., 1984; Sanyal, 1984), whereas
cAMP PDE activity is higher (Sanyal, 1984). This is in agreement with the
observation that cAMP is less concentrated in the photoreceptor outer segments,
whereas cGMP is preferentially concentrated in OS (Orr et al., 1976).
In terms of understanding the molecular basis underlying the retinal
degeneration in the rds/rds mutants there have been a number of suggestions. The
morphological observation that the formation of the disks, an essential step in the
development of the OS, is blocked from the first week of retinal development in
the rds/rds retina (Jansen & Sanyal 1984), while the degeneration takes a year to
be completed, demands an explanation. Travis et al., (1991) suggested that
photoreceptor degeneration might be happening because of three different
possibilities. Firstly, photoreceptor cells degenerate because of prolonged oxygen
toxicity. Steinberg (1987) showed that p02 is 120 mmHg at the level of the OS as
a result of the high density of choroidal capillaries in the area, and drops to 30
mmHg at the level of the IS, due to their high metabolic activity. Lack of OS
would therefore impose a high p02 on the IS. Secondly, failure to form OS may
lead to metabolic changes that, in turn, might cause degeneration. Finally,
degeneration could be explained by a loss of trophic factors, provided by other
retinal cells, like RPE or Muller cells that are required by OS. Previously Nir et
al., (1990) suggested that mutated Prph2 compromises a key metabolic process
and the defect of disc morphogenesis is only one of its downstream consequences.
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It seems however that a structural, rather than biochemical, role is attributable to
Prph2. Travis et al., (1991) proposed that the Prph2 protein stabilises discs
through either homophilic or heterophilic interactions with itself or with another
disc membrane protein, now known to be the rod outer segment membrane
protein 1 (Roml) (Bascom et al., 1992; Molday, 1994) This is compatible with
the postulate that lack of Prph2 would not prevent membrane biogenesis, but
would block the subsequent folding ofmembranes into discs, which is in fact the
case.
In conclusion, the retinal location of Prph2 and the phenotype associated
with the rds mutation both suggest that this membrane protein may play a role in
the assembly, morphogenesis and maintenance of the disk rim structure (Connell
etal., 1991; Molday, 1994).
1.3. The link between apoptosis, reactive oxygen species and RP
In the first part of the Introduction (section 1.1.2.) the generation of ROS in
mitochondria was discussed, as well as their damaging effects on DNA, protein
and lipids. Cellular defence mechanisms exist which protect against oxidative
stress, either at the stage of its generation or later, when it attacks cellular
molecules. In the second part of the Introduction (section 1.2.1.) a description of
the mouse eye was given, and its anatomy and function were discussed. Attention
was focused on photoreceptor cells since mutations in photoreceptor-specific
genes have been implicated in apoptotic cell death during RP-type retinal
degeneration.
The main question in this project is concerned with whether there is a link
between oxidative stress and retinal degeneration. If the answer is positive, what
is the role of oxidative stress in the disease phenotype? A number of points
support the assertion that there is a link between the two.
1.3.1. The susceptibility of the retina
The retina is particularly sensitive to oxidative damage (Figure 10) (Winkler et
al., 1999). Firstly, it is constantly exposed to different wavelengths of light, some
of which can cause injury to photoreceptor cells (Noell et al., 1966). Secondly,
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there is a high concentration of polyunsaturated fatty acids (PUFAs) in the outer
segments (op den Kamp, 1979; Stone et al., 1979), which can participate in
oxidative chain reactions that result in the disruption of retinal structure. Thirdly,
there is a high oxygen tension in the outer retina originating from the choroidal
blood flow (Rodieck, 1973). Towards the tip of the outer segments the oxygen
partial pressure is about 120 mm Hg, and it drops to about 30 mm Hg towards the
photoreceptor inner segment (Steinberg, 1987). Fourthly, rod photoreceptors have
one of the highest rates of energy utilisation of any cell in the body. The
metabolic rate, as this is reflected by oxygen consumption, has been reported to
be much higher in the retina than in most other tissues (Rodieck, 1973). For
example, in the human retina, the total rate of oxygen consumption has been
calculated to be 23 ml/ lOOg of retina/ minute (Rodieck, 1973), which is about 7
times higher than that reported for the brain (Kety & Schmidt, 1948). The
increased Na+K+ ATPase activity supporting the 'dark current', the high rate of
cGMP turnover and neurotransmission, each require large amounts of energy in
the retina, which is generated mainly by oxidative metabolism (Ames et al.,
1992). Finally, in the IS of photoreceptors there is a high density ofmitochondria
and high concentration of oxidative enzymes. Using electron microscopy, it was
demonstrated that the apical portion of rod IS has dense aggregates of
mitochondria (Sjostrand, 1953). Lowry et al. (1956) showed that, in the IS of
rabbit and monkey retinas, there was increased activity of the mitochondrial
enzymes malate dehydrogenase (MDH) and glutamic-aspartic transaminase.
Lastly, high cytochrome c oxidase (COX) and succinate dehydrogenase (SDH)
activities have been found in photoreceptor IS, using different staining methods
(Wislocki & Sidman, 1954; Andrews et al., 1999). For all these reasons, the retina
is particularly sensitive to metabolic stress, including oxidative stress.
68
Choroidal blood flow
Figure 10: The susceptibility of the retina
The factors that make the retina particularly susceptible to damage from
oxidative stress are shown. The retina is constantly exposed to visible light,
there is a high concentration of polyunsaturated fatty acids (PUFAs) in the
outer segments, there is high oxygen tension imposed on the cell due to their
close proximity to the choroidal blood flow, and there is a high density of
mitochondria in the inner segment.
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1.3.2. Mechanisms of cell death
Programmed cell death (PCD) is an essential event that takes place during both
development and disease. It is initiated by specific signals and requires both de
novo and controlled gene expression. PCD serves to remove unwanted cells from
a multicellular organism (Schwartz et al., 1993). There are different mechanisms
by which it can occur, namely apoptosis and autophagy, each ofwhich has
distinctive morphological, biochemical and physiological characteristics. In
autophagy, a cell destroys itself by digesting its own constituents. It is
characterised by the formation of large autophagosomes, autolysosomes,
autophagic vacuoles, myelin whorls, multivesicular bodies and engulfment of
entire organelles (Bursch, 2000; Larsen & Sulzer, 2002). Its genetic regulation is
not well understood. Morphologically, apoptosis is characterised by the
circularisation of the cell, nuclear and chromatin condensation, DNA
fragmentation, cytoplasmic vacuolisation, disruption of the nuclear envelope and
formation of vesicles (apoptotic bodies) destined for degradation and
phagocytosis by neighbouring cells such as macrophages (Kerr et al., 1987;
Bursch, 2000; Larsen & Sulzer, 2002). In addition to these two types of PCD, cell
death can also occur via necrosis, which is an unprogrammed type of cell death
and is the outcome of severe disruption of cellular processes (Allan et al., 1987).
Necrosis is characterised by mitochondrial swelling, rupture of internal and
plasma membranes, chromatin aggregation, nucleus invagination, organelle lysis
and eventually total disintegration of organised structures (Allan et al., 1987; Hall
etal., 1997).
The terms PCD and apoptosis are often used interchangeably, since the
latter is the best studied type of cell death. It has been repeatedly demonstrated
that apoptosis is triggered by various stimuli, including cellular stress, loss of
housekeeping functions and/or developmental signals. Once triggered, apoptosis
can be executed through different pathways, which involve members of a family
of cysteine proteases called caspases. Apoptosis can occur via three different
pathways; either via death receptors, involving caspase 8, or mediated by ER
stress and involving caspase 12, or by the intrinsic ormitochondrial pathway,
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mediated by mitochondria (Rao et al., 2004). The latter pathway is ofparticular
interest to this project as it involves the mitochondrion, the organelle that is not
only the major source of oxidative stress in the cell, but also the major source of
cellular energy, therefore controlling both the life and death of a cell.
The molecular events underlying this 'intrinsic' pathway of apoptosis have
been extensively studied (Figure 11) (Blackstone & Green, 1999; Green &
Kroemer, 2004; Spierings et al., 2005; Heath-Engel & Shore, 2006). It is defined
by the process ofmitochondrial outer membrane permeabilisation (MOMP). The
latter is both executed and regulated by members of the B-cell
leukemia/lymphoma 2 (BCL-2) protein family, which interact with the MOM and
with each other to activate or inhibit the release of apoptosis-promoting proteins
from the mitochondrial IMS. MOMP can happen either with or without the
involvement of the MIM (Green et al., 2004). In the former case, the non¬
selective mitochondrial permeability transition pore (MPTP) is formed by
constituents ofboth the MIM and the MOM. It leads to loss of the membrane
potential (Avj/m) and swelling of the mitochondrial matrix. This swelling can
disrupt the MOM and lead to MOMP (Green & Reed, 1998). If the MIM is not
involved, then members of the BCL-2 family, such as Bax and Bak, can act
directly on the MOM and cause MOMP. Upon MOMP, there is cytosolic release
ofproteins, like cytochrome c, HSP10, Smac, Omi, endonuclease G, and
apoptosis inducing factor (AIF), that are normally residing in the IMS. Once
released, cytochrome c interacts with apoptotic peptidase activating factor 1
(APAF1), changes its conformation and the two oligomerise to form part of the
apoptosome. The latter activates caspase 9 by causing it to dimerise, which in turn
activates the downstream 'executor' caspases 3 and 7, by cleaving the





Figure 11: The intrinsic pathway of apoptosis.
Upon stimulation of MOMP, cytochrome c is released from the
mitochondrial IMS into the cytosol, where it interacts with Apafl and
activates caspase 9. The latter then activates the executor caspase 3. The
initiation of apoptosis by MOMP is inhibited by Bcl2 but promoted by both
Bak and Bax. Together with cytochrome c, smac (DIABLO) is also
released and blocks the pro-apoptotic action of IAF (Modified image from
Mak et at. Arthritis Res 2002 4(Suppl 3): S243).
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Inhibitory and activating interactions between anti- and pro-apoptotic proteins
orchestrate apoptosis. Inhibitor of apoptosis proteins (IAPs) bind and ubiquitinate
caspases for proteasomal degradation. IAPs are themselves blocked by IAP
inhibitors, like second mitochondria-derived activator of caspases (Smac). AIF
translocates from the IMS to the nucleus via the cytosol to promote DNA
condensation (Cande et al, 2002). Also, the protein Omi is released from the IMS
into the cytosol, where it promotes apoptosis by blocking inhibitors (Wolf&
Green, 2002).
In some types of apoptosis, the morphology, intra-organellar organisation
and intracellular location ofmitochondria change, prior to cytochrome c release.
Mitochondrial morphology is determined by fusion and fission events and can
range from multiple spherical organelles to branched, tubular structures (Bereiter-
Hahn et al., 1994; Bleazard et al., 1999). Skulachev et al. (2004, 2006) showed
that during apoptosis there is massive 'thread-grain' transition from extended to
small round-shaped mitochondria. These move from the periphery of the cell
towards the nucleus, possibly to enable released proteins, such as endonuclease G,
to enter the nucleus for the execution of final apoptotic events.
The fission ofmitochondria and MOMP are both required but are not
sufficient for subsequent release of cytochrome c (Heath-Engel & Shore, 2006).
They have to be accompanied by remodelling of cristae, infoldings of the MIM,
2+where about 85% of cytochrome c is stored. This remodeling depends on Ca
released from the ER (Germain et al., 2002) and involves both fusion of
individual cristae and opening of the junctions between them and the IMS
(Scorrano et al., 2002).
It is also noteworthy that although caspases are believed to be the principal
proteins orchestrating and carrying out apoptosis (Samali et al., 1999; Slee et al.,
1999a, 1999b; Wolf & Green, 1999), a caspase-independent apoptosis pathway
also exists (Borner & Monney, 1999). This was discovered when apoptotic
phenotypes were still evident despite inhibition of caspases using Z-VAD.fmk
(McCarthy et al., 1997). As Borner and Monney (1999) discuss however, the non-
specificity of these inhibitors and/or the possible existence of as yet unidentified
caspases does not rule out the involvement of caspases in every apoptotic
pathway. However, in degenerating photoreceptor cells both during development
(Donovan et al., 2001) and in the rd/rd mouse model for RP (Donovan & Cotter,
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2002) a decreased level of APAF1 and a lack of release of cytochrome c from
mitochondria, indicate failure to form an apoptosome which would subsequently
activate caspases, consistent with an alternative apoptotic pathway.
1.3.3. Apoptosis and reactive oxygen species
The involvement ofmitochondria in apoptosis, and the fact that it is the major
source of oxidative stress in the cell, implicate ROS in this type of cell death.
Additionally, the dual nature of cytochrome c, as both an electron carrier in the
ETC and a pro-apoptotic substance released during apoptosis, supports the link
between oxidative stress and apoptosis. Indeed, the involvement ofROS and
cellular REDOX state in apoptosis has been the focus of a number of reviews (e.g.
Blackstone & Green, 1999), which suggest that ROS can be both a triggering
factor for apoptosis and a downstream consequence of it. Buttke & Sandstrom
(1994) point out that many chemical or physical treatments, like ionisation or UV
irradiation, are capable of inducing apoptosis and also evoke oxidative stress.
Increase of ROS, for example by exposure to low doses of H2O2 (Barbouti et al.
2002) or depletion of antioxidants (Matsui et al., 2003), has also been shown to
result in apoptosis in various cell types.
An antioxidant role for BCL-2 has also been proposed in the context of
cell death. In vitro work by Hockenbery et al. (1993), investigating the generation
of ROS during apoptosis, showed that cell death induced by H2O2 treatment or
interleukin 3-deprivation was blocked by BCL-2 or was repressed by GPX4 but
not by SOD2. Also, the antioxidant N-acetyl cysteine, which increases GSH, was
also shown to partially inhibit apoptosis. These results point towards a prominent
role for ROS in cell death and an antioxidant role for BCL-2 after O2"* and H2O2
production. BCL-2 has also been shown to block cell death induced by gamma-
irradiation, which produces hydroxyl radicals by direct radiolytic attack on water
(Blok & Loman, 1986; Sentman et al., 1991). Finally, Zhong et al. (1993)
reported that BCL-2 can inhibit the death of a neural cell line due to a range of
stimuli, including membrane peroxidation and free radical-induced damage
caused by menadione. It has been suggested that BCL-2 acts either as a direct
radical scavenging protein, or as a metal-binding protein (Kane et al., 1993).
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Jacobson and Raff (1995) argued however that protection against PCD by
BCL-2 is independent of its ability to inhibit the effects of ROS. Although
antioxidants have been shown to block certain ROS-dependent signal transduction
pathways that induce PCD, they do not block the effector phase of PCD. These
authors therefore concluded that ROS are not an essential part of PCD, but can be
generated as a consequence of it.
Nevertheless, genetic evidence for a role of ROS in cell death is suggested
by familial amyotrophic lateral sclerosis, since mutations in the antioxidant
enzyme SOD1 argue strongly for ROS-mediated loss ofmotor neurons (Rosen et
al., 1993).
1.3.4. Apoptosis and retinal degeneration
The cell death pathway by which photoreceptor cells degenerate in response to
different stimuli has been addressed in a number of papers (Travis, 1998; Pierce,
2001). It is apparent that there is not a single type of cell death associated with a
particular trigger for photoreceptor degeneration. The fact that markers for
apoptosis, autophagy and/or necrosis have been seen within a single model of
photoreceptor degeneration implies an overlap between them. It is known that
photoreceptor cell death in normal developing retina peaks at P7 and occurs
mainly by apoptosis (Young, 1984; Chang et al., 1993; Portera-Caillau et al.,
1994; Donovan & Cotter, 2002). Morphological signs of autophagy are observed
in the destruction ofphotoreceptor outer segments by the RPE (Reme et al.,
1999), although this is best described as heterophagy. Autophagy has also been
implicated in developmental retinal cell death (Guimaraes et al., 2003).
Photoreceptor degeneration induced by light damage has been shown to occur by
apoptosis (Donovan et al., 2001; Donovan & Cotter, 2002; Hao et al. 2002; Lohr
et al., 2006), necrosis (Moriya et al., 1986; Zhang et al., 2005; Lohr et al., 2006)
and/or autophagy (Reme et al., 1999; Lohr et al., 2006). In vitro work on
2+
chemically-msulted cultured retinal neurons, by Ca" overload or ceramide
synthesis inhibition, demonstrated apoptotic death of these cells (He et al., 2000;
Germain et al., 2006). Finally, photoreceptor degeneration in a rat model for
ischemia-reperfusion was also shown to occur through apoptosis (Katai &
Yoshimura, 1999).
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RP is a diverse group of hereditary disorders and consequently our interest
lies in the mechanisms by which photoreceptor cells die in response to different
genetic mutations, rather than as part of the tissue development or in response to
external insults. Photoreceptor degeneration in the rdl/rdl mouse model occurs
by apoptosis, as this has been repeatedly shown to include intra-nucleosomal
DNA fragmentation (Chang et ah, 1993; Lolley et ah, 1994; Portera-Cailliau et
ah, 1994). Nevertheless, signs of autophagy and necrosis have also been observed
in degenerating rdl/rdl retinas (Lohr et al., 2006). In the rds mouse model for
RP, which fails to produce a protein necessary for efficient OS formation,
photoreceptors have been shown to die by apoptosis (Chang et al., 1993; Portera-
Cailliau et ah, 1994; Lohr et ah, 2006), although signs of neuro-inflammation,
usually associated with necrosis (Allan et ah, 1987), have also been observed
(Lohr et ah, 2006). Finally, in the rhodopsin knockout mouse model,
photoreceptor degeneration occurs by apoptosis (Chang et ah, 1993; Portera-
Cailliau et ah, 1994) and there has been no evidence of alternative types of cell
death.
1.3.5. Reactive oxygen species and retinal degeneration
Evidence for a link between apoptosis and oxidative stress, as well as between
apoptosis and retinal degeneration has been presented. Is there evidence for an
involvement of oxidative stress in retinal degenerations?
Working in vitro, Sanvicens et ah (2004) investigated the role of oxidative
stress in photoreceptor degeneration, by treating the photoreceptor-related cell
line 661W with the nitric oxide donor sodium nitroprusside. ROS production did
increase in mitochondria and this in turn triggered the apoptosis of these cells, in a
manner requiring both calpains and caspases.
Photoreceptor degeneration in BALB/C mice following exposure to
• • • 2"h
excessive levels of white light was accompanied by increased intracellular Ca
levels, generation ofCV'and mitochondrial depolarisation (Donovan et ah, 2001),
all of which are signs of oxidative stress. Additionally, degeneration in this model
was successfully prevented by treatment with a nitric oxide synthase inhibitor,
indicating a role for nitric oxide in light damage.
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A direct involvement of oxygen toxicity in photoreceptor degeneration
was suggested by a study by Yamada et al. (2001). The authors exposed wild-type
mice to 75% O2 for one or two weeks. No effects were observed at the first time-
point, but the thickness of the ONL was significantly reduced after a 2-week
exposure, showing that hyperoxia can lead to photoreceptor cell death. However,
these concentrations of oxygen are unlikely to occur in vivo during retinal
degeneration.
The involvement of oxidative stress in the rdl/rdl and rds/rds mouse
retinal degeneration mutants has been suggested by Lohr et al. (2006). These
authors compared the relative expression of ceruloplasmin and clusterin during
these retinal degenerations. In the rd/rdl mutant, these markers of oxidative stress
were constitutively over-expressed, and in the rds/rds mutant they were also
elevated to varying degrees throughout the period studied.
Very little work has been done on investigating the effect of decreased
Sod2 expression in retinal diseases. Sandbach et al. (2001) analysed the ocular
pathology of Sod2-deficient mice. They studied Sod2~' mice at P10 and P20, since
their survival time was extended by the use of the Sod-mimetic, MnTBAP. In 10-
day-old mice, only the photoreceptor layer in the central retina was thinner when
compared to controls of the same age. In 20-day-old animals, both the INL and
the photoreceptor layers were thinner, while the RPE was the same as in wild-
type. The total retinal thickness was reduced compared to controls of the same
age. While the total retinal thickness in wild-type mice increased significantly
between P10 and P20, this was not the case for Sod2-deficient mice. The optic
nerve was smaller in the 20-day-old Sod2-deficient animals, but the extra-ocular
muscles appeared to be normal. In summary, mice showing homozygous Sod2
deficiency, a major antioxidant enzyme, showed a retinal degeneration phenotype.
This implies that oxidative stress can cause photoreceptor degeneration. Thus far




The rationale behind this project was stimulated by the publication of two papers.
The first one is a review on the mechanisms of cell death in inherited retinal
degenerations by Travis (1998). The author first discusses the genetic
heterogeneity ofRP, since mutations in 40 genes have been found to lead to
nonsyndromic RP, 30 of which have been identified (Table 1). These genes
influence many different aspects of photoreceptor and RPE function.
Additionally, mutations in genes whose expression is not confined to the retina
can cause photoreceptor degeneration as a secondary phenotype (e.g. tissue
inhibitor ofmetalloproteinase 3, TIMP3) (Fariss et al., 1998). According to Travis
(1998), this heterogeneity reflects the increased vulnerability of photoreceptor
cells, which, as discussed above, can be attributed to light exposure, high oxygen
tension imposed by the choroidal blood flow, high polyunsaturated lipid content
and the high metabolic rate of these cells. Irrespective of the genetic trigger and
the subsequent structural or metabolic changes leading to photoreceptor
degeneration, Travis (1998) suggested that the predominant mode of cell death in
all inherited retinal degenerations is apoptosis.
This proposal has to be reconciled with a paper that was published a few
years later by Clarke et al. (2001). These authors observed that in some models of
photoreceptor degeneration, the probability of cell death does not increase with
time and, instead of exhibiting sigmoidal kinetics, is consistent with exponential
kinetics (Figure 12). The model was called the 'one-hit model' and supports a
constant or decreasing probability of cell death with time, which is random and
independent of the death of any other cell. It contradicts the widely accepted
'cumulative damage' hypothesis, according to which neurons gradually
accumulate damage until a threshold is reached, after which the homeostasis of













Figure 12: Schematic representation of the kinetics of cell loss
Constant and increasing risk of neuronal death manifest as an exponential
or sigmoidal decline in cell number, respectively. [Image from Clarke et al.,
2001]
Clarke et al. (2001) suggest that this 'one-hit' model can be explained in
terms of a mutant steady state (MSS). Mutant neurons show an abnormal MSS,
but function normally and are at a constant, not increasing, risk of death during
the course of the degeneration. Alterations in the expression/function of a few
mutant-response genes/proteins are proposed to result in the crossing of the
threshold that leads to apoptosis.
The concept of a MSS was taken further byWright et al. (2004) and the
importance of oxidative stress as an underlying factor in retinal degeneration was
proposed. The authors examined the allometric relationships between rates of
neurodegeneration resulting from equivalent mutations in a diverse group of
genes from five mammalian species (mouse, rat, dog, pig and human) with
different maximum lifespan potentials (LSP). The rates of retina and brain
neurodegenerations varied by up to two orders ofmagnitude and were strongly
correlated with LSP and rates ofmitochondrial ROS production. Cell death in
these disorders is known to occur via the intrinsic apoptotic pathway and hence
the dual role ofmitochondria, as the mediator of this pathway and as the major
source ofROS, suggests that these two functions are linked. Wright et al. (2004)
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therefore proposed that redox status is a principal factor that sets the probability
of cell death in response to a diverse range of cellular stressors (Figure 13).
This influence is probably exerted at the level ofMOMP, as the pro- and
anti-apoptotic protein-lipid interactions in the mitochondrial membrane regulate
the commitment to apoptosis. The mitochondrion therefore acts as a stress sensor
where different types of stress integrate and determine the probability of
apoptosis. By changing the steady state level of oxidative stress within
mitochondria, rates of apoptosis would change accordingly, irrespective of the

















Figure 13: Species differences in rates of neurodegeneration on the
mitochondrial regulation of apoptosis
Species- and cell type-specific differences in steady state ROS production
are suggested to influence mitochondrial regulation of apoptosis and
apoptotic thresholds. The precise mechanism is unclear but may involve
altering ROS-mediated signalling pathways and/or influencing the degree
of oxidative damage to mitochondrial components of the apoptotic
machinery. [Image from Wright et at., 2004]
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The proposed model byWright et al. (2004) can be applied to RP. As
shown in Table 1, mutations in 40 genes have been implicated in photoreceptor
degeneration. These mutations are in a wide range of functionally different genes
and pathways which impose distinct types of stress to the cells. For example,
mutated RHO impairs visual transduction and may cause ER stress (Galy et al.,
2005), whereas mutated peripherin 2 compromises the formation ofOS. Each of
these mutations affects the apoptotic threshold of cells via different routes and
could influence MOMP, a critical step in the intrinsic apoptotic pathway.
Apoptotic thresholds are also influenced by ROS production, which is directly
implicated in some neurodegenerative diseases, like Alzheimer's disease and
Parkinson's disease. The differences in degeneration rates between species and
their correlation with ROS production (Wright et al., 2004), as well as cell
differences in ROS production and oxygen consumption (Hogan et al., 1971),
further suggest that ROS affect apoptotic thresholds. Oxidative stress does not
need to be directly implicated in a disease phenotype for constitutive ROS
production to affect apoptotic thresholds. Indeed, in some neurodegenerative
diseases, like the retinal degenerations caused by splicing factor mutations
(Hutton et al., 1998) there is no evidence for increased oxidative stress. Growth
factor withdrawal can influence MOMP and cell death without a direct effect on
oxidative stress (Leveillard et al., 2004). However, when the disease does cause
increased oxidative stress, this, combined with the species- and cell type-specific
steady-state ROS production, can further influence the probability of apoptosis.
As a result, modifying ROS production by altering their proposed influence on the
apoptotic machinery should affect the probability of cell death, regardless of
whether oxidative stress is directly implicated in the disease. Photoreceptors are
vulnerable cells because they are already exposed to high oxidative stress (Travis,
1998). They are therefore presumed to have an increased steady state ROS
production, which may increase the probability of apoptosis occurring compared
with other tissues. An additional insult in the form of any of the mutations known
to cause RP would therefore result in crossing of the apoptotic threshold and cell
death. This vulnerability could explain the extreme genetic heterogeneity
observed in RP.
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1.5. The current project
This project investigates the importance of oxidative stress in photoreceptor
degeneration. The hypothesis under test is that oxidative stress either directly or
indirectly influences the probability of apoptosis in photoreceptor degeneration.
Alteration of the cell's oxidative state should therefore change the rate of
photoreceptor degeneration. Decreased expression of the Sod2 gene should
increase the rate of cell loss, whereas increased antioxidant defence should slow it
down. Firstly, the mouse mutants retinal degeneration 1 (rdl/rdl), atypical retinal
degeneration 1 (atrdl/atrdl), rhodopsin knockout (R/zo"/_) and peripherin/retinal
degeneration slow (rds/rds) were investigated for evidence of oxidative damage,
by analysis of oxidative stress markers. The mutants were also crossed to a
superoxide dismutase 2 heterozygous mouse (Sod2+/~), which has decreased
mitochondrial antioxidant activity, to examine the effect on disease progression.
Finally, mutants were treated with the mitochondrially-targeted antioxidant
MitoQ, following a preliminary study assessing its toxicity by oral administration.
The rates of photoreceptor degeneration were estimated and the cellular REDOX







Different mouse mutants ofMus musculus were used in this project. All
procedures were carried out according to the Home Office's guidelines. Mice
were fed ad libitum and kept under standard lighting with a 12 hr light:dark cycle.
Sod2+i~ mice were provided by Dr. C.J. Epstein (University ofCalifornia, San
Francisco) and were on a C57BL/6J background. Prph2"k,nhm\cz were provided
by Dr. Robin Ali (UCL, London) and were on a CBA background. Rho ' mice, on
a C57BL/6 background, were made available by Dr. Peter Humphries (Trinity
College, Dublin). The Pde6brdI/rdl and Pde6batrd,/atrd' mice, both on a C3H
background, were provided by Prof. Ian Jackson (MRC HGU, Edinburgh). Each
retinal degeneration mutant was crossed to Sod2+/~ heterozygous mice to produce
double mutants.
2.2. Tissue collection
i. Ear-clips collected from the animals were used for DNA extraction and
genotyping.
ii. Following the culling of the animal by cervical dislocation, the eyes were
removed using L-shaped forceps and placed immediately in tubes on ice.
iii. For retina extraction and subsequent protein isolation, the eyes were
incubated in ice-cold PBS. Under a light microscope, at a magnification of x20,
the posterior part of the eye was immobilised with L-shaped forceps, and using a
metallic scalpel, a sagittal incision was made on the front of the eye at the centre.
Using fine forceps, pressure was then imposed on the back, at the area of the optic
nerve head, to push first the lens out, followed by the retina. Occasionally the
RPE was attached to the retina, which was removed with forceps.
iv. For tissue sectioning the eyes were incubated either in ice-cold phosphate
buffered saline (PBS) or ice-cold 4% paraformaldehyde (PFA).
2.3. Molecular genetic techniques
2.3.1. Animal genotyping
Animals were genotyped initially by Polymerase Chain Reaction (PCR) using




DNA was extracted from ear-clips taken from the animals. The clips were
incubated in 100 pi 25mM NaOH/0.2M EDTA and heated for 20 min at 95°C
using a PGR block. The incubation buffer was neutralised by addition of 100 pi of
40 mM Tris-HCl. The samples were finally mixed by vortexing and stored at 4°C.
This results in DNA in a buffer containing 20mM Tris-HCl / 0. ImM EDTA at
~pH 8.1 with ~25mM Na~ ions which is suitable for storing DNA.
2.3.3. Polymerase chain reaction
2.3.3.1. Primer design
The web resource Primer 3 (Rozen and Skaletsky, 2000) was used to aid design of
oligonucleotide primers, supplied as lyophilised pellets by MWG Biotech or
Sigma. Stocks were adjusted to 100 pmol/pl with dH20, mixed by inverting
overnight (o/n) at 4°C and stored at -20°C. 10 pmol/pl dilutions were prepared,
aliquoted and stored at -20°C for use in reactions.
2.3.3.2. PCR conditions
PCR was used to amplify the genomic regions of interest. All PCRs were carried
out in the following mixture:
Reagent Stock concentration Volume (pi) Final Concentration
dNTPs* 2 mM 2.5 0.2 mM
Buffer* x 10 2.5 x 1
MgCl2* 50 mM 0.75 1.5 mM
Taq Platinum* 5 units/pl 0.2 0.04 units




* Reagents supplied by Invitrogen
The primers and PCR conditions, for genotyping each mutant, are shown in the
table below.
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PCR conditions Primer info
TemplateAnnealing T °C Fragment size Direction Primer sequence 5'»3'
Sod2+/~ 56 wild-type 501 bp forward (shared) CGAGGGGCATCTAGTGGAGAA
mutant 400 bp reverse (wild-type) TTAGGGCTCAGGTTTGTCCAGAA
reverse (mutant) CACACATCGGGAAAATGGTTT
Pde6brdl 60 277 bp forward ACCTGAGCTCACAGAAAGGC
reverse GCTTCTAGCTGGGCAAAGTG
Pde6ba,rdl 53 224 bp forward TTGAAGATGCAGTGCCACAT
reverse CAGCCCAGAGGAGAAACAAC
Rho'~ 61 wild-type 394 bp forward (shared) TTCAAGCCCAAGCTTTCGCG
mutant 139 bp reverse (wild-type) AGGTTAGAGCTGGAGGACTG
reverse (mutant) TAAGACTGATTGGACCATTC
Prph2rds 57 wild-type 350 bp forward (shared) TCAAAGAGCCAGACGAGAAGT
mutant 250 bp reverse (wild-type) CCCGTTCTTCACAGACCAGG
reverse (mutant) TGGGCTGTATATGAATGAAAATC
2.3.3.3. Electrophoresis
To estimate the size ofDNA fragments that were amplified by PCR, the products
were separated by agarose gel electrophoresis. Agarose gels ('Hi Pure' Low,
BioGene) of the appropriate percentage (usually 2%) were prepared in 0.5x TBE
buffer (20x stock: 216 g Tris base, 110 g boric acid, 18.6 g EDTA, make to 1 litre
with dH20) with 0.2 mg/ml ethidium bromide. The PCR samples were incubated
in lx agarose gel DNA loading buffer (Stock 6x: 25 pg bromophenol blue, 25 pg
xylene cyanol, 3 ml glycerol, 6.95 ml H2O), loaded in a gel immersed in 0.5xTBE
buffer and run at 150 V for about one hour. The bands were visualised using a UV
transilluminator (Syngene). The size marker used routinely was bacteriophage
lambda DNA digested with Hindlll (DNA Marker X, Roche).
2.3.4. Purification of DNA gel bands
Fragments that were separated on agarose gels and required further manipulation
for analysis were excised and purified using the gel extraction kit by Qiagen,
according to the manufacturers' instructions.
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The rdl/rdl and atrdl/atrdl samples were purified in this way prior to
restriction digests and sequencing, respectively.
2.3.5. Restriction enzyme digests
Restriction enzymes were supplied by Boehringer Mannheim or by New England
Biolabs. The amount of each enzyme added was 5% or less of the final reaction
volume, using the appropriate lOx buffer diluted to lx concentration with dHaO.
Digests were left at 37°C for several hours or o/n before the digested fragments
were separated by electrophoresis on an agarose gel.
The rdl/rdl PCR products were digested with Ddel and SnaBI. The rdl
mutation in exon 7 of the Pde6b gene converts a SnaBI restriction site
(TAC/GTA; wild-type) to a Ddel site (C/TNAG; mutant).
2.3.6. Sequence analysis
Sequence analysis was required for genotyping the atrdl/atrdl mutants.
Following amplification of the desired genomic fragment by PCR, extraction of
the band from the agarose gel and purification using the Qiagen kit as described
above, the DNA sequence was analysed using the following protocol set up in a
96-well plate.
Sequencing reaction:
Extracted DNA 1 pi
Primer 1 pi







96 °C 5 min
96 °C 30 sec
55 °C 15 sec x 35 cycles
60 °C 4 min
12 °C forever
DNA precipitation:
Following sequencing, 5 pi of 125 mM EDTA and 60 gil of 100% alcohol were
added to each well and the mix was allowed to stand for at least 15 min at room
temperature (RT). The plate was sealed and centrifuged at 3,500 rpm for 30 min
at RT. The seal was then removed and the plate was turned up-side-down and re-
centrifuged at 1,000 g for 1 min to remove the supernatant (s/n). The pellet was
washed with 100 pi of 70% alcohol and the plate was centrifuged at 3,600 rpm for
10 min at RT, before removing the s/n as before. Finally the plate was allowed to
fully dry at RT for at least 15 min.
Sequencing products were separated using an ABI 3100 by FIGU technical staff.
Sequencing traces were analysed using Sequencher software.
2.4. Histological and histochemical methods
2.4.1. Preparation of frozen sections
2.4.1.1. Freezing of mouse eyes
Immediately after excision from the animal, the eyes were incubated in ice-cold
PBS and further processed as soon as possible. Working in a fume-hood, the eyes
were snap-frozen in melting iso-pentane and then incubated in OCT™ embedding
compound (Raymond Lamb) in appropriate small plastic vials (Agar Scientific).
The latter containing the frozen eyes, were then immersed in liquid nitrogen until
fully frozen, and placed into a -70 °C freezer for long-term storage.
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2.4.1.2. Sectioning of frozen mouse eyes
A Leica CM 3050S cryostat was used for cutting semi-thin frozen sections of
mouse eyes. The chamber and blade temperatures varied from -18 °C to -24 °C,
and the thickness of the sections ranged from 2 to 10 pm. Once cut, the sections
were transferred to glass slides, air-dried for one hour and either used
immediately or stored in slide mailers (Agar Scientific) at -20°C.
2.4.2. Preparation of paraffin-embedded sections
2.4.2.1. Paraffin-embedding of mouse eyes
Immediately after excision from the animal, the eyes were incubated in 4% PFA
for 15-20 hours at 4°C. They were then dehydrated by 30-minute incubations in
30%, 50% and 70% alcohol, prior to a series of 40-minute incubations in 70%,
85%, 95% and 2x100% alcohol, 2x in xylene and finally 4x in wax. These
incubations were done using the semi-automated Tissue-Tek® VIP™ tissue
processor (Miles Scientific). At the end of the program, the eyes were transferred
into moulds with molten wax, and following orientation using a pair of forceps,
the wax was allowed to set on ice.
2.4.2.2. Sectioning of paraffin-embedded mouse eyes
The wax block, with the specimen embedded in it, was trimmed to the desired
size and the edges angled to improve the capture of sections. The wax-embedded
tissue was sectioned at 5-10 pm on a microtome (Leica MZ6) and strips of
sections were floated out in a 47 °C water bath. With the aid of fine paintbrushes,
the sections were transferred to slides (Superfrost® Plus, BDH) and the slides
incubated at 65°C o/n to allow sections to dry.
2.4.2.3. De-waxing
To remove the wax from wax-embedded tissue sections, slides were incubated 3x
in xylene for 10 min each, followed by three 10-minute incubations in 100%
alcohol and single 10-minute incubations in 90%, 70%, 50%, 30% alcohol and
finally running tap water.
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2.4.3. Haematoxylin and Eosin (H&E) procedure
Tissue cryosections were air-dried for 15 min at RT, fixed for 10 minutes in
formal calcium solution (3.6% (v/v) formaldehyde, 1.1% (w/v) calcium chloride)
(Baker 1958) and then washed in dfhO.
Paraffin sections were de-waxed and washed in dffiO.
For both types of section, sequential incubations in haematoxylin (5 min),
acid/alcohol (10 sec), lithium carbonate (10 sec) and eosin (5 min) were
interrupted by 1-min-washes in running tap water. Finally, dehydration through
alcohols (3x5 min in 100% alcohol), clearing (3x5 min in xylene) and
mounting in distrine plastizer xylenlene (DPX) completed the staining procedure.
The slides were analysed by bright field microscopy.
2.4.4. Outer nuclear layer (ONL) analysis
Following the de-waxing of paraffin-embedded eye sections that included the
optic nerve head (ONH), the sections were stained with H&E as described above.
Using a bright field microscope and the IPLab program, images were taken at a
x40 or x60 magnification at the middle of the distance between the ONH and the
edge of the retina at each side. The number of rows of nuclei in the outer nuclear
layer (ONL) and the inner nuclear layer (INL) were counted and the data
transferred into Microsoft Excel files for analysis.
2.4.5. Dual COX/SDH histochemistry
Individual reactions for cytochrome c oxidase (COX) (Old & Johnson, 1989) and
succinate dehydrogenase (SDH) (Old & Johnson, 1989) were combined in order
to detect cells with no histochemically demonstrable COX activity.
The COX reaction medium was prepared by combining 200 pi
cytochrome c stock solution (500 pM cytochrome c in 0.2 M phosphate buffer pH
7.0) and 800 pi 3,3'-diaminobenzidine tetrahydrochloride (DAB) stock solution
(5 mM DAB in 0.2 M phosphate buffer pH 7.0).
The SDH reaction medium was prepared by combining 100 pi sodium
succinate stock solution (1.3 M sodium succinate), 10 pi sodium azide stock
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solution (100 mM sodium azide) and 800 pi NitroBlue Tetrazolium (NBT) stock
solution (1.875 mM NBT). All stock solutions were prepared in 0.2 M phosphate
buffer pH 7.0.
2pm-thick cryosections were air-dried for an hour at RT. The sections
were first incubated in the COX buffer at 37°C for 50 minutes. They were then
washed 3x5 min in PBS before being incubated in the SDH buffer at 37°C for 45
minutes. Sections were washed 3 x 5min in PBS (pH 7.4) and dehydrated in a
graded alcohol series (30, 50, 70, 90, 100%). They were then incubated for an
additional 10 minutes in 100% alcohol to remove all residual purple SDH stain.
Finally the sections were cleared in clearing agent (Histoclear; National
Diagnostics) and mounted in DPX (R.A. Lamb, Eastbourne, UK).
2.4.6. Terminal deoxynucleotidyl transferase-mediated dUTP
Nick End Labelling (TUNEL)
The commercial TUNEL kit, DeadEnd™ Fluorometric TUNEL System, supplied
by Promega, was applied on paraffin-embedded tissue sections of 5-10 pm
thickness and the manufacturer's instructions followed. The sections were de-
paraffinised by immersion in fresh xylene in a Coplin jar for 2 x 5min and
incubated in 100% alcohol for the same amount of time. They were then re-
hydrated by incubation in a series of alcohols (100%, 90%, 70%, 50%) for 3 min
in each, washed in 0.85% NaCl for 5min, followed by a 5-minute wash in PBS,
fixing in 4% methanol-free formaldehyde (MFF; 75 ml PBS, 25 ml 16%
methanol-free formaldehyde solution, pH 7.4) solution in PBS for 15min, and
permeabilising by treatment with proteinase K (20 pg/ml) for 8-10 min. Two 5-
minute washes in PBS were interrupted by an additional fixation step in 4% MFF
solution for 5 min, before the sections were covered with equilibration buffer for
10-15 min. All the incubations up to this point were done at RT. They were then
treated with recombinant terminal deoxynucleotidyl transferase (rTdT) Incubation
Buffer, including rTdT enzyme, labelled nucleotides and equilibration buffer, and
incubated at 37 °C for 1 hour in the dark. The reaction was terminated by
immersion of the slides in 2x saline-sodium citrate (SSC; 87.7 g NaCl, 44.1 g
sodium citrate, 500 ml dH20, pH 7.2) for 15 min at RT, followed by three 5-
minute washes in PBS and another three in dH20. Finally, the slides were
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mounted in Vectashield (Vector laboratories) with DAPI and analysed under a
fluorescence microscope.
For this protocol the proposed positive controls were sections treated with
DNase 1(10 u/ml) for 10 min at RT, prior to incubation in the reaction mix. The
negative control was a section treated with the reaction mix lacking the rTdT
enzyme.
2.4.7. Immunohistochemistry
De-waxed sections were circled with a wax pen and washed with PBS before
incubation in blocking agent (PBS with 1% BSA) for at least 2 hours at RT.
Sections were the incubated o/n with primary antibody in blocking agent at 4 °C,
followed by 2 hours of 20 min PBS washes. Sections incubated with a
fluorescently labelled secondary antibody in blocking agent for 2 hours at RT,
followed by 2 hours of 20 min PBS washes. Slides were mounted with
Vectashield mounting medium. Slides could be stored at 4 °C for several weeks.
2.4.8. Antigen retrieval
Since antigens are often affected by the processing ofwax sections, for effective
staining with antibodies, an antigen retrieval step was used. De-waxed sections
were incubated in 0.01 M tri-Sodium citrate and 0.01 M citric acid pH 6.0 (41 ml
0.1 M tri-sodium citrate, 9 ml citric acid, 450 ml dHiO) and boiled in a
microwave at full power for 20 minutes. They were then allowed to cool down to
RT and were briefly washed in PBS before any further use.
2.4.9. Antibodies used for immunohistochemistry
































































2.5.1. Protein extraction and quantification
The tissue was homogenised on ice, using a Dounce homogeniser, in a buffer
containing 1520 pi PBS, 400 pi 2% Triton-X 100 and 80pl of protease inhibitors.
Following centrifugation for 5 minutes at 100 g, the supernatant of the sample
was retained.
The protein concentration of the preparation was measured using the
Coomassie-Blue-based Bradford spectrophotometric assay (Pierce). Standard
curves were prepared using BSA in appropriate incubation buffers.
2.5.2. Western Blotting
Two different methods were followed for separating proteins, using either 'home¬
made' or pre-cast one-dimensional gels.
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2.5.2.1. Protein separation using Laemmli one-dimensional gels
Denaturing (SDS) polyacrylamide gel electrophoresis (PAGE) gels were prepared
in a Hoefer SE 600 Vertical Slab Unit. The appropriate percentage of resolving
gel was made (Sambrook et al., 1989) and poured to allow approximately 1 cm
below the comb for the stacking gel. It was then overlaid with 1 ml isobutanol
saturated with H2O, at a 1:1 ratio, while setting. Isobutanol was then washed away
and the stacking gel was poured on top of the resolving gel and allowed to set.






1.5 M Tris-HCl buffer pH 8.8 0 5 ml
1 M Tris-HCl buffer pH 6.8 2.4 ml 0
2% Bis-acrylamide 975 pi 2.68 ml
40% Acrylamide 1.8 ml 4.86 ml
20 % Sodium Dodecyl Sulfate (SDS) 188 pi 200 pi
10% Ammonium Persulfate (APS) 189 pi 200 pi
Tetramethylethylenediamine (TEMED) 37.5 pi 20 pi
dH20 13.35 ml 7.16 ml
Protein samples, with lx loading SDS-buffer (6x stock: 3.5 ml 1 M Tris-
HC1 pH 6.8, 3 ml glycerol, 1 g SDS, 0.93 g DTT, 1.2 mg bromophenol blue, made
up to 10 ml with dKbO), were denatured by heating at 70 °C for 20 minutes in a
PGR block and immediately returned to ice, prior to separation on the gel. A
Broad Range Protein Marker (BioRad) was used. The gels were run in lx SDS
running buffer (5x stock: 15.1 g Tris-base, 72 g glycine, 25 ml 25% SDS, make
up to 1 litre with water) at 50mV o/n or until the dye front reached the bottom of
the gel.
2.5.2.2. Protein separation using pre-cast NuPAGE Novex Bis-
Tris Gels (Invitrogen)
Protein samples were incubated with 2.5 pi 4x NuPAGE LDS Sample Buffer, 1 pi
lOx NuPAGE Reducing Agent and dH20 to a total volume of 10 pi. They were
then denatured at 70 °C for 10 min, prior to being loaded on 4-12% NuPAGE
Novex Bis-Tris Gels, immersed in lx SDS running buffer, prepared by adding 40
ml 20x NuPAGE MOPS SDS Running Buffer to 760 ml of dtEO. The SeeBlue
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Plus 2 prestained standard marker (Invitrogen) was used and the samples were run
for 45 min at 200 V constant voltage.
2.5.2.3. Semi-dry transfer of proteins to membranes
Depending on the protein separation protocol, different methods were used for the
transfer ofproteins onto membranes.
Following protein separation using Laemmli gels, proteins were
transferred to a Hybond-P membrane (Amersham Biosciences) using a semi-dry
transfer device (BioRad). The membrane was firstly pre-soaked in methanol, then
transferred in dFBO and finally transferred into transfer buffer (3.03 g Tris-base,
14.4 g glycine, 200 ml methanol, made up to 1 L with dfTO). Six pieces of filter
paper, the same size as the membrane, were also immersed in transfer buffer. On
the lower negative electrode of the transfer device, 3 pieces of filter paper, the
membrane, the gel with the separated proteins and finally another 3 pieces of filter
paper were layered in order. Air bubbles were removed by rolling a plastic roller
over the construct. Proteins were transferred at (1.5 x area) mA/cm2 or higher, at a
maximum of 25 V for 1-2 hrs.
2.5.2.4. Wet transfer of proteins to membranes
Following protein separation using the device supplied by Invitrogen, proteins
were transferred onto Hybond-P membrane according to the manufacturer's
instructions. A Hybond-P membrane and 2 pieces ofWhatman filter paper, cut to
the size of the gel, and blotting pads provided by the manufacturer were soaked in
transfer buffer. On the transfer device, starting from the cathode, 2 blotting pads,
a filter paper, the gel, the transfer membrane, another filter paper and finally 2
blotting pads were layered in order. Transfer of the protein was performed using
30 V constant voltage for 1 hour.
2.5.2.5. Ponceau staining
To ensure that the membrane transfer was successful, to allow the identification
of unstained markers and to verify equal loading of protein samples, the
membrane was stained with Ponceau S solution (Sigma) for several minutes and
de-stained in dH20.
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2.5.2.6. Immunodetection of proteins
2.5.2.7. Antibodies used in Western blots
Membranes were blocked for 30 min at RT or o/n at 4 °C in 5% non-fat dried
milk in Tris buffered saline with Tween (TBST: 10 ml 1M Tris-base pH 7.5, 30
ml 5M NaCl, 1 ml Tween 20, made up to 1 litre with H2O) on a rotary shaker,
followed by three 5-minute washes in TBST. Membranes were incubated in
primary antibody diluted in 5% milk in TBST in a sealed bag on a rotator for 1
hour at RT, followed by three 5-minute washes in TBST. The membrane was then
treated with horseradish peroxidase (HRP)-conjugated secondary antibody in the
same way, followed by three more washes in TBST.
Detection of the secondary antibody was carried out with Enhanced
Chemiluminesence (ECL) Western blotting detection reagents (Amersham
Biosciences), according to the manufacturer's instructions. Following draining of
excess wash buffer, the membrane with the protein side up, was covered with
detection reagent (equal volumes of detection solutions 1 and 2). Incubation lasted
for 1 minute. Excess detection reagent was drained off and the membrane was
placed in an X-ray film exposure cassette. A sheet of Kodak X-Omat AR imaging
film was placed on top of the membrane and, following sufficient time for
exposure, a phosphorimager X-ray machine (Konica Minolta) was used for
development of the film.
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2.5.2.8. Antibodies used for Western Blottings













MnSOD (SOD2) Rabbit Human MnSOD Stressgen SOD-110
2.6. Biochemical procedures
2.6.1. Enzyme assays
2.6.1.1. Preparation of mitochondrial fractions from mouse tissues
The method described by Taylor & Turnbull (1997) was applied. The tissue was
collected on ice, washed in isolation medium (120 mM KC1, 20 mM HEPES, 5
mM MgCh, 1 mM EGTA pH 7.2, 5 mg/ml BSA) for removal of any blood,
drained on a filter paper and weighed in plastic Eppendorf tubes. Using a Dounce
homogeniser, the tissue was homogenised on ice in 5x weight/volume isolation
medium and the homogenate centrifuged at 600 g for 10 min at 4 °C. The s/n was
collected and re-centrifuged under the same conditions. The second s/n was used
for enzyme measurements.
The specific amount of protein used for each assay was not possible to
measure due to the increased amount of BSA in the preparation medium. A
typical volume of 1 to 10 pi of homogenate, corresponding to 0.2 to 2 mg of
tissue, was used for each assay, and the appropriate calculations were performed
for activity measurements in pmol/min/g tissue.
2.6.1.2. Spectrophotometry
All spectrophotometric assays were done using a dual-beam, temperature-
controlled Cary 300 UV-Vis spectrophotometer (Varian). Data was analysed
using Cary WinUV software (Varian).
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2.6.1.3. Citrate Synthase assay (Taylor & Turnbull, 1997)
2.6.1.3.1. Reagents
Assay medium: 100 mM Tris-HCl, pH 8.0
5 mM acetyl-coenzyme A (CoA)
10 mM 5,5'-dithiobis-2-nitrobenzoic acid (DTNB)
50 mM oxaloacetate (freshly prepared by incubation of 0.033 g oxalacetic acid in
250 pi KHC03)
10% Triton-X 100 (w/v)
2.6.1.3.2. Protocol
Citrate synthase activity was measured following the formation of 5-thio-2-
nitrobenzoate ion (NBT) at 412 nm (E412 = 13.6/cm/mM). One ml assay medium
was supplemented with 50 pM acetyl-CoA, 100 pM DTNB, mitochondrial
preparation and 0.1% (w/v) Triton-X 100. Addition of 250 pM oxaloacetate
started the enzymatic synthesis of citrate, during which the reduced coenzyme A
(CoA-SH) released from acetyl-CoA reacted with DTNB to yield NBT. The
reaction was measured for 2 min at 30 °C.
2.6.1.4. Complex I (NADH: ubiquinone oxidoreductase)
assay (Taylor & Turnbull, 1997)
2.6.1.4.1. Reagents
Assay medium: 25 mM potassium phosphate, pH 7.2; 5 mM MgCh; 3 mM KCN;
2.5 mg/ml BSA
13 mM NADH
65 mM ubiquinone-1 in ethanol
1 mg/ml antimycin A in ethanol
1 mg/ml rotenone in ethanol
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2.6.1.4.2. Protocol
The activity of complex I was measured by following the decrease in absorbance
due to the oxidation ofNADH at 340 nm with 425 nm as the reference
wavelength (E340 = 6.22/cm/mM).
Mitochondrial fractions were diluted in the hypotonic assay medium and
rapidly freeze-thawed three times in liquid nitrogen. 0.13 mM NADH, 65 mM
Ubiquinone-1 and 2 jag/ml antimycin A were added to the assay medium and the
absorbance change was recorded for 1 min to establish the baseline of the
reaction. Following addition ofmitochondrial preparations, NADH:ubiquinone
oxidoreductase activity was measured for 4-5 minutes (Slope I) prior to addition
of 3 pg/ml rotenone, after which the activity was measured for an additional 3-4
minutes (Slope II). Complex I activity was calculated as the rotenone-sensitive
NADH:oxidoreductase activity, as indicated by the difference between Slope I
and Slope II.
2.6.2. Reduced glutathione (GSH) measurements (Tietze,
1969)
2.6.2.1. Sample preparation
As soon as the tissue was collected from the animal, it was washed in ice-cold
0.9% NaCl solution to remove any blood and was weighed. Using a Dounce
homogeniser, it was then homogenised on ice in 5 x weight/volume ice-cold 3%
perchloric acid. The homogenised tissue was centrifuged at 9,000 g for 10
minutes at 4 °C and the supernatant was retained for glutathione measurement.
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2.6.2.2. GSH assay
The reaction mix included the reagents listed below at the concentrations and
volumes noted.






EDTA buffer pH 7.5
as stock as stock 450 pi
DTNB 2.7 mM 1.12 pM 0.06 pM 500 pi
Glutathione reductase as bought 20 pi
NADPH 4.8 pM as stock 0.12 pM 25 pi
GSH concentration was measured by the production ofNBT. The assay started
with the above reagents and the background absorption was measured for a few
seconds. A known amount of the GSH standard or the tissue sample was added
and the production ofNBT monitored spectrophotometrically at 412 nm at 25 °C
for 5 minutes.
2.6.2.3. GSH standard curves
The concentration of glutathione was determined by comparison with a standard
curve generated by using appropriate concentrations of purified reduced
glutathione. The volumes of the reagents used for the standard curve are given in
the table below.
GSH (pM) 0 0.01 0.02 0.05 0.1 0.2 0.5 1 1.5 2
all volumes in pi
BUFFER 0.455 0.455 0.454 0.453 0.450 0.445 0.430 0.405 0.380 0.355
DTNB 0.06 pM 0.500 0.500 0.500 0.500 0.500 0.500 0.500 0.500 0.500 0.500
GR (1:50) 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020
NADPH 0.12 pM 0.025 0.025 0.025 0.025 0.025 0.025 0.025 0.025 0.025 0.025
STANDARD GSH 0.000 0.001 0.001 0.003 0.005 0.010 0.025 0.050 0.075 0.100
100
2.7. Administration of substances to mice and related assays
2.7.1. MitoQ experiments
2.7.1.1. Administration ofMitoQ
MS010 (MitoQ) was supplied by Antipodean Pharmaceuticals (New Zealand). It
is a yellow powder, which is stored at 4 °C in the dark. It was administered to the
animals orally through the drinking water at a concentration of 500 pM unless
otherwise specified. The water bottles were covered with tin foil to keep the
solution in the dark. Fresh dilutions were made and administered every three days.
2.7.2. IBTP experiments
2.7.2.1. In vivo administration of IBTP
4-iodobutyl-triphenylphosphonium (IBTP) was supplied by Antipodean
Pharmaceuticals (New Zealand) as a lyophilised powder and was stored in the
dark at 4°C. It was administered to animals orally through the drinking water at a
concentration of 500 pM and fresh dilutions were made and administered every
three days. The water bottles were covered with tin foil.
2.7.2.2. In vitro use of IBTP
2.7.2.3. Preparation ofmitochondrial fractions
Mitochondria from different mouse tissues were prepared by homogenisation in
STE medium (250 mM sucrose, 5 mM Tris-HCl, 1 mM EGTA, pH 7.4) followed
by centrifugation at 2,400 rpm for 10 minutes at 4 °C. Protein concentration was
determined as described in Section 2.5.1.
2.7.2.4. Energisation of mitochondrial fractions and IBTP
treatment
Mitochondrial fractions were energised by incubation in KC1 buffer (110 mM
KC1, 10 mM Hepes, 1 mM EGTA, pH 7.2) containing 10 mM succinate and 8 pg
/ml rotenone for 5 minutes at RT. Addition of 5 pM IBTP and subsequent
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incubation at 30 °C for 15 minutes, was followed by repeated washing steps after
centrifugation at 600 g and re-suspension in STE medium. The samples were
finally suspended in a small volume of STE and their protein concentrations
measured as described above.
2.7.2.5. Detection of IBTP
Following its use both in vivo and in vitro, IBTP was detected immunologically
on Western blots. Control (non-treated) and treated samples of known
concentration were loaded on denaturing SDS PAGE gels and separated
electrophoretically using the protocols described in sections 2.5.5.2 and 2.5.2.4
were followed. The primary antibody provided by Antipodean Pharmaceuticals
(New Zealand), was raised in rabbit and typically used at a dilution of 1:2,000.
2.7.3. 3H-MitoQ experiments
2.7.3.1. Administration of 3H-MitoQ
Tritium-labelled MitoQ (0.743 mCi/ml) was provided by Antipodean
Pharmaceuticals (New Zealand) in a liquid form and stored in the dark at -20 °C.
It was administered to wild-type animals orally, through their drinking water, for
a period of 10 days. 0.0743 pCi of 3H-MitoQ was added to 500 pM dilutions of
unlabelled MitoQ and, to minimise handling and contamination with
radioactivity, the total volume required for the 10-day experiment was prepared at
the start of the assay and then stored in the dark at 4 °C.
2.7.3.2. Preparation of samples for scintillation
counting
Following the culling of the 3H-MitoQ administered animal, the tissues of interest
(heart, brain, liver and eyes) were quickly collected and placed in pre-weighed
Eppendorf tubes. The latter were weighed again to determine the weight of the
tissues. The tissue samples were then homogenised, using a Dounce homogeniser,
in ice-cold STE. The homogenates of known concentration (weight/ml) were
stored at -20 °C until assayed in a scintillation counter.
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2.7.3.3. Scintillation counting
The tritium content of the samples was measured in liquid scintillant (BDH) using
a LS 6500 Multi-Purpose scintillation counter (Beckman Counter™). In 5 ml
scintillation vials (LabLogic) samples of known protein content were mixed with
an equal volume of the scintillation fluid. The quenching program was set for 5
minutes.




Bench-top microcentrifugation Biofuge fresco Heraeus
Cassettes for film development Amersham
Coplin jars Agar Scientific








Microtome Reichert-Jung 2030 Biocut Leica
Microwave Proline Microchef
Oven (37 incubations) HERACell 240
Thermo Electron
Corporation
Paraffin section mounting bath Electrothermal
PCR machines PTC-225 MJ Research
pH meter Fisher Scientific




Scintillation counter LS 6500 Multi-Purpose Beckman Counter TM
Silica quartz cuvettes Ultrospec
Software programs Microsoft Excel Microsoft




6505 UV/Vis Spec Jenway
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UV illuminator Gene Genius Syngene
UVP Inc
VIP machine Tissue-Tek® Mikes Scientific
Vortexing Whirlmixer





Cassettes for VIP Tespa or Surgipath
Eppendorf pipettes (P2-P1000) Pipetman Gilson





Hybond-P membrane Amerxham Biosciences
Invitrogen gels Invitrogen
PAP pen Miles Scientific
Parrafin Tissue Tek III Sakura
PCR tubes (0.5or 1.5 ml) Eppendorf
Scalpel Swann-Morton
Scintillation vials FabFogic
Slide coverslips VWR International
Slide mailers Agar Scientific
Slides Microscope slides H.V. Skan Ltd
Superfrost slides BDH
Small plastic vials Agar Scientific
2.8.3. Reagents
2.8.3.1. - Molecular reagents
Reagents Supplier
Big Dye VIII ABI PRISM
Bromophenol blue BDH
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SnaBI New England Biolabs
Platinum Taq polymerase Invitrogen















Haematoxylin Raymond A. Lamb
Histoclear Raymond A. Lamb
Iso-pentane BDH GPR
Liquid nitrogen from Technical Services
Lithium carbonate Sigma
NaCl BDH AnalaR
NitroBlue tetrazolium (NBT) Sigma
OCT Raymond Lamb












Ammonium persulfate (APS) Sigma
Bis-acrylamide BioRad








Phosphate buffered saline from Technical Services
Ponceau S solution Sigma
Protease inhibitors Roche
Sodium Dodecyl Sulfate (SDS) Fisher Scientific










Bovine serum albumin (BSA) Sigma
Dithionitrobenzoic acid Sigma












Reduced GSH standard Aldrich
Rotenone Sigma






MEASURING OXIDATIVE STRESS AND
PHOTORECEPTOR DEGENERATION
3.1 Introduction
In this chapter the selection and optimisation of methods for the detection and
analysis of both retinal degeneration and oxidative stress in mouse retinal
degeneration mutants are discussed.
There are a number ofmethods available for following the progression of
retinal degenerative diseases. In humans, RP can be detected and studied by
functional assays, such as electroretinography (ERG), where the ability of the
photoreceptors to respond to light is assessed. When working with animal models,
the use of ERGs is technically difficult and requires specialised equipment, so that
it is most suitable for confirming structural changes at later stages of a project.
However, the ready availability ofmurine tissue samples allows the use ofwhole
mouse eyes for a straightforward experimental approach to monitor rates of
degeneration. The organisation of the retina into layers, each comprised of distinct
cell types, allows the counting of the number of cells present in the tissue and the
collection of information on its structural and functional integrity.
As discussed in the Introduction, the main cellular mechanism of
photoreceptor degeneration in inherited retinal degenerations, such as RP, is
apoptosis. Methods have been developed for studying apoptosis at the
morphological, molecular, biochemical and genetic levels. In this project, the
level of apoptosis in mouse retinal degeneration mutants was assessed by terminal
deoxynucleotidyl transferase dUTP nick end labelling (TUNEL) assays, by a
modified Annexin V assay and by immunohistochemistry for the apoptosis-
associated proteins poly (ADP-ribose) polymerase (PARP) and caspase 3.
Oxidative stress can be quantified either directly, by measuring the
production of free radicals, or indirectly, by measuring the extent of their
damaging effects. Although the direct measurement approach would be more
accurate, the short half-life of free radicals and their fast reactivity with target
molecules compromises this approach. Therefore, the level of oxidative stress in
this project was indirectly quantified via its damaging effects on macromolecules,
and methods for measuring oxidative damage at the DNA, protein and lipid level
were used. DNA damage was detected immunohistochemically for the DNA
lesion 7,8-dihydro-8-oxoguanine (8-oxoG) and indirectly by the cytochemical
assay cytochrome c oxidase/ succinate dehydrogenase (COX/SDH). Oxidative
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damage at the protein level was quantified both by immunohistochemistry for
nitrotyrosine (Ntyr), the major product obtained by the nitration of tyrosine by
peroxynitrite, and by spectrophotometric assays measuring the specific activities
of oxidative stress-sensitive enzymes. Finally, the level of lipid peroxidation in
the mutant samples was monitored by immunohistochemical assays for the two
major natural products of lipid peroxidation, namely 4-hydroxynonenal (HNE)
and malondialdehyde (MDA).
The methods of choice are introduced and briefly discussed below. The
optimised protocols of the methods that were eventually selected for measuring
oxidative stress and photoreceptor degeneration are outlined in detail in Chapter
2.
3.1.1 Measuring photoreceptor degeneration by outer nuclear
layer analysis
Outer nuclear layer (ONL) analysis is an unbiased method for following
photoreceptor degeneration. The basis of this method is purely observational. The
loss of nuclei in the ONL is a reflection of the degeneration of the corresponding
photoreceptor cells. As the phenotype of RP is predominantly characterised by the
loss of photoreceptor cells, the disease does not affect the survival of inner
nuclear layer (INL) cells. The thickness of the latter is therefore not affected,
making it a good internal control for measuring photoreceptor degeneration in
retinal degeneration mutants.
Retinal degeneration has often been analysed by ONL thickness analysis.
Sarra et al. (2001), investigated the beneficial effects of gene replacement therapy
on OS formation and photoreceptor function of the rds mouse and measured the
ONL thickness on semi-thin paraffin-embedded mouse eye sections, cut in the
horizontal plane. Only sections including the optic nerve head (ONH) were
included in their analysis, which was based on measuring the area covered by the
ONL in section fragments at set distances from the ONH. Frederick et al. (2001)
studied the mechanisms leading to photoreceptor degeneration in mouse models
of autosomal dominant RP and also followed the progression of photoreceptor
degeneration by counting the number of rows of nuclei present in the ONL.
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3.1.2 Measuring apoptosis
3.1.2.1 Terminal deoxynucleotidyl transferase dUTP nick
end labelling (TUNEL) assay
The terminal deoxynucleotidyl transferase dUTP nick end labelling (TUNEL)
assay is commonly used for detection of apoptotic cells. Using chromatin
cleavage, the most characteristic feature of apoptotic cell death, as a marker,
Gavrieli et al. (1992) developed this method for in situ labelling ofDNA breaks.
The specificity of the assay is based on the binding of terminal deoxynucleotidyl
transferase (TdT) to the 3' OH end ofDNA, and the subsequent incorporation of
biotinylated deoxyuridine at these sites, resulting in the synthesis of
polydeoxynucleotide polymers. Avidin-peroxidation is used to amplify the signal
and the samples are analysed by conventional light microscopy.
3.1.2.2 Annexin V assay
Apoptotic cell death is often accompanied by changes in the structure of the cell's
plasma membrane (PM). The latter is highly asymmetric in its phospholipid
composition, with predominantly phosphatidylcholine and sphingomyelin on the
external leaflet, and phosphatidylethanolamine and phosphatidylserine (PS) on the
inner leaflet (Op den Kamp, 1979). Soon after the onset of apoptosis, PS is
translocated by flippases from the inner to the outer leaflet of the PM, which
functions as a tag for specific recognition by macrophages and subsequent
phagocytosis of the dying cells (Fadok et al., 2003). PS also becomes accessible
to the negatively charged phospholipid binding protein, annexin V, which
specifically binds PS in the presence of Ca2+ (Bevers et al., 1999).
3.1.2.3 Poly(ADP-ribose) polymerase (PARP) assay
The role of poly(ADP-ribose) polymerase (PARP) in apoptosis has been
extensively investigated (Uchida et al., 2001; Smulson et al. 1998; Diefenbach &
Burkle, 2005). PARP-1 acts as an endogenous detection system for DNA breaks.
Once activated, PARP-1 produces ADP-ribose polymers, causing the depletion of
intracellular NAD+ and a fall in ATP levels. NAD+, which requires ATP for its
production, serves as a precursor for NADP and regulates vital cellular processes.
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It is therefore proposed that cellular NADP depletion, following over-activation
of PARP-1, can lead to cell death if the energetic requirements for its re-synthesis
are not met. In early apoptotic cells, a transient PARP-1 stimulation leads to
poly(ADP ribose) accumulation. To prevent excessive NAD+ consumption and to
ensure that there is sufficient energy for execution of apoptosis, PARP1 is
inactivated by caspase-3 cleavage. Two fragments are generated: a 24-kDa
fragment, which stays in the nucleus, retains its DNA-binding activity and inhibits
the uncleaved nuclear PARP1, and an 89-kDa fragment that is transferred to the
cytoplasm at a late stage of apoptosis.
Commercially available antibodies that specifically detect the 85kDa
(apparent molecular weight) fragment of the caspase-cleaved PARP, but do not
detect the intact molecule, are available. Their specificity for the cleaved from of
PARP makes them good markers for apoptosis induced by a variety of
environmental stimuli, including free radicals and oxidising molecules.
3.1.2.4 Caspase 3 assay
It has been extensively documented that apoptosis is orchestrated by caspases,
which are proteins that are present in the cells as inactive precursors and require
proteolytic processing for activation. Once activated, caspases can themselves
proteolyse downstream caspases and generate a cascade of reactions that results in
the cleavage of key structural components, as well as of proteins critical for cell
survival (Wolf et al., 1999). Caspase-3, a key executioner of apoptosis, is
synthesised as a 32-kDa pro-enzyme and requires cleavage to its 17-20 kDa active
subunit. Its expression has been shown to be increased after IR injury both at the
gene and at the protein levels (Katai & Yoshimura, 1999). Additionally, caspase 3
activation has been reported during photoreceptor degeneration in transgenic rats
with the S334ter mutation in the rhodopsin gene. The specificity of caspase 3
activation in apoptosis makes it an ideal marker for detection of apoptotic cells in
mutant retinas
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3.1.3 Measuring oxidative damage
3.1.3.1 Measuring oxidative damage at the DNA level
3.1.3.1.1 7, 8-dihydro-8-oxoguanine assay
DNA is prone to oxidative damage and a number of different DNA lesions, in
both nuclear and mitochondrial DNA, have been reported following exposure to
different reactive agents, including UV light, ionising radiation and ROS. DNA
lesions can be generated in the form of base modifications or DNA strand breaks.
The most important, stable and well-studied product of oxidative DNA damage is
7,8-dihydro-8-oxoguanine (8-oxoG). If not repaired, this results in mutagenesis
due to G:C to T:A transversions during DNA synthesis (Shibutani et al., 1991).
3.1.3.1.2 Cytochrome oxidase/Succinate dehydrogenase (COX/SDH)
assay
Of particular interest in this project is the integrity of the mitochondrially-encoded
ETC subunits of cytochrome c oxidase (COX), which is the fourth complex of the
ETC that transfers electrons from the reduced cytochrome c to molecular oxygen
and at the same time pumps protons from the matrix into the IMS of
mitochondria. Of its 14 subunits, only three are encoded by mtDNA, the
remaining being nuclear encoded (Nijtmans et al., 2004). In contrast to COX,
succinate dehydrogenase (SDH), the second complex of the ETC, is only nuclear
encoded. This difference between the two complexes has been used for the
generation of reliable cytochemical methods to visualise the activities of these
complexes and to make inferences about damage to mtDNA. It is therefore
assumed that a compromised COX activity in the presence of intact SDH activity,
reflects damage to mtDNA. Due to the close proximity ofmtDNA to the main
source of oxidative stress in the cell, it is further postulated that compromised
COX activity is indicative of oxidatively damaged mtDNA.
The COX/SDH assay assesses the functional integrity of these two enzymes. The
failure of a cell to be stained brown for COX activity can indicate that
mitochondrially encoded COX subunits fail to assemble in the multi-subunit
enzyme. This type ofCOX-negative cell would then be easily detected by its blue
SDH-positive staining.
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3.1.3.2 Measuring oxidative damage at the lipid level
3.1.3.2.1 Hydroxynonenal and malondialdehyde assays
Additional potential targets of free radicals include cellular lipids. In this context,
the rod outer segment membranes of the retina are highly enriched in long chain
polyunsaturated fatty acids (PUFAs), making them highly susceptible to lipid
peroxidation.
Lipid peroxidation (LP) is a process that starts with the interaction
between free radicals and lipids and involves hydrogen abstraction from fatty
acids (Meagher & Fitzgerald, 2000; Yang et al., 2002). PUFAs are susceptible to
LP because of their double bonds that allow easy hydrogen abstraction by ROS.
The lipid peroxides that are formed are unstable compounds and tend to rapidly
degrade into a variety ofproducts, such as short-chain aldehydes, which are in
turn capable of covalent attachment to proteins by forming adducts with amino
acid residues. Such aldehydes are relatively stable and are therefore able to
diffuse out of the cell and attack distant targets. Malondialdehyde (MDA) and 4-
Hydroxynonenal (HNE) are the major LP products formed and commercially
available antibodies, capable of identifying these protein adducts are often used
for measuring levels of LP.
3.1.3.3 Measuring oxidative damage at the protein level
3.1.3.3.1 Nitrotyrosine assay
Protein tyrosine nitration is an additional marker for oxidative stress (reviewed by
Ischiropoulos, 2003). It is a covalent modification ofproteins that results from the
addition of a nitro group onto one of the two equivalent ortho carbons of the
aromatic ring of tyrosine residues. The source of nitrogen is nitric oxide (NO),
which can react with superoxide anions and form peroxynitrite that is in turn
capable of nitrating tyrosine residues in proteins and form nitrotyrosines (NTyr)
(McBride et al., 1999). The latter can be identified by commercially available
antibodies, which are often used to measure this form ofprotein modification.
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3.1.3.3.2 Enzyme assays
Increased levels of oxidative stress may result in reduction of the activity of
enzymes whose chemical and physical structures make them sensitive to such an
inactivation. For example, an enzyme with iron-sulfur (Fe-S) clusters is
particularly prone to inactivation because superoxide anions can react with the
iron to form hydroxyl radicals (Fenton reaction), which disturb its structure and
activity. Additionally, the close proximity of an enzyme to the source of free
radicals can also influence the degree of its oxidative damage.
3.1.3.3.2.1 Citrate synthase assay
Citrate synthase (CS) catalyses the first reaction of the citric acid cycle (Krebs
cycle), which is the condensation ofacetyl coenzyme A with oxaloacetate (OAA)
to form citrate and co-enzyme A (CoA-SH). It is localised in the mitochondrial
matrix, but is nuclear encoded, synthesised on cytoplasmic ribosomes and
subsequently transported into the mitochondrial matrix (Remington, 1992). CS is
commonly used as a quantitative enzyme marker for the presence ofmitochondria
and, since it has no iron-containing prosthetic groups or Fe-S centers, it is not
prone to inactivation by free radicals. The activity ofCS can be measured
spectrophotometrically in mitochondrial fractions prepared from tissue
homogenates, following the method of Shepherd and Garland (1969). The assay
medium contains Tris-HCl buffer at pH 8.0, which has been shown to be the
optimal pH for citrate synthase activity. This is supplemented with acetyl-
coenzyme A, 5,5'-dithiobis (2-nitrobenzoic acid) (DTNB), mitochondrial protein
and Triton-XlOO. The latter is a detergent that is required for the disruption of
mitochondrial membranes to ensure the complete release of total measurable CS
activity. As shown in Figure 14, the background absorption is measured for 10 to
20 seconds, before addition of excess OAA initiates the formation of citrate. The
CoA-SH released from acetyl CoA during the enzymatic synthesis of citrate
reacts with DTNB to yield 5-thio-2-nitrobenzoate ions, whose formation is
monitored at 412 nm (E412 = 13.6/cm/mM) for about one minute.
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Figure 14: The citrate synthase assay
(A) The activity of citrate synthase is measured spectrophotometrically for about 1.5
minutes at 412 nm. The background absorption is measured for about 30 seconds,
before addition of oxaloacetate (OAA) results in formation of citrate. (B) Typical
citrate synthase rate from a wild-type mouse retinal sample (C) Typical citrate
synthase rate from a mutant mouse retinal sample.
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3.1.3.3.2.2 Complex I assay
Complex I (CI), also known as NADH:ubiquinone oxidoreductase, is the first and
largest complex of the ETC. It removes two electrons from NADH and transfers
them to ubiquinone and at the same time pumps four protons out of the matrix,
contributing to the generation of the proton gradient. CI is a complex of 46
subunits, which include 8 Fe-S clusters (Brink et al., 1987; Nijtman et al., 2004).
As mentioned above, Fe-S clusters are prone to react with superoxide anions
(Fenton reaction) to produce hydroxyl radicals that compromise CI acivity.
Prior to assaying CI, the mitochondrial fractions prepared from tissue samples
need to be rapidly freeze-thawed three times in liquid nitrogen to ensure complete
release of total measurable CI activity. The assay medium includes potassium
phosphate at pH 7.2, MgC'E, KCN and BSA, as the latter increases rotenone
sensitivity in human skeletal muscle mitochondrial fractions. The medium is
hypotonic to further ensure measurement ofmaximum CI activity. At the start of
the assay, the reaction mix also includes the electron donor NADH, the electron
acceptor ubiquinone-1 and the complex III inhibitor, antimycin A. As shown in
Figure 15, the specific activity ofCI is measured by following the decrease in
absorbance due to the oxidation ofNADH at 340 nm with 425 nm as the
reference wavelength (E340 = 6.22/cm/mM, Ragan et al., 1988). Total
NADH:ubiquinone oxidoreductase activity is measured for 4-5 minutes (Rate 1)
before addition of rotenone, after which the assay is continued for a further 4-5
minutes (Rate 2). CI activity is calculated as the rotenone-sensitive
NADH:ubiquinone oxidoreductase activity by the substraction of the two rates,
prior and after rotenone addition (Rate 1- Rate 2). The difference between the two
rates reflects not only the activity ofCI but also the purity of the sample, as
contamination with other cellular compartments can increase the measurable
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Figure 15: The complex I assay
(A) The activity of complex I is measured spectrophotometrically for 10 minutes at 340 nm with 425
nm as reference. The background absorption is measured for a few seconds before addition of
mitochondrial protein. Total NADH:ubiquinone oxidoreductase activity is measured for 4-5 minutes
(Rate 1). After addition of rotenone the rate is measured for another 5-6 minutes (Rate 2). Complex
I activity is calculated as the rotenone-sensitive NADH:ubiquinone oxidoreductase, by the difference
between the two rates (Rate 1-Rate 2) (B) Typical complex I rate from a wild-type retinal sample (C)
Typical complex I rate from a mutant retinal sample.
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3.1.3.4 Measuring oxidative status
3.1.3.4.1 Reduced glutathione measurements
Glutathione is one of the most abundant soluble antioxidants in the brain
(Mytilineou et ah, 2002). It is a tripeptide containing cysteine, glycine and
glutamate which serves to detoxify hydrogen peroxide to water and oxygen,
together with the enzymes glutathione peroxidase (GPX) and glutathione
reductase (GR). Its active group is the cysteine thiol (-SH) (Pastore et al., 2003),
which helps maintain the cysteinyl-thiol groups of proteins in the reduced state
(Mytilineou et al., 2002).
Although the reduced glutathione (GSH) levels can be readily measured,
accurate measurement of oxidised glutathione (GSSG) is considered a challenge,
because of the much lower GSSG levels present within cells, the limited retina
availability, and the absence of a convenient chemical signature, which would
allow its robust measurement. The reduced form of glutathione can be measured
using a modified version of an assay first outlined by Tietze (Tietze, 1969) which
is based on the following chemical reactions
GSH + DTNB -» NBT + GS-NBT (Ellman reaction)
GS-NBT + GSH -» NBT + GSSG
GSSG + NADPH + H+ -*2 GSH + NADP+
DTNB + NADPH + H+ -» 2 NBT + NADP+
The sulfhydryl group ofGSH reacts with 5,5'-dithiobis (2-nitrobenzoic
acid) (DTNB) and produces nitroblue tetrazolium (NBT), which is yellow. GS-
NBT is concomitantly produced, and is then reduced by glutathione reductase
(GR) to recycle the GSH and produce more NBT. GR also reduces GSSG to
GSH, which reacts with DTNB. In these reactions, the rate ofNBT production is
directly proportional to this recycling reaction, which is in turn proportional to the
concentration of GSH in the sample. The chromophoric product NBT absorbs at
412 nm and the colour formation is monitored for 5 min at 25°C.
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3.2 Results and optimisations
3.2.1 Positive controls
To be able to select and optimise methods for measuring apoptosis and oxidative
stress, samples known to include apoptotic cells and/or oxidative modifications
were selected and used as positive controls in subsequent experiments.
Three types of positive control were used.
1. Samples from mouse lines known to develop retinal degeneration.
Tissue samples from two mouse retinal degeneration mutant lines were used.
Atypical retinal degeneration (Pde6b atrd,~3} mutants, that were generated by N-
ethyl-.A-nitrosourea (ENU) mutagenesis, have mutations in the rod cGMP
phosphodiesterase beta subunit (Pde6b) gene and have been shown to lose all the
retinal photoreceptor cells within a few weeks of age (Thaung et al., 2002; Hart et
al., 2005). Similarly, the retinal degeneration 1 (Pde6brd,/rdI) mutants are also
mutated in the pde6b gene and develop photoreceptor degeneration which is
complete by the third week of the animal's age.
2. Cell cultures in which apoptosis was induced.
The efficiency of apoptotic detection methods was also assessed in HeLa cell
cultures that were treated with various concentrations (0.5pM-5 mM) of
hydrogen peroxide (H202). The latter is known to induce apoptosis mediated by
oxidative damage (Barbouti et al, 2002).
3. Brain sections from a mouse model for multiple sclerosis
Matyszak et al. (1995) generated a mouse model for multiple sclerosis, a chronic
demyelinating disease in which infectious agents have been implicated in the
pathogenesis. The animals were intra-cranially injected with heat-killed Bacillus
Calmette-Guerin (BCG), which resulted in an acute inflammatory response and
formation of cerebral white matter and apoptotic lesions. A limited number of
frozen brain sections from these mice were available and were used for assessing
the efficiency of apoptosis- and oxidative stress-specific antibodies.
3.2.2 Outer Nuclear Layer (ONL) analysis
In this project, two approaches were initially investigated for following
photoreceptor degeneration in the mutants. Although they were both based on the
principle ofmeasuring the thickness of the ONL, they differed in the staining
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method of the sections and the subsequent approach to analysis. In deciding
which type of sections (frozen or paraffin-embedded) was more appropriate for
comparative histopathology, it was clear that the aim was the preservation of
histological structure. Both paraffin-embedded and frozen sections of wild-type
mouse eye were prepared and stained with haematoxylin and eosin (H&E). As
shown in Figure 16, the histological structure was intact in the pre-fixed paraffin-
embedded section, while in the frozen section, although the retinal layers are still
detectable, the histological structure was not usually as well preserved. It was
therefore decided to proceed with investigating methods of analyzing ONL
thickness by working on paraffin-embedded mouse eye sections.
The first approach (Figure 17) involved staining of the sections with 4', 6-
diamidino-2-phenyl-indol (DAPI), the most common DNA-specific dye that is
excited by ultraviolet (UV) light and stains the nuclei bright blue. Although DAPI
staining is very specific, even a moderate increase in the concentration of the dye
can result in an image of such brightness that detection of individual nuclei in
retinal layers is compromised. For this reason it was decided that, on DAPI-
stained sections, the approach mentioned above by Sarra et al. (2001) would be
used and the area covered by nuclei, rather than their exact number, would be
measured. Following de-paraffinisation, the sections were immediately mounted
in Vectashield with DAPI staining and analyzed by fluorescent microscopy.
Images were taken at a magnification of x40 and transferred to the IPLab program
for analysis. Each image was segmented and rotated in such a way that the retinal
layers were parallel to the horizontal plane. A rectangular area of set width and
height such that it fully included both the ONL and INL was selected at the centre
of the image and the areas occupied by the ONL and INL were measured in
pixels. The data were entered in Microsoft Excel worksheets for further data
analysis.
The second approach (Figure 18) involved H&E staining of the eye
section. Images at x63 magnification were captured by bright-field microscopy
and, as before, were analysed using the IPLab program. Each image was rotated
so that the retinal layers were parallel to the horizontal plane, and the number of
rows of nuclei in each layer was counted. The data was collected and analysed in
Microsoft Excel spreadsheets.
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Figure 17: Outer nuclear layer analysis by DAPI staining
ONL analysis was performed on mouse eye sections stained with DAPI. (A) Serial
images of a whole section were taken at a magnification of x63. (B) On each of the
images captured, the thickness of the ONL was measured in terms of its area (pixels)
(C) Sections from 3 animals were analyzed and the results are presented graphically.

































Figure 18: Outer nuclear layer analysis by H&E staining
ONL analysis was performed on mouse eye sections stained with H&E. (A) Serial
images of a whole section were taken at a magnification of x63. (B) On each of the
images captured, the thickness of the ONL was measured in terms of number of rows
of nuclei (C) Sections from 3 animals were analyzed and the results are presented
graphically. The error bars are standard deviations. (ONH: optic nerve head)
Using both methods, ONL thickness analysis was first performed on wild-
type retinas. For each method, three eye sections corresponding to three different
wild-type animals were stained and serial images covering the whole of the retina
(from one edge to the other) were taken. To ensure a fair comparison between
sections, all the sections used were sagittal (horizontal plane) and included part of
the optic nerve head (ONH). Also, to overcome the problem of different retinal
lengths, the sections under comparison were aligned at the ONH. The ONL and
INL thicknesses were measured and the data was analysed.
The results are shown in Figures 17 and 18. As shown, the thickness
pattern of the retina revealed by the two methods was very similar. The ONL and
INL were of equal thickness at one edge of the retina, but the ONL became
gradually thicker towards the ONH, peaking halfway through that distance, and
then staying constant, until interrupted by the ONH. On the other side of the
ONH, the retina was almost a mirror image of the opposite side of the ONH, with
the ONL and the INL becoming increasingly equal in thickness towards the edge
of the retina.
The inter-sample variation of ONL thickness analysis was also assessed.
For this, the selected protocol was applied on samples from 5 male and 5 female
C57B1/6 mice aged 8 weeks. The results of the analysis, shown in Figure 19,
reveal that different samples had very similar nuclear layer thickness patterns
irrespective of sex.
3.2.3 Terminal deixynucleotidyl transferase dUTP nick end
labelling (TUNEL) assay
In this project, the efficiency of the DeadEnd Fluorometric TUNEL System
(Promega) to detect apoptotic photoreceptor cells in mouse retina sections was
assessed. It is a modified TUNEL assay in which the levels of fragmented DNA
in apoptotic cells can be measured. The terminal deoxynucleotidyl transferase
recombinant enzyme (rTdT) catalytically incorporates fluorescein-12-dUTP at 3'-
OH DNA ends and the fluorescein- 12-dUTP-labelled DNA can then be visualised
directly by fluorescence microscopy.
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Figure 19: Outer nuclear layer analysis on male and female mouse eyes
Outer nuclear layer analysis was performed on mouse eye sections from 5 male
(A) and 5 female (B) mouse samples. These 'spidergrams' show the thickness
patterns of the outer nuclear (ONL) and the inner nuclear layers (INL) of the retina.
Combined data (C) show no differences between male and female samples.
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As shown in Figure 20, the application of this assay for the detection of
apoptotic cells on paraffin-embedded mouse eye sections was successful. The
positive control section was treated with Dnasel so that all cell nuclei present in
the tissue section were labelled as TUNEL positive. The negative control section
was treated with Dnasel in the same way as the positive control, but the reaction
mix lacked the rTdT enzyme, preventing incorporation of fluorescein-12-dUTP.
As expected, no cell nuclei were positively labelled in these samples. Apoptotic
cells were successfully detected in mouse eye sections from the atrd mutants,
while the wild-type sample was clear of any labelling. Additionally, application of
the assay on frozen brain sections of the BCG multiple sclerosis model
successfully showed TUNEL positive cells
3.2.4 Annexin V assay
Two commercially available annexin V assays (Sigma and US Biological) were
applied to both paraffin-embedded and frozen mouse eye sections from atrd
mutant mice. In addition, their efficiency was assessed on cultured HeLa cells
treated with various concentrations of H2O2. No Annexin V-positive cells were
detected in any of the positive controls.
3.2.5 Poly(ADP-ribose) polymerase (PARP) assay
A commercially available antibody (Promega) was used for detection of the large
fragment of the caspase-cleaved PARP-1. Immunocytochemistry and
immunohistochemistry were performed on EECL-treated, at various
concentrations, HeLa cells and on eye sections from atrd mice, respectively. In
neither experiment were any apoptotic cells detected by this antibody.
3.2.6 Caspase 3 assay
A commercially available anti-caspase-3 antibody (BD Biosciences) was used for
the detection of apoptotic cells. Immunocytochemistry and immunohistochemistry
were performed on H202-treated HeLa cells and on homozygous atrd mutant
mouse eye sections, respectively. In neither of the two positive control samples
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3.2.7 7, 8-dihydro-8-oxoguanine assay
A commercially available anti-8-oxoG antibody (QED Biosciences) and the
Fab 166 antibody generated by phage display technology by Soultanakis et al.
(2001) were used for the detection of oxidative damage at the DNA level. The
conventional protocol for immunohistochemistry was applied to both frozen and
paraffin sections from atrd mouse eyes. Additionally, the antibody was used for
detection of apoptotic cultured HeLa cells following H2O2 treatment at various
concentrations. None of the antibodies showed efficient staining of 8-oxoG
lesions in any of the controls.
3.2.8 COX/SDH assay
In this project, the COX/SDH assay was applied to frozen sections of atrdl mouse
eyes (Figure 21). The thickness and histology of the sections was first optimised
for detection of individually stained photoreceptor cells. Although the efficiency
of both COX and SDH staining was confirmed in COX-deficient colonic crypts
and by individual application to eye sections, no COX-deficient photoreceptors
were detected in the mutant samples. Modification to the protocol, including
reversal of the order of staining and different incubation times, failed to detect
COX-negative cells. This could imply species- or tissue-specific differences in the
presence of COX-negative cells.
3.2.9 Hydroxynonenal and malondialdehyde assays
Commercially available antibodies to MDA (Alpha Diagnostics) and HNE
(Alexis Biochemicals) were used in this project to detect and quantify LP in
retinal degeneration mutants. They were initially applied to both paraffin and
frozen eye sections from atrdl/atrdl mice, by following the conventional
protocol for immunohistochemistry. In addition, the efficiency of the antibodies to
detect LP adducts was assessed in cultured HeLa cells following H2O2 treatment
at various concentrations. No positive staining using either antibody was seen on
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retinal sections from the retinal degeneration mutants. Similarly, application of
the antibodies to cultured HeLa cells subjected to H2O2 treatment at various
concentrations failed to detect any signs of LP.
3.2.10 Nitrotyrosine assay
A commercially available antibody against NTyr (Calbiochem) was used in an
attempt to detect and quantify the degree ofprotein tyrosine nitration in the
retinas of retinal degeneration mutants. The antibody was applied at a range of
different concentrations to both paraffin and frozen eye sections of atrdl/atrdl
mice, on frozen brain sections from the BCG model and on HeLa cells treated
with H2O2 at different concentrations. No staining was seen in any of the positive
controls and the levels ofprotein nitration in retinal degeneration mutants could
not be measured.
3.2.11 Citrate synthase assay
As shown in Figure 22 and Table 2, all the constituents of the reaction
mix for the spectrophotometric assay of CS were optimised to ensure maximum
measurable activity. The spectrophotometric assay for CS was optimised using
wild-type mouse liver samples. Retinal samples from wild-type and mutant mice
were also assayed to ensure that the assay conditions were optimal for this tissue.
Typical examples of the graphical results from wild-type and mutant retinas are
shown in Figure 14, where they are seen to be practically identical. The
optimised concentrations of the different assay constituents are given in the
Materials & Methods section. The assay was robust when applied to different
mouse tissues.
3.2.12 Complex I assay
As shown in Figure 23 and Table 3, all the reagents included in the
spectrophotometric assay for CI were optimised to ensure maximum measurable
activity. This was done mainly on mouse liver samples, and the finalised
concentrations of all the reagents included in the assay are given in the Material &
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Figure 22: Optimisation of the citrate synthase assay
The constituents of the reaction mix for the spectrophotometric assay for citrate
synthase were optimized to ensure maximum measurable activity. Using
mitochondrial preparations from wild-type mouse liver samples, the activity of citrate
synthase was measured with increasing concentrations of (A) oxaloacetate, (B)
acetyl CoA and (C) DTNB. The measured activities are given in Table 2. (D) Using
the optimised concentrations, the linear relationship between activity and amount of
sample used was confirmed.
OAA (nM) activity sd CoA (mM) activity sd DTNB (nM) activity sd sample weight (pg) activity sd
25 0.0915 0.0013 16.7 0.1154 0.0001 0 0.0011 0.0001 1 0.0926 0.0028
50 0.1327 0.0015 33.3 0.1585 0.0054 20 0.1813 0.0022 2 0.1923 0.0026
100 0.1272 0.0027 50.0 0.1717 0.0012 40 0.2246 0.0022 3 0.2555 0.0039
200 0.1471 0.0011 66.7 0.1842 0.0028 60 0.2393 0.0057 4 0.3327 0.0004
300 0.1441 0.0008 83.3 0.1662 0.0011 80 0.2680 0.0012
400 0.1809 0.0023 100 0.2798 0.0039
500 0.1614 0.0008 150 0.2790 0.0006
1000 0.1346 0.0010
Table 2 : Optimisation of the citrate synthase assay
The activity of citrate synthase was measured in mouse liver samples with
increasing concentrations of the reagents included in the spectrophotometric assay.
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Figure 23 : Optimisation of the complex I assay
The constituents of the reaction mix for the
spectrophotometric assay of complex I were
optimised to ensure maximum measurable activity.
Using mitochondrial preparations from wild-type
mouse liver samples, the activity of complex l was
measured with increasing concentrations of (A)
ubiquinone-1, (B) NADH, (C) antimycin and (D)
activity of rotenone . The measured activities are
given in Table 3. (E) Using the optimised
concentrations, the linear relationship between
activity and amount of sample used was confirmed.
UQ1 pM Activity sd NADH mM Activity sd Rotenone pg/ml Activity sd Antimycin pg/ml Activity sd Sample weight pg Activity sd
0 -0.0016 0.0045 0 0.0023 0.0035 0 -1.4E-17 4.5E-03 0 0.0008 0.0057 1 0.00233 0.0035
13 0.2476 0.0227 0.065 0.2235 0.0023 0.3 2.2E-01 3.4E-03 0.5 0.1109 0.0432 2 0.21624 0.0080
26 0.3039 0.0000 0.13 0.2355 0.0148 0.6 1.9E-01 6.6E-02 1 0.0764 0.0034 3 0.459 0.0466
39 0.3682 0.0023 0.195 0.2323 0.0330 1.2 2.2E-01 3.9E-02 2 0.0908 0.0171 4 0.5627 0.0068
52 0.5088 0.0580 1.8 1.9E-01 3.4E-02 3 0.0860 0.0057 5 0.80707 0.0318
65 0.4783 0.0102 3 2.2E-01 5.7E-03
Table 3: Optimisation of the complex I assay
The activity of complex I was measured spectrophotometrically in mouse liver
samples with increasing concentrations of the reagents included in the assay.
Highlighted in red are the optimised concentrations of the reagents.
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3.2.13 Strain Comparison
As mentioned in the Introduction, a number of investigators have highlighted the
importance of the genetic background on the viability ofSod' null mice. Mice on
a C57B1/6, DBA or CD1 background survive for up to 1, 8 or 10 days,
respectively (Li et al., 1995; Huang et al., 2001). It was necessary therefore to
ensure that the markers of oxidative stress used in this project were not
significantly different between the different genetic backgrounds on which the
retinal degeneration mutants were present. Additionally, a comparison was made
between male and female samples.
In this context, the activities of citrate synthase and complex I were measured in
tissues collected from 5 male and 5 female animals on a Balb/c, CBA, CD1,
C57B1/6 or DBA backgrounds. The results, shown in Figure 24, revealed that, for
these enzymes, there was no difference between the genetic backgrounds or the
genders.
3.2.14 Reduced glutathione (GSH) measurements
The concentrations of all reagents used in GSH measurement were optimised
using mouse liver samples and the results are shown in Figure 25 and Table 4.
Before a new series of assays was performed, a standard curve was prepared
based on a minimum of four different concentrations ofpurified GSH (Table 5).
A typical GSH standard curve is presented in Figure 26.
It is worth noting that the original protocol suggested the addition of
triethanolamine (TE) to the samples, at a final concentration of 5%, prior to
measuring contents. TE is an organic compound that is often used as a buffer,
and since the samples for GSH measurements were prepared in perchloric acid,
the pH would need to be adjusted to neutrality. As shown however in Figure 27A,
addition of 5% TE to the GSH standard samples, used in setting up the standard
curve, completely inhibited the measurements and the linearity of the standard
curve was lost. It was therefore decided to further investigate this by assessing
how TE exerted its apparent inhibitory effect on GSH measurements. For this,
mouse brain and liver samples were used, as well as a standard concentration of 5
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Figure 24: Strain comparison for citrate synthase and complex I enzyme activities
The activities of citrate synthase (blue columns) and complex I (maroon columns) were measured in
(A, B) liver, (C, D) brain and (E, F) retina samples from wild-type Balb/c, CBA, CD1, C57BI/6 and DBA
mouse strains. For each strain a comparison was done between male and female samples (A, C, E)
[n=5]. Samples from both sexes were pooled for a comparison between the strains (B, D, F). There





Figure 25: Optimisation of the reduced glutathione (GSH) concentration protocol
The different ingredients of the reaction mix used in the protocol for measuring reduced
GSH content were optimised. (A) Optimisation of NADPH (B) Optimisation of DTNB (C)
Optimisation of GR. The measured activities are given in Table 4.
DTNB nM Rate sd NADPH nM Rate sd GR yl Mean sd
0 0.0003 0.0003 0 0.00005 7E-05 0 0.0001 0.0001
3 0.0074 0.0010 0.0024 0.0314 0.003 5 0.0140 0.0003
6 0.0142 0.0005 0.0048 0.0352 6E-04 10 0.0303 0.0015
12 0.0240 0.0021 0.0072 0.03525 0.003 15 0.0506 0.0011
24 0.0339 0.0021 0.012 0.0396 0.001 20 0.0678 0.0013
36 0.0377 0.0028 0.024 0.04265 0.008 25 0.0879 0.0018
48 0.0413 0.0012 0.048 0.04165 0.007 30 0.1129 0.0101
60 0.0489 0.0028 0.072 0.0381 0 40 0.2863 0.0181
90 0.0448 0.0013 0.12 0.04215 0.007 60 0.3617 0.0159
112 0.0475 0.0025 0.144 0.03485 2E-04 100 0.5403 0.0502
Table 4: Optimisation of the reduced glutathione measurement protocol
The protocol for measuring the reduced glutathione concentration in samples was
optimised for all the different ingredients included in the reaction mix. Highlighted in









Figure 26: The reduced glutathione (GSH) standard curve
The concentration of glutathione was determined by comparison to a standard curve
generated by using appropriate concentrations of purified reduced glutathione
GSH (nM) 0 0.01 0.02 0.05 0.1 0.2 0.5 1 1.5 2
all volumes in ^1
BUFFER 0.455 0.455 0.454 0.453 0.450 0.445 0.430 0.405 0.380 0.355
DTNB (0.06UM) 0.500 0.500 0.500 0.500 0.500 0.500 0.500 0.500 0.500 0.500
GR 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020
NADPH (0.12 uM) 0.025 0.025 0.025 0.025 0.025 0.025 0.025 0.025 0.025 0.025
STANDARD 0.000 0.001 0.001 0.003 0.005 0.010 0.025 0.050 0.075 0.100
Mean Rate 0.0021 0.0029 0.0026 0.0066 0.0117 0.0189 0.0485 0.0799 0.1308 0.2230
St.Dev. 0.0000 0.0006 0.0006 0.0022 0.0031 0.0039 0.0156 0.0166 0.0436 0.0739
Table 5: Volumes for the reduced glutathione standard curve
Using the optimised concentrations of the reagents included in the protocol for GSH

















Figure 27: The inhibitory effect of triethanolamine on reduced glutathione measurements
(A) Addition of 5% triethanolamine (TE) in the reaction mix for measurements of GSH, as
suggested by the original protocol by Tietze (1969), had an inhibitory effect on the measurements
of purified GSH. (B) The rates obtained from mouse liver, mouse brain and purified GSH samples
with increasing percentages of TE were measured. (C) The inhibitory effect of TE on the above
samples was also expressed in percentages.
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|uM ofpurified GSH. As shown in Figures 27B and C, measurements of the GSH
standard sample changed with increasing TE concentration, and at 5%, the
measured GSH level had decreased by a significant 30% (p=0.04). TE treatment
did not affect the GSH measurements in mouse brain samples however. In the
liver samples, addition of TE even at a low 1 % final concentration significantly
decreased by 20% the measured GSH concentration (p=0.04). The inhibitory
effect of TE in this sample increased progressively with TE concentration, so it
was omitted from the final reaction mixture.
The optimised concentrations of the reagents used in the GSH measurement
protocol are given in the Materials & Methods section. The protocol was also
applied to different mouse tissues, including liver, brain, heart and retina. The
results given by the different tissues and genotypes were found to show good
reproducibility.
In summary, the protocol for GSH measurements worked robustly in all
mouse tissues assayed, including the retina.
3.3 Summary and Conclusions
The aim of this project was to investigate the role of oxidative stress in
photoreceptor degeneration and, in this chapter, methods for measuring these
parameters were evaluated.
3.3.1 Apoptotic assays
The rates of photoreceptor degeneration were measured by ONL analysis and
TUNEL assays. Two methods for measuring the thickness of the nuclear layers
were compared and were shown to produce very similar results. The ONL and
INL in both DAPI- and H&E-stained sections showed similar thickness patterns,
measured in pixels and number of rows of nuclei, respectively. However, it was
decided to perform ONL analysis on H&E-stained sections only. Reasons for this
decision included the ease of tissue staining and analysis, as well as the
preservation of the stained samples for a long period of time. Additionally, a
comparison between male and female retinal samples demonstrated that the
retinal layers in males and in females do not show any significant difference in
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thickness, and hence, no further sex distinction should be made when selecting
samples for analysis.
Although the ONL analysis as a method for measuring the rate of
photoreceptor degeneration is based on measuring the number of living cells in
the retina, TUNEL assays are used for detecting dying cells. The TUNEL assay
has been previously used for the detection of apoptotic cells on eye sections.
Arroyo et al. (2005) detected increased numbers of apoptotic photoreceptor cells
in frozen human eye sections from patients with primary or recurrent retinal
detachments. Also, Doonan et al. (2003), while investigating the involvement of
caspases in apoptosis, applied the TUNEL assay on samples from the rdl/rdl
mouse and from an iV-methyl-A-nitrosourea-treated Balb/c mouse and
successfully detected apoptotic photoreceptor cells. In this project, a
commercially available kit by Promega was used and proved to be an efficient
means of detecting apoptotic cells in paraffin-embedded mouse eye sections.
However, as discussed by Stadelman & Lassmann (2000), in contrast to
other methods, the TUNEL assay is not specific to apoptosis and can also detect
necrotic cells. For example, it has been demonstrated that in human
atherosclerotic plaques nonapoptotic nuclei can be labelled by the TUNEL
technique (Koeck et al., 1998). Therefore, it has been recommended that this
assay be applied in conjunction with other methods, more specific to apoptosis.
For this reason methods specific to apoptosis were also used. The annexin
V method has the advantage of being highly specific to apoptosis (Martin et al.,
1995). However, for the purpose of this project, a potential disadvantage of the
assay is that it was initially developed for the detection and quantification of
apoptosis in living cells after separation by flow cytometry. Hence, the assay
needed to be appropriately modified for application to tissue sections. No
published work has been reported in which the annexin V assay has been applied
to tissue sections, and, as a result, the failure of the assay to work was to some
extent predictable.
The cleaved form of PARP is also used as a marker for apoptotic cells.
Poly (ADP-ribosyl)ation is a post-translational modification of a series of proteins
involved in DNA repair, transcription and apoptotic cell death. This modification
occurs in every nucleated cell ofmammals, plants and lower eukaryotes, but is
not present in yeast cells (Lindahl et al., 1995). The reaction is regulated by the
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joint action of PARP and of Poly (ADP-ribose) glycohydrolase (PARG) (Scovassi
& Diederich, 2004; Burkle et al., 2005; Diefenbach & Burkle, 2005). In the
presence ofDNA strand breaks, PARP-1 is activated and binds to the substrate
nicotinamide adenine dinucleotide (NAD+). The latter is cleaved into
nicotinamide and an adenosine diphosphate (ADP)-ribosyl moiety, which is then
transferred to glutamate or aspartate residues in target proteins. Additional ADP-
ribosyl transfer cycles result in the formation ofnegatively-charged polymers on
the proteins, whose function is consequently compromised. Target proteins of
PARP include DNA polymerase a and p and various histones. The formation of
NAD+ polymers is transient as they are rapidly removed by PARG for NAD+ re¬
cycling. Therefore, the orchestrated action of PARP and PARG determines
cellular NAD+ levels.
An antibody against PARP has been previously used for detecting
apoptotic photoreceptor cells. Miller et al. (2006) used the mouse 661W
photoreceptor cell line as a neuronal model ofCI-1010 ((R)-alpha-[[(2-
bromoethyl)-amino]methyl]-2-nitro-1H-imidazole-1 -ethanol
monohydrobromide)-mediated retinal degeneration and demonstrated a link
between onset of apoptosis and PARP cleavage. Additionally, Li et al. (2002)
were able to detect apoptotic ganglion cells in retinal sections from p53-deficient
mice that were injected with NMDA. In this project however, the antibody against
the cleaved form of PARP that was used failed to detect apoptotic cells. Possible
explanations are the inefficiency of the antibody and/or the absence of apoptotic
cells with cleaved PARP. The latter explanation is the least likely, given that the
assay was applied to positive controls of two types, atrdl/atrdl retinal sections
and H2O2 treated cells. Given, therefore that the antibody used was not
appropriate, additional methods specific to apoptosis were used.
The involvement of caspase 3 in apoptosis is also well documented, and
therefore an antibody specific to this protein was applied to apoptotic positive
controls. It should be noted however that the involvement of caspases in certain
types of photoreceptor degeneration has been controversial, as although they were
initially thought to play a central role in the mechanism, it was later shown that
certain apoptotic characteristics can occur in the absence of caspase activity
(Borner & Monney, 1999). In mouse retinal degeneration models of light damage
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used by Donovan et al. (2002) to demonstrate caspase-independent apoptosis,
caspase-3 levels were markedly reduced in the mature retina and did not increase
following light exposure. Therefore, these authors supported the view that it does
not play a role in the apoptosis of photoreceptors in the light damage model. In
this context, lack of caspase-3-positive cells in the atrdl/atrdl eye sections could
be explained by a lack of involvement of the protein in photoreceptor
degeneration in this model. The fact that the antibody also failed to work on
cultured cells however points to its inefficiency in detecting apoptotic cells with
the protocol used.
In this project however, and under the conditions specified in the Methods
& Materials section, none of these three apoptosis-specific antibodies were able to
successfully detect dying photoreceptor cells in the positive control samples. It
was therefore decided not to pursue their optimisation for detection of apoptotic
photoreceptor cells in the retinal degeneration mutants analysed in this project.
3.3.2 DNA damage
Attempts to measure oxidative damage at the DNA, lipid and protein level were
also carried out using different methods. Firstly, an antibody against the most
common oxidative DNA lesion 8-oxoG was used. Increased amounts of 8-oxoG
have been found in mtDNA isolated from brain tissue from Alzheimer's patients
(Nunomura et al., 1999). Also, Soultanakis et al. (2001) studied oxidative DNA
damage in rat alveolar type II epithelial cells (RLE) and TK6 (a human B
lymphoblastoid cell line) cells treated with various concentrations of H2O2 to
induce oxidative damage. By coupling staining for Fab 166 with the mitochondrial
marker MitoTracker, the authors were able to demonstrate mtDNA damage in
cells. Finally, Cortina et al. (2005) showed increased levels of 8-oxoG in
photoreceptor synaptic terminals, following bright light treatment in rats. In the
current project however, the antibody against 8-oxoG failed to stain any cells in
the positive controls. As in the case of the antibody against the cleaved form of
PARP, the most likely explanation for this result involves the inefficiency of the
antibody, under the experimental conditions used, to detect DNA oxidative
damage, rather than the lack ofDNA damage in the samples that were assayed.
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Secondly, the COX/SDH assay was applied to positive control samples in
an attempt to quantify mtDNA damage. Mitochondria have their own genome
(mtDNA) and its mutation rate has been shown to be at least 10-fold higher than
that of nuclear DNA (Brown et al., 1979). This can be attributed to limited
mtDNA repair, absence of protective histones on mtDNA and its close proximity
to the free-radical generating ETC. Mutations in mtDNA have been repeatedly
shown to be the cause of various human diseases, including Leber's hereditary
optic neuropathy (LHON) (Chinnery & Turnbull, 2000). A retinal degeneration
phenotype is also often observed with mtDNA mutations. Retina is a good
candidate therefore for detecting mtDNA mutations, as it is a tissue that is highly
metabolically active and is primarily composed ofpostmitotic non-proliferative
neurons. The retina is also exposed to wavelengths of light that have been shown
to damage mtDNA (Wallace, 2005). It is therefore conceivable that mutations in
mtDNA impair the function of the encoded genes to a greater extent in mutants
with retinal degeneration than in wild-type retinas.
The COX/SDH method is commonly used for the detection and analysis
ofmtDNA mutations in a variety of tissues, but most extensively in human
muscle and colon. Limited work has been done on COX/SDH assay in retina. In
1999, Andrews et al. cytochemically studied COX and SDH staining in the
human retina and RPE. Their observations were very interesting, revealing high
COX and SDH activity in unmyelinated parts of retinal ganglion cell axons, the
OPL, the IS of photoreceptor cells and the RPE. There was essentially no or very
low reactivity in the OS of photoreceptor cells and in the INL respectively. In a
subsequent study, Barron et al. (2001) investigated the occurrence of somatic
mtDNA mutations in the macula during aging. The COX/SDH assay was applied
to section of human eyes donated from aged humans (Figure 21). The
observation of a much higher rate ofmutated mtDNA in the central than the
peripheral retina, and its correlation with the presence of COX-negative
photoreceptors, confirmed the reliability of the assay for detection ofmtDNA
damage. These authors provided the following explanation for their results.
Damaged COX impairs the function of the ETC and causes further
biochemical/metabolic defects, influencing the production ofATP and the
integrity ofATP-dependent cellular processes. One such process is the ATP-
binding cassette transporter, which is responsible for transferring retinoids
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between the neural retina and the RPE. Inhibition of this transporter has been
shown to lead to lipofuscin accumulation in the RPE, generation of free radicals
and RPE cell death. The latter effect could lead to death of the associated
photoreceptor cells. Finally, the COX/SDE1 staining method has been
successfully used to detect COX-negative colonic crypts from patients with
colorectal cancer (Greaves et al., 2006).
In this project, although the efficiency of the assay was confirmed by the
detection ofCOX-deficient crypts on colon sections from cancer patients, no
COX-negative photoreceptor cells were detected in any of the mouse retina
samples assayed. This result can be explained either by the lack of this type of cell
in the samples or by species and age differences between the samples analysed by
Barron et al. (2001) and the present study. It was therefore concluded that in this
project the COX/SDH assay would not be used further as an indication of
oxidative stress in the mutants of interest.
3.3.3 Lipid damage
Oxidative damage to lipids was attempted to be measured by the levels ofMDA
and HNE. MDA is mainly formed by the peroxidation of PUFAs with at least two
methylene-interrupted double bonds (Del Rio et al., 2005). When present at low
basal concentrations (<1 pM), MDA has low chemical reactivity and often acts as
a signalling molecule (Petersen & Doom, 2005). IncreasedMDA levels however
result in its interaction with cellular molecules and formation of adducts with
nucleic acid bases and protein residues. These adducts have been associated with
a number of disease phenotypes, including amyotrophic lateral sclerosis and
Parkinson's disease. MDA is therefore often used as a biological marker for
progression ofneurodegenerative diseases (Dib et al., 2002).
HNE, which was discovered in 1980 by Benedetti et al. (1980), is an a|3-
unsaturated acyl aldehyde that can covalently modify cellular target proteins,
thereby affecting their structure and/or function (Bennaars-Eiden et al., 2002;
Petersen & Doom, 2004). Like MDA, HNE has been shown to act as a signalling
molecule at low concentrations, and even at higher concentrations, it was initially
considered a second messenger for free radicals (Awasthi et al., 2003; Yang et al.,
2003). Now however, the cytotoxic nature ofHNE is well established and is
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• • • • . . . • 2+ •attributed to its ability to initiate LP, disturb cellular Ca homeostasis, deplete
GSH and cause apoptosis. Altered levels ofHNE have been implicated in a
number of neurodegenerative diseases, like Alzheimer's disease and
atherosclerosis (Zarkovic, 2003a; Zarkovic, 2003b). HNE is therefore commonly
used as marker for oxidative stress and LP.
The levels of these two markers of lipid peroxidation in retinal
degeneration mouse mutants have not been previously reported. However, failure
to efficiently detect signs of LP in the positive controls, using antibodies either to
MDA or to HNE, resulted in the decision not to use these antibodies as markers
for LP in this project
3.3.4 Protein damage
Oxidative damage to proteins was assessed by both immunohistochemistry for
nitrotyrosine and by enzyme assays.
Although the signalling role ofNO at low, basal concentrations has been
well established (Bishop & Anderson, 2005), at higher nanomolar concentrations
it can reversibly inhibit the mitochondrial respiratory chain at either complex I
and/or complex IV (Brown, 2001; Brown et al., 2004). At these concentrations
NO can also cause nitration of other proteins. At higher (mM) concentrations NO
and its derivatives are capable of irreversibly inhibiting respiration, which
eventually leads to cell death (Brown, 2001). Protein nitration appears to be a
mechanism whose specificity is dictated by the proximity of proteins to the site of
generation of nitrating agents, by the abundance of candidate protein targets and
of tyrosine residues within them, as well as by the secondary and tertiary structure
of the proteins (Ischiropoulos, 2003; Gow et al., 2004). Consequently, a
substantial number ofmitochondrial proteins are nitrated in vivo, covering all
essential metabolic and antioxidant pathways (Aulak et al., 2001; Aulak et al.,
2004; Koeck et al., 2005). An increasing amount of evidence associates elevated
nitrotyrosine levels with disease phenotypes, leading to the former's role as a
biomarker of oxidative stress attributed to production of nitrating species
(Halliwell, 1997). Tyrosine nitration has been documented in retinal proteins of
diabetic mice (Du et al., 2002), aged rats (Louie et al., 2002), rats exposed to
damaging light (Miyagi et al., 2002) and in different models of ischemic
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proliferative retinopathy (e.g., diabetes mellitus, retinopathy of prematurity,
retinal vein occlusion) (Sennlaub et al., 2002). Here, an antibody against
nitrotyrosine was applied to mutant retinal sections, however with no success. A
possible explanation is the lack of efficiency of the specific antibody used in
detecting this type of protein modification.
Spectrophotometric assays for oxidative-stress sensitive and insensitive
enzymes were also optimised in this project. Since the main source of oxidative
stress is the mitochondrion, enzymes participating in mitochondrial functions are
likely candidates of such an insult. Reduced mitochondrial enzyme activities have
previously been reported in a number of human neurodegenerative diseases, like
Alzheimer's and Parkinson's disease (Gibson et al., 1998; Schapira, 1999;
Krasnianski et al., 2005). In this study the mitochondrial enzymes citrate synthase
and complex I were used as oxidative stress-insensitive and -sensitive activities
respectively, and both were successfully assayed and optimised for use in the
study.
3.3.5 GSH measurements
The method for measuring the concentrations of reduced glutathione (GSH) was
optimised. Glutathione is a ubiquitous molecule that is produced in all
mammalian organs and tissues, although its concentration varies markedly
between tissues. The liver has the highest glutathione concentration, whereas this
is lower in the plasma and urine (Pastore et al., 2003). GSH is synthesised in the
cytosol, where more than 85% of the cellular content is present at a millimolar
concentration (Pastore et al., 2003). Mitochondria lack the glutathione synthetic
machinery and therefore rely on this antioxidant's uptake from the cytosol for the
maintenance of the mitochondrial pool, whose importance is evident by its close
proximity to the main intracellular source of oxidants.
In cells, total GSH can be free or bound to proteins. When free, it is
mainly in its reduced form (GSH), which can be converted to the oxidative form
(GSSG) by GPX, which is normally 'recycled' back to GSH by GR. The relative
amounts of these two forms of glutathione are an indication of the oxidative state
of the cells. In the resting state, when the reduced form of glutathione
predominates over the oxidised one, the ratio GSH/GSSG exceeds 100, whereas,
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under oxidative stress, this is reduced to 1-10 (Pastore et al., 2003). In addition to
changes in the relative amounts of the two forms of glutathione, the level of total
glutathione in the cell also decreases under oxidative stress. Different mechanisms
have been suggested for this, including insufficient supply of glutathione
precursors (Dringen, 2000) and production of nitric oxide, cytokines or other
oxidants (Mytilineou et al., 1999). The expression levels and activities of the
enzymes responsible for synthesising glutathione have been shown to remain
unchanged, ruling out the possibility that glutathione depletion can be attributed
to failure of synthesis. Increased expression of gamma-glutamyltranspeptidase
might reflect compromised glutathione re-synthesis. A rapid depletion of
intracellular glutathione has been demonstrated in an in vitro model of
photoreceptor apoptosis, accompanying an early and sustained increase ofROS
production (Carmody et al., 1999).
In this project, the protocol for measuring reduced GSH levels in mouse
tissue samples was optimised efficiently and was therefore used in order to
measure the GSH concentration in the retinal degeneration mutants.
3.3.6 Conclusion
To summarise, although various methods were attempted for measuring
photoreceptor degeneration and oxidative stress, only some were efficiently
optimised for application to the retinal degeneration samples. In the following
chapters, photoreceptor degeneration will be assessed by ONL analysis and
TUNEL assays. Oxidative damage will be assessed by spectrophotometric








In this chapter, a phenotypic analysis of four mouse models ofRP, representing
mutations in three genes implicated in the disease, was carried out to provide a
baseline for comparison with later experiments, in which oxidative stress
pathways are manipulated in various ways. We used the retinal degeneration 1
(rdl) mouse and the recently generated atypical retinal degeneration 1 (atrdl)
mouse. They both have mutated forms of the pde6fi gene, whose product, the P
subunit of cyclic 3' 5' guanosine monophosphate phosphodiesterase 6 (cGMP
PDE6P), is involved in the process of rod phototransduction. The rdl/rdl mutant
has a naturally occurring transversion in the 7th exon of the gene (Beck et al.,
2000), whereas the atrdl/atrdl mutant has a missense mutation (T1860A) in exon
15 of the same gene, which converts a histidine residue to a glutamine at codon
620 (Thaung et al., 2002). The extensively studied Rho" and rds/rds mice were
also analysed in this project. The rhodopsin knockout mouse was generated by
Humphries et al. (1997) by targeted homologous recombination and disruption of
the rhodopsin gene which is also in the visual transduction cascade, in which it
initiates the whole process of signal transduction. The rds/rds (Prph2 rds/rds)
mouse results from a spontaneous mutation in the peripherin 2 (Prph2) gene, in
which a 9.2-Kb insetion into exon 2 results in premature truncation of the protein
(Ma et al., 1995). Peripherin 2 has a structural role in the formation of rod outer
segments. Details on the known specific pathologies of each of these models were
given in the Introduction (part 1.2.2.1.).
The rates of degeneration in the above mutants were estimated both by
outer nuclear layer (ONL) analysis and by TUNEL assays for detection of
apoptotic photoreceptor cells. The expression level and localisation of the proteins
rhodopsin and phosphodiesterase 6 were also assessed by immunohistochemistry
on paraffin eye sections. For each mouse mutant, the activities of the
mitochondrial enzymes citrate synthase and complex I were measured
spectrophotometrically in four different tissues, including the retina. Finally, the
reduced glutathione (GSH) concentration was measured in the same tissues
collected from all of the mutants. The aim of this chapter was to phenotypically
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analyse the retinal degeneration mutants, and to elucidate the role of oxidative
stress in the manifestation of the disease phenotype.
4.2. Results
4.2.1. Rates of photoreceptor degeneration in retinal
degeneration mutants
The rate ofphotoreceptor degeneration was measured in all four mutants by both
ONL and TUNEL analysis. Paraffin sections were stained with H&E and the
thickness of the ONL was compared to that of the INL, which does not
degenerate. The thickness of the two nuclear layers was measured by the number
of rows of nuclei. Age-matched wild-type animals were used as controls for each
mutant.
The rdl/rdl mutants were analysed at set one-week periods up to the age
of one month (Figure 28). At P7, the mutant was indistinguishable from the wild-
type. Although the ONL in the wild-type and the mutant were identical,
comprising 13 (s.d. 0.00) and 12.7 (s.d. 0.58) rows of nuclei respectively, there
were no IS or OS yet developed in either. At 2 weeks of age, photoreceptor
degeneration was markedly evident in the rdl/rdl mutants. Although in the wild-
type samples the ONL remained at a thickness of 12.7 (s.d. 0.58) rows of nuclei,
in the mutant the same layer was reduced to 2.3 (s.d. 0.58) rows. From this time-
point onwards there was a significant difference between the ONL measurements
in the mutant and wild-type samples (p<0.001; n=5). The degeneration in the
mutant was complete by the third postnatal week. At no time-point was the
thickness of the INL significantly different between the mutant and wild-type
samples (p-values not significant).
In agreement with the ONL analyses, the TUNEL analyses for detection of
apoptotic cells in rdl/rdl samples showed progressive degeneration of
photoreceptor cells with age (Figure 28). At P7, both the wild-type and the
mutant samples had a low percentage of apoptotic cells in the ONL with values at
3.3 % (s.d. 5.6) and 7% (s.d. 2.7), respectively, that were not significantly
different from each other. At all later time-points, the percentage ofTUNEL-
positive cells in the wild-type was zero, but was significantly increased in the
mutant samples (all p<0.05, n=5). A decrease observed in the percentage of
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TUNEL-positive cells at the last time-point, at 4 weeks of age, was not
significantly different to the previous one at 3 weeks (p>0.05; n=5). It is also
worth noting that in some of the oldest rdl/rdl samples, but in none of the wild-
type, there were some nuclei in the INL, as well as some ganglion cells, that
showed positive TUNEL staining.
The atrdl/atrdl mutant showed photoreceptor degeneration that was
complete at 6 weeks of age (Figure 29). At the first time-point of analysis, at 2
postnatal weeks of age, the wild-type and the mutant samples had an identical
mean ONL thickness at 12 rows of nuclei. Thereafter however, there was a
change in the thickness of this layer in the mutant with increasing age, which was
significantly reduced compared with wild-type at all time-points (all p < 0.05;
n=5). The thickness of the INL remained relatively constant with time and was
not significantly different between wild-type and mutant genotypes. At the last
time-point, at 6 weeks of age, the thickness of the INL in the mutant was
significantly lower than that of the wild-type (p=0.02; n=5), probably reflecting
the extension of the disease phenotype (cell death) to other retinal layers.
TUNEL analysis on atrdl/atrdl samples showed comparable results to the
ONL analysis (Figure 29). Firstly, even in the wild-type samples there was a
small number of apoptotic cells within the first three weeks of age. However there
was an increased number of apoptotic cells detected in the atrdl/atrdl mutants at
the same time-points, but these were not significantly different from wild-type
(p>0.05; n=5). This can be probably attributed to the large variation seen in the
detection ofTUNEL-positive cells in the controls. At 4 weeks of age however, the
difference between the two genotypes was significant (p<0.001; n=5) with the
mutant having more than 20% of its photoreceptor cells stained positive for
TUNEL. This percentage decreased to about 10% at 6 weeks of age and remained
significantly different from wild-type.
ONL analysis was also performed on samples of the Rho'~ mutant (Figure
30) at 1-month intervals, as it is known from published data that it takes about 3
months for degeneration to be complete in this mutant. Indeed, it was confirmed
that the thickness of the ONL was noticeably reduced to about one-third of the
normal by the second month of age and further decreased to a single row of
photoreceptor nuclei by 3 months of age (p<0.001; n=4). It remained at this
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was constant at about 5-6 rows of nuclei throughout the analysis and was never
significantly different from control samples (p>0.05; n=4).
TUNEL analysis on Rho~'~ samples was done at the same time-points as
the ONL analysis (Figure 30). At no point did the wild-type samples show any
signs of TUNEL-positive cells. In the mutants, there was an increased percentage
of apoptotic cells detected within the first two months of retinal degeneration
(p=0.002; n=4). Thereafter however, the percentage of cells that stained positively
for TUNEL was not significantly different from control samples (p>0.05; n=4).
The final mutant to be analysed for photoreceptor degeneration was
rds/rds (Figure 31). In contrast to the other mutants analysed above, this was the
only one that had a significantly thinner ONL at the first time-point of the analysis
(1 month), when compared to the wild-type (p=0.01; n=3). Initially, the decrease
in ONL thickness in the mutant progressed rapidly, falling to about one-third of
wild-type by the second month of age, and more slowly afterwards, until complete
at 3-4 months of age. The INL in both genotypes remained at a stable thickness at
each time-point.
The results from TUNEL analysis on rds/rds sections agreed well with
those collected by ONL analysis of the same samples (Figure 31). There was an
increasing number of apoptotic cells detected in the mutant at 1 month of age, but
this was not significantly different from wild-type controls of the same age
(p>0.05; n=3). Lack of significance was again due to the large variation seen
between mutant samples analysed. At 2 months of age, in the mutant more than
10% of the ONL photoreceptor cells were TUNEL-positive, compared to none in
wild-type (p=0.03; n=3). However both the percentage of detectable apoptotic
cells and the significance were significantly reduced at subsequent time-points.
4.2.2. Photoreceptor markers in the retinal degeneration mutants
4.2.2.1. Immunohistochemical detection of rhodopsin
The expression level and localisation of rhodopsin (Figure 32) was assessed in
retina sections from the four mutants. The efficiency of the anti-rhodopsin
antibody was confirmed on adult wild-type sections, where it localises to the OS
of rod photoreceptor cells.
156
Figure 32: Immunohistochemical detection of
rhodopsin in retinal degeneration mutants
The expression levels and pattern of rhodopsin
were assessed by immunohistochemistry in the
mutants. The structure of the retina is shown by
H&E staining (A). The negative control (B) was
completely clear of any rhodopsin staining,
whereas the positive adult wild-type control (C)
showed rhodopsin localisation in the outer
segments of photoreceptor cells. The localisation
and expression levels of rhodopsin were assessed
in the retinal degeneration mutants. rd1/rd1 1
week (D), 2 weeks (E) and 3 weeks (F);
atrd1/atrd1 2 weeks (G), 3 weeks (H) and 6 weeks
(I); Rho-'- 1 month (J), 2 months (K) and 3 months
(L) old; rds/rds 1 month (M), 2 months (N) and 3
months (O). [INL: inner nuclear layer, ONL: outer
nuclear layer, IS: inner segment and OS: outer
segment of photoreceptor cells]
In the 1-week old rdl/rdl mouse retina, when the OS and IS ofphotoreceptor
cells have not yet formed, rhodopsin expression was localised at the ONL. One
week later, when degeneration was already evident, the protein remained in the
same layer, which was nevertheless reduced in thickness by that time. With the
completion ofphotoreceptor degeneration, at 3 weeks of age, rhodopsin
expression had disappeared.
In a 2-week old atrdl/atrdl mutant, rhodopsin seemed to be localised in
the shortened OS of the photoreceptor cells. As in the case of the rdl/rdl mutant,
with completion of the degeneration, rhodopsin expression in the atrdl/atrdl
mutant was abolished.
Rhodopsin expression in the Rho~'~ mutant was completely absent,
consistent with the genotype of this rhodopsin null mouse.
Finally, in the rds/rds mutant, which fails to form any OS, rhodopsin was
localised initially at the tips of the IS, in the area from where OS would normally
protrude. As degeneration progressed, rhodopsin expression was evident in the
ONL only, localising at the plasma membrane surrounding the remaining nuclei
of the ONL.
4.2.2.2. Immunohistochemical detection of rod cGMP
phosphodiesterase 6b
The efficiency of the anti-Pde6b antibody was confirmed on wild-type adult
sections where it localised at the OS of photoreceptor cells (Figure 33). Faint
staining was also seen in the inner plexiform layer.
The rdl/rdl mutant, before any evidence of degeneration at 1 week of age,
the protein was localised where OS would potentially form. However, as soon as
degeneration was evident at 2-3 weeks, Pde6b showed a non-specific pattern of
expression spreading in all retinal layers. Faint localisation in the IPL was the
only positive sign of this protein's expression at later stages.
A very similar pattern of Pde6|3 localisation was seen in the atrdl/atrdl
mouse, which is also mutated in the Pde6b gene, but whose mutation lies in a
different exon of this gene. It was initially found expressed apically of the ONL,
but as soon as degeneration was markedly evident, the protein was localised in the
IPL.
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Figure 33: Immunohistochemical detection
of rod cGMP phosphodiesterase 6b in
retinal degeneration mutants
The expression levels and pattern of
phosphodiesterase 6 beta were assessed by
immunohistochemistry in the mutants. The
structure of the retina is shown by H&E
staining (A). The negative control (B) was
completely clear of any pde6(J staining,
whereas the positive wild-type control (C)
showed pde6p localisation mainly in the outer
segments of photoreceptor cells and faintly in
the IPL. The localisation and expression levels
of pde6p were assessed in the retinal
degeneration mutants. rd1/rd1 1 week (D), 2
weeks (E) and 3 weeks (F); atrd1/atrd1 2
weeks (G), 3 weeks (H) and 6 weeks (I); Rho-A
1 month (J), 2 months (K) and 3 months (L);
rds/rds 1 month (M), 2 months (N) and 3
months (O). [IPL: inner plexiform layer, INL:
inner nuclear layer, OPL: outer plexiform layer,
ONL: outer nuclear layer, IS: inner segment
and OS: outer segment of photoreceptor cells]
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In the Rho~'~ mutant, Pde6b staining was low from an early age, and was
effectively absent by completion of photoreceptor degeneration.
Finally, in the rds/rds mutant retina, which fails to form outer segments,
Pde6[3 was again expressed at a very low level and was found mainly in the IPL
4.2.3. Complex I and citrate synthase enzyme activities in
wild-type and retinal degeneration mutants
The specific activities of the mitochondrial enzymes citrate synthase (CS) and
complex I (CI) were measured spectrophotometrically. Liver, brain, heart and
retina samples were collected from each of the retinal degeneration mutants and
assayed as described in the Materials & Methods (section 2.6.1.). The samples
collection was performed before progressed photoreceptor degeneration, to ensure
presence of the cells of interest. Therefore, the 'fast' strains (rdl/rdl and
atrdl/atrdl) were assayed at 1 week of age, whereas the 'medium' strains were
assayed at 1 month of age. They were compared to wild-type samples. (Table 6,
Figure 34).
In the wild-type liver, the activity ofCS was 1.6949 pmol/min/g tissue
and none of the mutants showed citrate synthase activity significantly different
from the wild-type in this tissue (all p>0.05; n=3-5). The CI activity in the wild-
type liver was significantly lower than that of CS at 0.5969 pmol/min/g tissue
(p=0.0073; n=4). The activity ofCI in the liver samples from all the mutants
remained at levels similar to wild-type (all p>0.05; n=3-5).
In brain samples, the results were comparable to those obtained in liver
samples, in terms of unchanged enzyme activities in the mutants compared to the
wild-type control. In brain samples, however, the specific activity ofCS was
consistently higher than in liver samples, within the range of4-6 pmol/min/g
tissue. The specific activity ofCI in the same brain samples was lower than in the
liver, ranging from 0.24 to 0.38 pmol /min/g tissue. As in the case of the liver,
none of the enzymes showed decreased activity in any of the mutants compared to
the wild-type (all p>0.05; n=3-5).
The specific activity ofCS in the heart samples was considerably higher
than in liver or brain, ranging from 14 to 27 pmol/min/g tissue. The results
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LIVER
Citrate Synthase Complex I
Stra i n n activity se pw-value activity se Pw-value
Wild type 4 1.6949 0.1893 0.5969 0.2011
rd1/rd1 4 2.4467 0.4353 0.1644 0.4743 0.0779 0.5904
atrd1/atrd1 5 1.7838 0.4554 0.8744 0.4807 0.0564 0.5559
Rho'/- 4 2.3787 0.3408 0.1300 0.3215 0.1168 0.2812
rds/rds 3 2.3260 0.3538 0.1499 0.4796 0.1843 0.6964
BRAIN
Citrate Synthase Complex 1
Strain n activity se pw-value activity se Pw-value
Wild type 5 3.7515 0.7808 0.2444 0.0518
rd1/rd1 4 5.3456 0.4538 0.1446 0.3236 0.0522 0.3235
atrd1/atrd1 4 4.3842 0.9078 0.6118 0.3758 0.0211 0.0704
Rho 3 4.0025 0.2766 0.8208 0.3001 0.0613 0.5236
rds/rds 3 6.0147 0.6241 0.0935 0.3430 0.0513 0.2564
HEART
Citrate Synthase Complex I
Stra i n n activity se pw-value activity se Pw-value
Wild type 4 13.9632 2.3818 1.8227 0.3594
rd1/rd1 3 27.5270 6.5664 0.0794 1.3934 0.0998 0.3672
atrd1/atrd1 3 18.0613 5.9593 0.5063 1.3424 0.3161 0.3815
Rho 3 15.4951 5.4382 0.7862 2.5000 0.0325 0.1728
rds/rds 3 14.3333 3.2423 0.9283 3.2235 0.8895 0.1631
RETINA
Citrate Synthase Complex I
Strain n activity se pw-value activity se Pw-value
Wild type 6 1.1066 0.1144 0.7248 0.1651
rd1/rd1 6 1.0074 0.2115 0.6885 0.1541 0.0370 0.0071
atrd1/atrd1 4 1.3502 0.3817 0.4865 0.1969 0.0630 0.0377
Rho "A 6 0.8719 0.0632 0.1028 0.1058 0.0087 0.0038
rds/rds 3 0.8983 0.1653 0.3309 0.0991 0.0107 0.0361
Table 6: Enzyme activities in wild-type and retinal degeneration mutants
Citrate synthase and complex I activities (pmol/min/g tissue) were measured in liver, brain, heart and
retina from wild-type and retinal degeneration mutants (rd1/rd1, atrd1/atrd1, Rhor'- and rds/rds). The
standard errors (se) and statistical significance compared with wild-type (pw-value) are shown. Statistical
significant values pw <0.05 are highlighted in red.
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showed no significant difference in activity between controls and mutants. The
activity ofCI in heart samples was higher than that measured in other tissues,
ranging from 1.3 to 3.2 pmol/min/g tissue. No significant differences were
recorded in CI activity of heart between control and mutant samples (p>0.05;
n=3-4).
The CS activity measured in the wild-type retina was similar to that in the
liver, at 1.1 pmol/min/g tissue. In the mutants, it ranged from 0.9 to 1.4
pmol/min/g tissue, and was similar to the control (p>0.05; n=3-6). In the wild-
type retina, the specific activity ofCI was similar to that in liver, at 0.7
pmol/min/g tissue. It was however significantly reduced in the retinas from all
four mutants (all p<0.05; n=3-6).
4.2.4. Reduced glutathione (GSH) measurements in wild-type
and retinal degeneration mutants
Reduced glutathione (GSH) concentrations were measured in the liver, brain,
heart and retina ofwild-type animals and retinal degeneration mutants (Table 7,
Figure 35). In the wild-type liver the GSH measured was 4.2 pmol/g protein.
GSH concentrations were not significantly different from wild-type in liver
samples from all four mutants, ranging from 3.6 to 5.2 pmol/g protein (all p>0.05;
n=3). The GSH concentration in the wild-type brain samples was much lower
than liver, at about 1 pmol/g protein. In the rdl/rdl, atrdl/atrdl and Rho"
mutants, the GSH concentration remained the same as wild-type, within a range
of 1.2 to 1.4 jumol/g protein (all p>0.05; n=3). In the brain samples of rds/rds
mutants GSH levels were significantly greater than wild-type, at 2.1 pmol/g
protein (p=0.04; n=3). The GSH content was even lower in the wild-type heart,
compared to both liver and brain samples of the same genotype. In wild-type heart
the GSH concentration was 0.7 pmol/g protein. GSH concentrations were
significantly reduced in the rdl/rdl and atrdl/atrdl mutants (p=0.044 and
p=0.048, respectively; n=3), but not in the Rho'1' or rds/rds mutants (p>0.05;
n=3). Finally, the GSH concentration ofwild-type retina samples was the lowest
of all four tissues analysed, at 0.08 pmol/g protein. This was significantly reduced
to about half of this value in the retinas
163
LIVER
Genotype n concentration se pw-value
Wild type 3 4.2027 0.1542
rd1/rd1 3 3.8625 0.7369 0.7752
atrd1/atrd1 3 3.5817 0.1700 0.2250
Rho 3 5.1527 0.1507 0.0758
rds/rds 3 4.2940 0.0485 0.8157
BRAIN
Genotype n concentration se pw-value
Wild type 3 0.9631 0.1082
rd1/rd1 3 1.3998 0.0433 0.1586
atrd1/atrd1 3 1.3015 0.0751 0.3598
Rho 3 1.1672 0.0314 0.4683
rds/rds 3 2.1092 0.2360 0.0437
HEART
Genotype n concentration se pw-value
Wild type 3 0.6642 0.0619
rd1/rd1 3 0.2579 0.0274 0.0440
atrd1/atrd1 3 0.3288 0.0273 0.0480
Rho 3 0.4714 0.0718 0.3324
rds/rds 3 0.9538 0.1623 0.3439
RETINA
Genotype n concentration se pw-value
Wild type 3 0.0841 0.0052
rd1/rd1 3 0.0430 0.0029 0.0253
atrd1/atrd1 3 0.0747 0.0125 0.6852
Rho'' 3 0.0411 0.0023 0.0235
rds/rds 3 0.0778 0.0046 0.6741
Table 7: Reduced glutathione (GSH) concentrations in wild-type and retinal degeneration mutants
Reduced glutathione concentrations (pmol/g protein) were measured in liver, brain, heart and retina from
wild-type and retinal degeneration mutants (rd1/rd1, atrd1/atrd1, Rho~'- and rds/rds). The standard errors
(se) and statistical significance compared with wild-type (pw-value) are shown. Statistical significant values
(pw<0.05) are highlighted in red.
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Figure35:Red cedlutathione(GSH)concentrationsimoustiss sfr mwild-typaretinal degenerationmut nts GSHconcentrationsw remeasur dithliv r,br ihe ta dtinafild-typer ldege ra i n (rd1/rd1,atrd1/atrd1,Rhords/ s)mutants.(*p<0.05
of rdl/rdl (p=0.03; n=3) and the Rho" (p=0.02; n=3) mutants, but remained at
wild-type concentrations in the atrdl/atrdl and rds/rds mutants.
4.3. Summary and Conclusions
In this chapter the rates of photoreceptor degeneration in four different retinal
degeneration mutants were investigated. Photoreceptor degeneration in the
rdl/rdl, atrdl/atrdl, Rho ' and rds/rds mutants was estimated to be complete by
3 weeks, 6 weeks, 3 months and 3 months of age respectively. These results are
compatible with previous reports (Portera-Cailliau et al., 1994; Humphries el al.,
1997; Hart et al., 2005; Lohr et al., 2006). The results from TUNEL assays for the
detection of apoptotic photoreceptor cells were also in good agreement with
previously published data. In the rdl/rdl mutant, the number ofTUNEL-positive
cells has been reported to be low until PI2 and then to peak at P14 (Portera-
Cailliau et al., 2004; Lohr et al., 2006). In our analysis, the peak of apoptosis was
delayed to P21, although there was a highly significant increase in apoptotic cells
at about P14 and P28. The detection of apoptotic cells in Rho'' mutants has been
shown to peak at P24 (Hobson et al., 2000), which was a week later than observed
in this study. Finally, although positive TUNEL staining in rds/rds mutants has
been shown to peak at PI8 and P60 (Portera-Cailliau et al., 1994; Lohr et al.,
2006), only a single peak at P14 was detected here. There have been no published
reports on the detection of apoptotic cells in the atrdl/atrdl mutant, which peaks
later (4 weeks) than in rdl/rdl (3 weeks), consistent with the slower rate ofONL
loss. The discrepancies in TUNEL staining between published data and the data
collected in this project could be explained by the fact that the time-points of
analysis in this project were not very frequent. The authors in some published
reports monitored photoreceptor degeneration daily, whereas in this project,
sample collection for analysis was performed at weekly or monthly intervals.
Also, it is worth noting that the genetic backgrounds of the mutants analyzed in
the published reports are the same to the ones analyzed in this project. Therefore,
the discrepancies cannot be attributed to genetic background differences.
In this analysis, the percentage of TUNEL-positive cells present in the
mutant retinas depended on the rate at which the retina degenerates. In a 3-week
old rdl/rdl mutant retina, more than 50% of the remaining photoreceptor cells
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were apoptotic. The maximum detected percentage of apoptotic cells in the
atrdl/atrdl mutant was 20% at 4 weeks of age. Finally, in the case of both the
Rho' ' and rds/rds mutants, the highest percentage of TUNEL-positive cells was
just above 10%. This apparent inverse relationship between the number of
apoptotic cells and the rate of degeneration raises an issue of timing. It is not
known how long it takes between DNA cleavage -which is detected by the
TUNEL assay- and disappearance of the apoptotic photoreceptor cell from the
retina. In the fast degenerating mutants, namely rdl/rdl and atrdl/atrdl, samples
were assayed weekly, whereas this was done on a monthly basis for the Rho'1' and
rds/rds mutants. Consequently, this could imply that, by the time apoptosis was
assayed in these mutants, many apoptotic photoreceptor cells may have
disappeared. However, in the case of the faster mutants, the tight time-points of
analysis may have allowed the detection ofmore apoptotic cells than the 'slower'
mutants.
Another interesting observation in the TUNEL assay results was the
detection of apoptotic cells in additional retinal layers. Although the disease
phenotype ofRP is known to primarily involve the degeneration ofphotoreceptor
cells, positive TUNEL staining was also observed in the ganglion cell layer of 4-
week-old rdl/rdl samples. This agrees with previous reports demonstrating that,
during photoreceptor degeneration, other cell types may make chemical
adjustments as a result of the loss of photoreceptor cells. Consequently, in
advanced stages of the disease, structural changes may involve all retinal cell
types (Sanyal et al., 1980).
The expression patterns of rhodopsin and rod cGMP phosphodiesterase
have previously been analysed in some of the mutants studied in this project.
Rhodopsin plays an important role in phototransduction and is often used as a
marker for photoreceptor OS. Therefore it was expected that altered rhodopsin
expression would be present in the retinal degeneration mutants in which the
photoreceptors degenerate. Although immunohistochemical detection of
rhodopsin was not performed on 1 or 2-week old wild-type retinas, it is known
that rhodopsin is expressed in the tissue at P5 (Tartelin et al., 2003). In a wild-
type retina, at P7, rhodopsin is localised at an irregular array ofmembraneous
structures, at PI 1, although it is present over the entire retina surface, it is
considerably increased in outer segment disks and by PI4, rhodopsin is
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uniformely expressed at OS (Jansen et al., 1987). As expected, rhodopsin
expression was completely abolished in the Rho ' mutant, but some was evident
in the remaining mutants. At the first time-point of analysis at 1 week of age,
before the formation ofOS, rhodopsin expression in rdl/rdl mutants was
localised at the ONL. It is not surprising that the protein was localised there
because the OS, where it would normally localise, were not formed yet. At 2
weeks however, when photoreceptor OS should have started to be formed and
degeneration in this mutant was evident, rhodopsin remained at the ONL. At the
final time-point of analysis, rhodopsin expression was abolished in the rdl/rdl
mutant, consistent with completion of degeneration. In the atrdl/atrdl mutant, at
the first time-point of analysis at 2 weeks of age, rhodopsin was mainly localised
at the OS, which were not fully differentiated. At 3 weeks, rhodopsin was found
solely in the ONL, possibly due to the degeneration of photoreceptor cells. As it
would have been expected due to progressed degeneration, rhodopsin expression
was almost absent in the 6-week-old atrdl/atrdl mutant. Finally, in the rds/rds
mutant, which fails to form OS, the rhodopsin localisation observed was
consistent with previous work by Jansen et al. (1987) and later by Nir et al.
(1990). Jansen et al. (1987) reported that in the rds/rds mutant, before the onset of
degeneration, rhodopsin expression was evident in the ciliary protrusions, as in
the wild-type retina. At the onset of degeneration, however, some photoreceptor
cells had small membrane-bound vesicles that were rhodopsin-positive. Similarly,
Nir et al. (1990) initially detected rhodopsin in vesicular membrane profiles and
membrane whorls that appeared at the distal tip of the cilium, probably reflecting
failure to form OS. In older retinas, the same authors detected the hishest labelling
density for rhodopsin along the plasma membrane that surrounds nuclei.
The expression of Pde6b was also immunohistochemically detected in
retinal degeneration mutants (Figure 33). The suitability of the antibody used was
assessed on adult wild-type samples, in which Pde6b was localised mainly at the
photoreceptor OS and faintly at the OPL and IPL. Although the localisation of
Pde6b was not assessed on age-matched wild-type controls, it was not surprising
that in the rdl/rdl mutants it was localised in the area where photoreceptor OS
would potentially form. As soon as photoreceptor degeneration was evident
however, Pde6(3 expression in the rdl/rdl mutant was more prominent in inner
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retinal layers (like IPL and OPL) and was abolished upon completion of the
degeneration. At the first (2 weeks) and last (6 weeks) time-points of analysis of
the atrdl/atrdl mutant, Pde6b expression was very faint and unspecific,
consistent with the genotype of this mutant. In Figure 33H, the increased
expression of Pde6b observed in the IPL was probably an experimental artefact.
This cannot be interpreted as mislocalisation of the protein because, firstly, at the
previous and subsequent time-points its expression was comparatively low, and,
secondly, mislocalisation should be confined in photoreceptor cells, in which
Pde6b is normally localised, and not in a different type of cells where it is not
expressed. In the Rho'~ mutant, the expression of Pde6b was very faint compared
to the adult wild-type and, as expected, remained at this low level as degeneration
progressed. Finally, in the 1-month-old rds/rds mutant, Pde6b expression was
faint compared to the adult wild-type and localised where OS would potentially
form. In subsequent time-points however, expression was more prominent in
inner retinal layers. Although, even in the wild-type retina there was faint Pde6b
expression at the IPL, the increased signal observed at the IPL of 2 and 3-month-
old rds/rds mutant was considered an artefact, rather than mislocalisation.
The four retinal degeneration mutants studied in this project were also
analysed for signs of oxidative damage. The specific activity of the oxidative
stress-sensitive complex I (CI) was spectrophotometrically measured in liver,
brain, heart and retina samples, using the activity of the oxidative stress-
insensitive citrate synthase (CS) as an internal control.
Indeed, the CS activity was at wild-type levels in all the samples,
irrespective of genotype. The activity ofCI remained at normal levels in all the
liver, brain and heart samples, but was significantly reduced in the retina samples
collected from each retinal degeneration mutant. These results indicate that there
is increased oxidative damage in the retinas of these mutants as a consequence of
the specific mutations. Signs of oxidative stress have been previously reported in
the rdl/rdl and rds/rds mutants by Lohr et al. (2006), who found increased
expression of the oxidative stress markers ceruloplasmin and clusterin,
accompanying the degeneration. However, thist is the first time that oxidative
damage has been reported in the atrdl/atrdl and Rho ' mutants, since a decrease
in the specific activity ofCI is a marker of oxidative stress.
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The oxidative status of different tissues was also assessed by measuring
the concentration ofGSH, which serves as an indicator of oxidative stress. In
wild-type liver, brain, heart and retina, the GSH concentrations were 4.2, 1, 0.6
and 0.1 pmol/g protein. The GSH concentration in the mouse retina has not been
previously reported, but information on liver, brain and heart is available. For
example, van Remmen et al. (1999) reported that the GSH concentration in wild-
type liver, brain and heart are at a 12:1.5:1 ratio, which is in line with the findings
of this project. In the retinal degeneration mutants, the GSH concentrations
remained at wild-type levels in most samples. They were however significantly
increased in rds/rds brain (p=0.04; n=3), decreased in rdl/rdl and atrdl/atrdl
heart (both p=0.04; n=3), and decreased in rdl/rdl (p=0.3; n=3) and Rho" retina
(p=0.02; n=3) samples. It is not clear why differences were detected in tissues
other than the retina, since the mutated genes in these mice are specifically
expressed in the retina and the degeneration is confined to this tissue. The
decreased GSH concentrations however in the rdl/rdl and Rho'1' retinas may also
indicate increased oxidative stress in retina.
Various papers have reported the involvement of oxidative stress in
neurodegenerative diseases, including some involving a retinal phenotype. In a
paper by Travis et al. (1991), the authors suggest that a possible mechanism
explaining photoreceptor degeneration in the rds/rds mutant is the increased
oxygen tension to which the cells are imposed, due to the lack ofOS. If increased
oxygen availability in the cell increases the production of its harmful ROS by¬
products, then this could explain the observed results. Outer segments do not
develop in any of the retinal degeneration mutants analyzed in this chapter, and
this could therefore provide a unifying explanation for the observed results.
Other explanations are possible, such as calcium overload in the Pde6b
mutants. As discussed by Hussain et al. (1992), the compromised activity of
Pde6b in rdl/rdl and atrdl/atrdl mutants results in increased concentration of
free cGMP in the photoreceptor OS, greater dark current and consequently
• 2"b • • 2+increased intracellular Ca concentration. An increase in Ca intracellular levels
has been shown to act as a trigger for cell death (Olshevskaya et al., 2004) and
2+
high outer segment Ca~ concentration has also been implicated as a causal factor
in apoptosis in other retinal degenerations (Yuan et al., 2003, Fain 2006).
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Additionally, Ca" can affect the activity of cGMP phosphodiesterase and
rhodopsin and potentially influence the sensitivity of rod photoreceptor cells
(Hussain et al., 1992).
Finally, photoreceptor degeneration in Rho' ' mutants is possibly attributed
to both the functional and structural role of rhodopsin in the retina. Liang et al.
(2004) set out to understand how the lower expression of rhodopsin affects the
structure and physiology of photoreceptor cells in Rho+/~ heterozygotes and
reported lower Rho density, OS of decreased size and accelerated
electrophysiological responses in these mutants. These authors proposed that the
electrophysiological differences between wild-type and Rho+/~ heterozygotes were
due to changes in the volume of the OS and concomitant changes in cation
homeostasis, including that of calcium. The smaller volume ofOS would
2_|_accelerate the cellular fluxes of Ca , and as in the case of the Pde6b mutants,
2+Ca overload could account for photoreceptor degeneration in Rho mutants, both
homozygous and heterozygous. Another possibility, also suggested by Liang et al.
(2004) is the altered expression of critical genes involved in ion homeostasis.
Therefore, photoreceptor degenertion in Rho''' mutants could be attributed to a
combination of structural changes, altered cation exchanges and gene expression
levels.
In summary, retinal degeneration was complete within a few weeks or
months, in all the mouse mutants analysed in this chapter. Although they were
each mutated in functionally different genes, signs of oxidative damage to the
retina were detected in each mutant. However, these results do not necessarily
imply that oxidative stress is a primary factor in these retinal degenerations.
Although oxidative stress has been shown to be a primary cause of cell death in
other neurodegenerative disorders like Alzheimer's and Parkinson's (Ninomura et
al., 1999; Kim et al. 2002), its presence in the retinal degeneration mutants
analysed here might be independent to the photoreceptor degeneration observed.
Additional work including analysis with more markers of oxidative stress, to
elucidate the exact nature of oxidative stress in mutated retinas, and experimental




PHENOTYPIC ANALYSIS OF RETINAL DEGENERATION
MUTANTS CROSSED TO SOD2 HETEROZYGOTES
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5.1. Introduction
In this chapter, the role of oxidative stress in photoreceptor degeneration is
investigated by genetically modifying the levels of Sod2 in the retinal
degeneration mutants. The rdl/rdl, atrdl/atrdl and Rho~' mutants were crossed
to Sod2+/~ heterozygous mice and double mutants were generated. The genotypes
of the animals analysed were rdl/rdl Sod2+/', atrdl/atrdl Sod2+l~ and Rho''
Sod2+The rds/rds mutant was not crossed to the Sod2 mutant as the Prph2 locus
is closely linked to Sod2 (~10 cM) on mouse chromosome 17. In this chapter, the
genotype ofSod2+/~ mutants was initially confirmed and their retinal phenotype
was analysed, by both ONL and TUNEL analysis. The rates of retinal
degeneration in the double mutants were measured by the same methods and
comparisons were made with age-matched wild-type and single retinal
degeneration mutants. In addition, the effect of decreased Sod2 expression on the
activities of citrate synthase (CS) and complex I (CI), as well as on retinal
reduced glutathione (GSH) concentrations, were assessed in liver, brain, heart and
retina samples from the mutants.
5.2. Results
5.2.1. Confirming the genotype of Sod2+l~ mutants
Different methods were used to confirm the decreased levels of Sod2 enzyme in
the Sod2+l' mice. Western blots were performed on protein samples prepared from
retinas ofmutant and wild-type animals (Figure 36A-D). Although the level of
Sodl, the cytosolic isoform of superoxide dismutase, remained the same in the
two genotypes, the level of Sod2 was markedly decreased in the heterozygote,
consistent with the expected 50% reduction in Sod2+l~ mutants.
Additionally, immunohistochemistry for Sodl and Sod2 was performed on
frozen eye sections from wild-type and mutant animals (Figure 36E-I). Sodl was
most strongly expressed in the OS of photoreceptor cells and its level remained
the same in the two genotypes. Sod2, however, was strongly expressed in the IS
ofphotoreceptor cells, as well as in the IPL and OPL. Sod2 expression was
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Figure 36: Confirming the genotype of Sod2*'- heterozygous mice
The decreased Sod2 content of Sod2+'- mutant retinas was confirmed by using anti-Sod1 (a-Sod1) and anti
Sod2 (a-Sod2) antibodies separately in Western blotting (A-D) and by immunohistochemistry (E-l). The level
of Sodl was the same in the wild-type (A) and SodF'- mutant (C) whereas that of Sod2 was decreased in the
mutant (D) in comparison to the wild-type (B). However, lack of a loading control in this experiment demands
confirmation of the result. Immunohistochemistry for Sodl and Sod2 on frozen eye sections from wild-type
(Sodl, F; Sod2, G) and mutant (Sodl, H; Sod2, I) mice also confirmed decreased levels of Sod2 in the
heterozygous sample [IPL: inner plexiform layer, INL: inner nuclear layer, OPL: outer plexiform layer, ONL:
outer nuclear layer, IS: inner segment and OS: outer segment of photoreceptor cells]
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5.2.2. Phenotypic analysis of Sod2+l~ mouse eyes
5.2.2.1. Photoreceptor degeneration analysis
ONL analysis and TUNEL analysis were performed on paraffin-embedded
sections of eyes from Sod2+l~ mice to assess the degree of retinal degeneration in
these mutants. Samples were collected at set time intervals of two months until
one year of age.
No retinal degeneration was evident in the Sod2+/~ mutant by ONL
analysis (Figure 37A). The mean thickness of the ONL across all time-points
remained unchanged in the mutants, as did that of the INL, at 11.07 (s.d. 0.64)
and 5.54 (s.d. 0.52) nuclei thick, respectively (Figure 37B). The corresponding
values for the wild-type animals were 11.11 (s.d. 0.76) for the ONL and 5.63 (s.d.
0.4) for the INL. No degeneration of either nuclear layer was noted in either
genotype up to one year of age (Figure 37C), as the thickness of both the ONL
and INL was not significantly different between the first and last time-points of
the analysis.
TUNEL analysis was performed for the detection of apoptotic cells in the
retina of Sod2+/~ animals. In agreement with the results from the ONL analysis, no
TUNEL-positive cells were detected at any age (Figure 38), confirming the lack
of a retinal degeneration phenotype in Sod2+/~ animals up to one year of age.
5.2.2.2. Markers for photoreceptor cells
Paraffin-embedded eye sections from Sod2+' mice were subjected to
immunohistochemistry using different markers of photoreceptor cells. The
staining patterns for rhodopsin and rod cGMP phosphodiesterase (Pde6b) were
assessed in the Sod2+/~ mutants and compared to wild-type samples of the same
age (Figure 39). Rhodopsin was successfully localised in the OS of rod
photoreceptor cells and was unaltered by the age or genotype of the samples
analysed. Similarly, the antibody against Pde6b stained the same retinal layers in
both the wild-type and mutant samples, namely the OS of rod photoreceptor cells


































Figure 37: Outer nuclear layer (ONL) analysis of Sod2*' heterozygous mice
Paraffin-embedded eye sections from Sod2+l- mutants were stained with H&E for histology
evaluation and ONL analysis. Samples were collected every two months for one year. (A)
The histology of the Sod2+/- eyes remained very good throughout the first year. (B) The
mean thickness of the outer and inner nuclear layers across all time-points remained
unchanged, irrespective of genotype. (C) ONL analysis showed no degeneration of
photoreceptor cells with time.
negative positive 2 mo 4 mo 6 mo 8 mo 10 mo 12 mo
Figure 38: TUNEL analysis of Sod2*'- mutants
TUNEL assays on paraffin-embedded eye sections from Sod2+l- mutant
mice. No TUNEL-positive apoptotic cells were detected in the negative
control (a) but all nuclei were TUNEL-positivie in the positive control (b). No
apoptotic photoreceptor cells were detected in the Sod2+/- heterozygote
samples (c, 2; d, 4; e, 6; f, 8; g, 10; h, 12 months old)
Sod2*'* Sod2*'* Sod2*' Sod2
b I c Id I e
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Figure 39: Photoreceptor markers in SodT'~ mutants
Immunohistochemistry for rhodopsin (Rho) (a-e) and rod cGMP
phosphodiesterase 6 p subunit (Pde6b) (f-j) on paraffin-embedded eye
sections from wild-type (b, c, g, h) and Sod2heterozygous (d, e, i, j)
mice. Samples were collected at 2 (b, d, g, i) or 12 (c, e, h, j) months of
age. The negative controls for the antibodies are shown (a, f).
5.2.3. Effect of the Sod2+l~ genetic background on
degeneration rates of retinal degeneration mutants
As previously shown, in the rdl/rdl mutants, retinal degeneration is completed by
3 weeks of age. ONL analysis showed that there was no significant difference in
the rate ofphotoreceptor degeneration between the single rdl/rdl and double
rdl/rdl Sod2+'mutants, in both ofwhich cell loss was completed by postnatal
week 3 (Figure 40). At no time-point of the analysis was there a significant
difference in the thickness of either the ONL or the INL, between the two
genotypically different mutants.
In agreement with the ONL analysis results, TUNEL assays showed an
increasing number of apoptotic cells in the mutants compared to wild-type
controls. The results were similar whether Sod2 was fully or partially expressed
(Figure 40). At all time-points when samples were analyzed the percentage of
TUNEL-positive cells was comparable between the two groups. The TUNEL
staining previously observed in retinal layers in older rdl/rdl mutants, was also
observed on a Sod2+/~ background.
Similar to the rdl/rdl mutants, decreased levels of Sod2 in the atrdl/atrdl
mutants had no effect on the rate of photoreceptor degeneration (Figure 41). All
nuclei were lost from the ONL of double atrdl/atrdl Sod2+,~ mutants within 6
weeks of age. The ONL and INL thicknesses remained almost identical between
the single and double mutants.
Similar to the ONL analysis, TUNEL-positive cells were increasingly
detectable with time in the atrdl/atrdl Sod2+l' double mutants (Figure 41). At no
point in the analysis were the double mutants significantly different from the
single retinal degeneration mutants, in terms of the percentage of TUNEL positive
cells.
In Rho~ ~ mice, it takes significantly longer for photoreceptor degeneration
to be completed, namely 3 months. Crossing these mutants to Sod2+' mice and
ONL analysis, revealed that the course ofphotoreceptor degeneration did not
change in response to decreased Sod2 levels (Figure 42). All photoreceptor cells
were lost by three months of age and the rate at which
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this happened was also almost identical between the two genotypes. At no time-
point was there a significant difference in the thickness of either the ONL or the
INL between the single and double mutants.
The results from TUNEL assays performed on Rho'1' Sod2+/~ double
mutants, with half the wild-type Sod2, showed a similar pattern to that seen in the
single Rho'1' mutant (Figure 42). Detection of TUNEL-positive cells peaked at the
second month of age, after which the percentage of apoptotic cells remained at
lower levels. Although fewer apoptotic cells were detected on a Sod2+/'
background, this was not statistically significant.
5.2.4. The effect of decreased Sod2 expression on the
enzyme activities of retinal degeneration mutants
The specific activities ofCS and ofCI, representing oxidative stress-insensitive
and -sensitive activities respectively, were measured in mitochondrial samples
prepared from different tissues collected from mutant mice, and a comparison was
made between single retinal degeneration mutants and those crossed to Sod2+/'
mice. The specific activities of these two enzymes were measured in the liver,
heart, brain and retina isolated from the animals, and mitochondrial fractions were
prepared for spectrophotometric assays. Comparisons between the two Sod2
genetic backgrounds (wild-type and heterozygous knock-out), were made and the
numerical results of the analysis are given in Table 8. The results are also
graphically presented in Figure 43.
There were two general observations from the numerical results obtained.
Firstly, as expected, CS activity was always higher than that ofCI in all the
tissues, with the CI/CS ratio ofwild-type animals ranging from 0.07 to 0.12.
Secondly, the CI/CS ratio was highest in the retina when compared to the other
tissues.
The CI enzyme activities in the Sod2+/' single mutant samples were
uniformely affected by the decreased expression of Sod2. CS activity remained
the same as wild-type in all tissues assayed (Table 8). In contrast, the specific
activity ofCI was reduced in liver (p=0.05; n=5), brain (p=0.03; n=5), heart
(p=0.04; n=5) and retina (p=0.05; n=3) by approximately 50-80% in each tissue.
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LIVER
Citrate Synthase Complex I
Genotype n activity se pw-value Pm-value activity se pw-value Pm-value
Wild type 4 1.6949 0.1893 0.5969 0.2011
Sod2+l~ 5 2.0647 0.2043 0.2358 0.1608 0.0454 0.0496
rd1/rd1 4 2.4467 0.4353 0.1644 0.4743 0.0779 0.5904
rd1/rd1 Sod2+'- 5 2.275 0.2821 0.1516 0.7404 0.1495 0.0272 0.0413 0.0035
atrd1/atrd1 5 1.7838 0.4554 0.8744 0.4807 0.0564 0.5559
atrd1/atrd1 Sod2+'- 5 2.175 0.3255 0.2743 0.5045 0.1752 0.0201 0.0498 0.0009
Rho 4 2.3787 0.3408 0.13 0.3215 0.1168 0.2812
Rho'1- Sod2+l- 4 2.0165 0.3001 0.3995 0.4555 0.4522 0.1767 0.6083 0.5602
BRAIN
Citrate Synthase Complex I
Genotype n activity se pw-value Pm-value activity se pw-value Pm-value
Wild type 4 3.7515 0.7808 0.2444 0.0518
Sod2+'- 5 3.875 0.5603 0.9175 0.0509 0.0116 0.0323
rd1/rd1 4 5.3456 0.4538 0.1446 0.3236 0.0522 0.3235
rd1/rd1 Sod2+'- 5 3.8162 0.4261 0.9482 0.0493 0.2251 0.0442 0.792 0.2000
atrd1/atrd1 4 4.3842 0.9078 0.6118 0.3758 0.0211 0.0704
atrd1/atrd1 Sod2+'- 5 5.1783 0.5236 0.1958 0.4773 0.215 0.0571 0.7153 0.0384
Rho -'- 3 4.0025 0.2766 0.8208 0.3001 0.0613 0.5236
Rho~'- Sod2+'- 4 3.9824 0.8009 0.8416 0.9858 0.217 0.0453 0.7016 0.3112
HEART
Citrate Synthase Complex I
Genotype n activity se pw-value Pm-value activity se pw-value Pm-value
Wild type 4 13.9632 2.3818 1.8227 0.3594
Sod2+l- 5 15.8853 1.5219 0.5014 0.8714 0.1706 0.037
rd1/rd1 3 27.527 6.5664 0.0794 1.3934 0.0998 0.3672
rd1/rd1 Sod2+'- 3 16.9338 2.2636 0.4217 0.2019 1.5166 0.293 0.5601 0.7108
atrd1/atrd1 3 18.0613 5.9593 0.5063 1.3424 0.3161 0.3815
atrd1/atrd1 Sod2+'- 3 15.3039 1.6449 0.6868 0.6787 1.5622 0.1226 0.5773 0.5523
Rho -'- 3 15.4951 5.4382 0.7862 2.5 0.0325 0.1728
Rho-1- Sod2+l- 3 15.2696 1.1299 0.6787 0.9696 0.5895 0.1955 0.0424 0.0006
RETINA
Citrate Synthase Complex I
Genotype n activity se pw-value Pm-value activity se pw-value Pm-value
Wild type 6 1.1066 0.1144 0.7248 0.1651
Sod2+'~ 3 0.6581 0.2472 0.0955 0.1393 0.0618 0.0482
rd1/rd1 6 1.0074 0.1148 0.6885 0.1541 0.0370 0.0071
rdVrdl Sod2*'- 3 0.8824 0.0337 0.2614 0.7065 0.0857 0.0326 0.0337 0.2793
atrd1/atrd1 4 1.3502 0.3817 0.4865 0.1969 0.0630 0.0377
atrd1/atrd1 Sod2+l' 5 0.932 0.1200 0.3387 0.3361 0.0402 0.0057 0.0106 0.0479
Rho'/~ 6 0.8719 0.0632 0.1028 0.1058 0.0087 0.0038
Rho-'- Sod2+l- 3 0.9706 0.1047 0.4768 0.4197 0.1206 0.0418 0.0419 0.6398
Table 8: Enzyme activities in wild type and retinal degeneration mutants crossed to Sod2
heterozygotes
Citrate synthase and complex I activities (pmol/min/g tissue) were measured in liver, brain, heart and retina
from wild type, retinal degeneration mutants (rd1/rd1, atrd1/atrd1 and Rhcr'-) and retinal degeneration
mutants crossed to Sod2 heterozygotes (rdl/rdl Sod2+/~, atrd1/atrd1 Sod2+/~, and Rho'1' Sod2+/~) . The
standard errors (se) and statistical significance compared with wild type (pw-value) and with single retinal
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Decreased Sod2 levels in the retinal degeneration double mutants did not have the
same effect in reducing CI as in the Sod2+' mutants in all tissues. Although the
specific activity of CS in the double mutants remained at wild-type levels in all
tissues, CI activity was significantly lower than the wild-type only in some. None
of the brain or heart samples from the double mutants had significantly reduced
CI activity, which was found only in the rdl/rdl Sod2+,~ (p=0.04; n=5) and
atrdl/atrdl Sod2+,~ livers (p=0.05; n=5). However, the activity ofCI was
significantly decreased in all the retina samples from double mutants (all p<0.05;
n=3-6).
What is ofparticular interest in this chapter is the effect that the decreased
Sod2 expression had on the retinal degeneration mutants. Therefore, comparisons
between the single and the double mutants, rather than with wild-type (Table 8)
were made. CS activity in double mutants remained unaffected by decreased Sod2
levels, apart from in the brain rdl/rdl Sod2+/~ sample, where CS activity was
marginally increased (p=0.05; n=5). Compared with single retinal degeneration
mutants, CI activity was reduced in the liver samples from the rdl/rdl Sod2+l~
(p=0.004; n=5) and atrdl/atrdl Sod2+/' (p=0.0009; n=5) mutants, in the
atrdl/atrdl Sod2+'~ brain samples (p=0.04; n=5), the Rho'1' heart samples
(p=0.0006; n=3) and finally in the retina samples of atrdl/atrdl Sod2+'~ mutants
(p=0.05; n=5).
5.2.5. Reduced glutathione concentrations in the retinal
degeneration mutants crossed to Sod2+~ mice
GSH concentrations were measured in liver, brain, heart and retina samples from
retinal degeneration mutants crossed to Sod2+' mice (Table 9, Figure 44).
Comparisons were made between these double mutants and the respective single
retinal degeneration mutants, to elucidate the effect of the decreased Sod2
expression on GSH concentrations.
GSH concentrations were significantly decreased in the Sod2+l~ mutants in
the liver (p=0.002; n=3), brain (p=0.05; n=3) and retina (p=0.004; n=3) by 57, 70
and 72%, respectively. They were also decreased in the heart samples by
approximately 25% but this was not statistically significant (p=0.33; n=3).
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LIVER
Genotype n concentration se pw-value pm-value
Wild type 3 4.2027 0.1542
Sod2+l~ 3 1.7984 0.1704 0.0020
rd1/rd1 3 3.8625 0.7369 0.7752
rd1/rd1 Sod2+'- 3 3.6429 0.2300 0.3088 0.8775
atrd1/atrd1 3 3.5817 0.1700 0.2250
atrd1/atrd1 Sod2+/- 3 3.8118 0.1111 0.3437 0.5916
Rhov~ 3 5.1527 0.1507 0.0758
Rho''- Sod2+l~ 3 2.8714 0.2620 0.0527 0.0121
BRAIN
Genotype n concentration se pw-value Pm-value
Wild type 3 0.9631 0.1082
Sod2+l' 3 0.2903 0.0342 0.0495
rd1/rd1 3 1.3998 0.0433 0.1586
rd1/rd1 Sod2+l' 3 1.3087 0.2107 0.4255 0.8189
atrd1/atrd1 3 1.3015 0.0751 0.3598
atrd1/atrd1 Sod2+l" 3 1.5251 0.0369 0.0845 0.1046
Rho 3 1.1672 0.0314 0.4683
Rho-1- Sod2+'- 3 1.0280 0.0513 0.8174 0.2525
HEART
Genotype n concentration se pw-value Pm-value
Wild type 3 0.6642 0.0619
Sod2+l- 3 0.5032 0.0451 0.3340
rd1/rd1 3 0.2579 0.0274 0.0440
rd1/rd1 Sod2+'- 3 0.6515 0.0329 0.9376 0.0060
atrd1/atrd1 3 0.3288 0.0273 0.0480
atrd1/atrd1 Sod2+/- 3 0.4575 0.0393 0.2086 0.2274
Rho -'- 3 0.4714 0.0718 0.3324
Rho-'- Sod2+'- 3 0.3786 0.0530 0.1449 0.6464
RETINA
Genotype n concentration se pw-value Pm-value
Wild type 3 0.0841 0.0052
Sod2+'- 3 0.0236 0.0041 0.0039
rd1/rd1 3 0,0430 0.0029 0.0253
rd1/rd1 Sod2+/" 3 0.0390 0.0037 0.0202 0.6456
atrd1/atrd1 3 0.0747 0.0125 0.6852
atrd1/atrd1 Sod2+'- 3 0.0465 0.0094 0.0955 0.3559
Rho -'- 3 0.0411 0.0023 0.0235
Rho''- Sod2+'- 3 0.0292 0.0026 0.0032 0.1466
Table 9: Reduced glutathione (GSH) concentrations in wild type and retinal degeneration mutants
crossed to Sod2 heterozygotes
Reduced glutathione concentrations (pmol/g protein) were measured in liver, brain, heart and retina from
wild type, retinal degeneration mutants (rd1/rd1, atrd1/atrd1 and Rho-'-) and retinal degeneration mutants
crossed to Sod2 heterozygotes (rd1/rd1 Sod2+/~, atrd1/atrd1 Sod2+/~, and Rho-'- Sod2+/~) . The standard
errors (se) and statistical significance compared with wild type (pw-value) and with single retinal
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The decrease in the expression ofSod2 in the retinal degeneration double
mutants did not have an effect on the GSH concentrations compared with the
single mutants in retina or brain samples. It did however cause a significant
reduction of GSH concentrations in the Rho~ ' liver (p=0.01; n=3) and rdl/rdl
heart (p=0.006, n=3) samples.
5.3. Summary and conclusions
In this chapter, the influence of oxidative stress on photoreceptor degeneration
was investigated by genetically decreasing the levels of the mitochondrial
antioxidant enzyme Sod2 in retinal degeneration mutants. The progression of
photoreceptor degeneration and the level of oxidative stress were assessed in
rdl/rdl Sod2+/~, atrdl/atrdl Sod2+l~ and Rho~'~ Sod2+/~ mutants and comparisons
were made with the single retinal degeneration mutants analyzed in the previous
chapter.
Initially, the single Sod2+l~ mutants were analysed. The decreased levels of
Sod2 in retinal samples from the mutants were confirmed by both immunoblotting
and immunohistochemistry. In the same samples, the levels of Sodl were
unchanged, confirming previous reports that there is no compensatory increase in
the level of the cytosolic isoform of superoxide dismutase, in response to a
decrease of the mitochondrial isoform (Williams et al., 1998). In addition, the
increase in oxidative state in the liver, brain, heart and retina of Sod2+l~ mutants
was confirmed by spectrophotometric enzyme assays and GSH measurements. As
expected, the activity of citrate synthase (CS) remained at wild-type levels, while
that of complex I (CI) was significantly reduced in all the Sod2+' tissues assayed.
Although the 50% reduction in CI activity measured in heart samples (p=0.037;
n=5) is compatible with previous results by van Remmen et al. (2001), the 70%
reduction in liver samples (p=0.049; n=5) was higher than the previously reported
30% decrease in the same tissue (van Remmen et al., 1999). Brain and retina
samples had the most pronounced reduction in CI activity, at 80% (brain:
p=0.032; n=5, retina: p=0.048; n=3), but no published data are available for
comparison. The previously reported reduction or lack of change in the GSH
concentration ofSod2+' livers and hearts, respectively (van Remmen et al., 1999;
2001) were confirmed in our analysis. Additionally, the GSH level was
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significantly reduced in brain and retina samples from Sod2 heterozygous
knockout mice (brain: p=0.049; n=3, retina: p=0.004; n=3). The increased
oxidative status of the Sod2+l~ mutants used in this project was therefore
confirmed.
Having confirmed both the decreased level of Sod2 and its effects on
oxidative damage to the mutant retina, Sod2+' samples were further analysed for
signs of photoreceptor degeneration. Sandbach et al. (2001) previously reported
that MnTBAP-treated Sod2~/' null mice develop a retinal degeneration phenotype
which, although it included thinning of some inner retinal layers, did not include
photoreceptor degeneration. Here, Sod2+/~ heterozygotes showed no signs of
photoreceptor degeneration up to the age of one year, as neither the ONL became
thinner with age, nor were any photoreceptor cells stained positively for TUNEL.
It is doubtful whether in these mutants photoreceptors would degenerate after one
year of age, as even in slowly degenerating mutants, like Roml'the
degeneration is evident within the first year (Clarke et al., 2000). The unchanged
expression of the OS photoreceptor markers rhodopsin and rod cGMP
phosphodiesterase further supported the lack of an altered retinal phenotype in
Sod2+/~ mutants. In summary, the retinal phenotype of Sod2+/~ mutants was limited
to decreased CI activity, but did not show any evidence ofphotoreceptor
degeneration.
In an attempt to assess the effect of decreased Sod2 expression on the
different retinal degeneration mutants, double mutants were generated. Decreased
levels of Sod2 did not however influence the degeneration rates in any of the
double mutants analyzed. In rdl/rdl Sod2+,~, atrdl/atrdl Sod2+'~ and Rho~'~ Sod2+/~
samples all photoreceptor cells were lost by the third week, sixth week and third
month of age, respectively. These measurements were identical to those collected
in the previous chapter when the single retinal degeneration mutants with wild-
type levels of Sod2 were analysed.
The lack of an effect of decreased Sod2 expression on rates of
degeneration was not completely unexpected. In the homozygous rdl and the
atrdl mutants, both of which have mutations in the Pde6b gene, photoreceptor
degeneration is evident at two weeks of postnatal age, even before the
differentiation of the photoreceptor cells is complete. This could therefore imply
that the specific Pde6b mutations are of such severity that increased cellular
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stress, in the form of genetically decreased levels of Sod2, cannot increase the
rates of degeneration any further. In this context, the unaltered degeneration rate
in the Rho~'~ mutant was unexpected. The slower degeneration rate in Rhd'~ retinas
implies a less severe mutation, whose effect would, in theory, be more readily
modified.
Nevertheless, biochemical analyses in the double mutants revealed some
evidence of oxidative damage resulting from decreased Sod2 expression. As
expected, the activity of CS remained at wild-type levels in all the tissues assayed
irrespective of genotype. Surprisingly, however, although decreased Sod2
expression should have caused a decrease in the activity ofCI in all the double
mutant tissues, this was only the case in some, namely in the rdl/rdl Sod2+l~ and
atrdl/atrdl Sod2+l~ livers and in all the double mutant retinas. What is particularly
noteworthy is the comparison between the measurements obtained in the previous
chapter, in single retinal degeneration mutants, and those collected in this chapter,
in double mutants. Only in the case of the atrdl/atrdl mutant was retinal CI
activity further reduced due to the Sod2 heterozygote background (p=0.048; n=5).
Finally, the GSH measurements in the retina of double retinal degeneration
mutants remained unaffected by decreased Sod2 levels.
To summarise, the genetically decreased levels of Sod2 activity neither caused
a retinal degeneration in mice nor did they change the rates of retinal degeneration
or the number of detected apoptotic cells in mouse retinal degeneration models.
The reduced activity of complex I in rdl/rdl, atrdl/atrdl and Rho1' mutant
retinas was only further decreased in the atrdl/atrdl mutant, as a result of the
Sod2 heterozygous genetic background.
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CHAPTER 6
THE EFFECT OF MITOQ ON RETINAL
DEGENERATION MUTANTS
6.1. Introduction
In this chapter, the redox state of the mouse retinal degeneration mutants rdl/rdl,
atrdl/atrdl, Rho~'~ and rds/rds was altered by administration of the
mitochondrially-targeted antioxidant MitoQ. A preliminary study was performed
on wild-type animals to investigate the toxicity of the drug, as well as its
distribution in different tissues, and in particular in the retina. The degeneration
rates of the photoreceptor cells were measured in the different mutants after
administrating the antioxidant, by both ONL and TUNEL analyses. Finally,
spectrophotometric assays assessing the activity of the mitochondrial enzymes
citrate synthase (CS) and complex I (CI), and the reduced glutathione (GSH)
concentrations of different tissues, were performed in MitoQ-treated and -
untreated retinal degeneration mice.
6.2. Preliminary study: assessing the toxicity, uptake and distribution
ofMitoQ
6.2.1. Study set-up
A preliminary experiment was set up to assess the stability ofMitoQ in drinking
water as well as its effects on food and water consumption, health and breeding
capacity of the mice that were administered this antioxidant.
The layout of the experiment is shown diagrammatically in Figure 45.
Three cages (referred to as 'Adult'), each with 5 wild-type C57BL/6 male mice,
were set up. The animals had free access to drinking water that was supplemented
with 0 pM, 250 pM or 500 pM ofMitoQ corresponding to control, low or high
doses of the drug, respectively. At the start of this part of the study, which lasted
for 3 months, the animals were 4 weeks old. The weight, food and water
consumption of the animals were measured on a daily basis, and regular health
checks were performed, based on coat condition, salivation, respiration and
behaviour/movement. Three additional cages (referred to as 'Young'),
corresponding to the same doses of the drug as above, were also set up, this time
with breeding trios (one male x two females) in each cage, starting at the age of 6
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in the same way as the 'Adult' mice and the effects of MitoQ on both the breeding
capacity of the mice and the survival of litters were assessed.
6.3. Results
6.3.1. Stability
MitoQ, which is a yellow powder, was stored at 4°C and kept in the dark. It was
dissolved in water at the desired concentrations and administered to mice at room
temperature. It was also protected from light, by covering water bottles with tin
foil. The stability of MitoQ was assessed spectrophotometrically at 268 nm on a
daily basis for a period of 3 weeks (Figure 46A). Starting from an initial
absorbance measurement of 2.941 (s.d. 0.036) and 2.786 (s.d. 0.032) for the high
and low doses, respectively, on day one, a significant decrease in absorbance was
observed 4 days later. It was concluded that fresh solutions ofMitoQ needed to be
made up every three days.
6.3.2. Food consumption
The food consumption of the animals in the 'Adult' cages was measured by
weighing the chow daily for a period of 4 weeks. Food consumption was
increased with the age ofmice, from about 3.2 g/animal/day at 4 weeks old to 4
g/animal/day at 8 weeks old in the MitoQ-untreated controls (Figure 46C). The
food consumption was almost identical for the mice treated with no MitoQ, low or
high dose. The mean food consumption during the period of the preliminary study
was 3.5 ± 0.36, 3.49 ± 0.40 and 3.70 ± 0.48 g/animal/day for the control, low and
high doses, respectively (Figure 46D).
6.3.3. Water consumption
The water consumption of the animals also increased slightly with age (Figure
46E). Animals administered plain water started with a water consumption of 4.9
ml/animal/day and by the end of the study they were consuming 5.1
ml/animal/day. Mice, administered with MitoQ started offwith very low water

















Figure 46: Preliminary study assessing the stability of MitoQ and the effects of its
administration on weight gain, food consumption and water consumption.
Wild-type C57BI/6 adult mice were administered plain water (control) or water supplemented with a low
(250 pM) or high (500 pM) dose of MitoQ. (A) The stability of MitoQ was monitored daily by its
absorbance at 268 nm for a period of 3 weeks. A significant drop in absorbance was recorded 4 days
after preparation, although this was not consistent. Fresh MitoQ dilutions were subsequently prepared
every three days. The weight gain (B) of adult male animals was monitored daily for a period of 4
weeks and weekly thereafter for an additional 2 months. No significant dose-related differences in
weight gain were observed. The food (C, D) and water (E, F) consumption of the animals were
measured daily for a period of 4 weeks. No significant differences were observed in food consumption.
The water consumption of the animals on either dose of MitoQ was significantly reduced (indicated by
*; p=8.14 x 10-7 (low dose); p=1.33 x 10-4 (high dose)) but this did not correlate with any side effects or
weight loss which might compromise the animals' health.
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respectively. This decrease in volume probably reflected the reluctance of the
mice to consume drinking water with a new flavour. The consumption ofwater
supplemented with the antioxidant increased and became more stable with time.
However, comparing overall mean water consumption between controls (mean
5.2 ml/animal/day) and treated, there was a significant decrease in the latter, with
p-values at 8 x 10"7 (mean 4.1 ml/animal/day) and 0.0001 (mean 4.2
ml/animal/day) for the low and high doses respectively (Figure 46F). It was
decided however that this was not an alarming decrease in water consumption,
since there were no health effects associated with this and the animals gained
weight normally (see below).
6.3.4. Side effects
The health of the mice was monitored daily to assess any toxic effects that could
be attributed to oral MitoQ administration. The coat condition, salivation,
respiration, behaviour and movement of the animals showed no difference
between the control and MitoQ-administered mice. No deaths were reported in the
'Adult' cages. However, one of the two females in the 'Young' cage on the high
dose ofMitoQ was culled 6 days into the experiment, following constant loss of
weight, with abnormal behaviour and limited movement. The severity of this
incident and its rapid manifestation, as well as the lack of similar cases, prevented
us from attributing this death to the administration of the antioxidant drug.
6.3.5. Weight gain
Noticeable changes in weight can reflect metabolic or physiological problems. At
the beginning of the study, the animals in both 'Adult' and 'Young' cages were at
an age when developmental weight gain had not ceased. Their weights were
measured daily for the first month and weekly thereafter until the end of the study
at 3 months. Typically, mice of the C57BL/6 strain show a sharp increase in
weight in the first few postnatal weeks of age, which then stabilises at around 20
and 25 grams for a female and a male mouse, respectively.
In the 'Adult' cages there were only male mice. At 4 weeks old, the mean
weight of control mice was 16.9 ± 1.4 g which steadily increased to 29.6 ± 1.7 g
by 4 months of age (Figure 46B). Mice administered a low or high dose ofMitoQ
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weighed 16.8 ± 0.7 g and 17.1 ± 0.6 g at the start of the study and 28.6 ± 1.3 g and
30.5 ± 0.9 g respectively at the end of it. None of these differences in weight gain
were significantly different from each other (p>0.05). The fluctuations in weight,
seen in the controls on week 5, did not correlate with a similar fluctuation in water
and/or food consumption, and since weight gain soon stabilised, the incident was
not considered significant.
The weight gain of the breeding trios in the 'Young' cages was also
monitored daily (Figure 47A-C). The female pregnancies resulted in fluctuations
in their weights, which increased steadily for 19-20 days and dropped sharply
once the litters were delivered. Of the two females administered control water,
only one produced litters during the time of the experiments. Also, as mentioned
above, constant loss ofweight by one of the females given the high dose of
MitoQ, resulted in the decision to cull the mouse when its health was seriously
compromised. The cause of death of this mouse remains unknown.
It was important for the study to ensure the well-being of the litters, and so
their weight was also measured daily from the day of birth (PI) at least up to
weaning, 21 days later (P21). The mice on the control, low and high MitoQ doses
were born weighing 1.29 ±0.1 g, 1.55 ± 0.3 g and 1.20 + 0 g, respectively
(Figure 47D). Litters on either dose ofMitoQ showed both weights that were
significantly different from the controls (Low dose: p=0.005, n=33; high dose:
p=0.001, n=19), but in opposite directions. There was no correlation between pup-
weight and MitoQ dose so this was not considered further. A sharp weight gain
was observed in all three groups, with the weight measurements at P21 being 9.48
± 0.6 g in controls, 11.6 ± 1.9 g in the low dose and 8.54 ± 1.21 g in the high
dose-administered pups (Figure 47E). The weights of the treated mice were not
significantly different from the controls.
6.3.6. Breeding capacity
To assess the effect of long-term oral MitoQ administration on the breeding
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administered to the animals from the day the breeding trios were set up. The
reproductive performance of the mice was assessed by both the number and the
size of the litters born. The trios administered water, low and high dose ofMitoQ
produced 2, 7 and 3 litters respectively, ofwhich 0, 3 and 2 litters died within the
first day after birth. The mean litter size was 7.0, 4.6 and 6.3 for the control, low
and high MitoQ doses, respectively (Figure 47F). Although there was a
significant difference in the number of litters produced by the breeding trios, their
size was not significantly affected (Low dose: p=0.14; high dose: p=0.81).
6.3.7. Uptake of MitoQ
The uptake ofMitoQ by mitochondria, cells and tissues was investigated by using
either IBTP or tritium-labelled MitoQ (3H-MitoQ).
The uptake of IBTP by tissue extraxts was firstly investigated. For this,
wild-type heart, liver and retina homogenates were treated with IBTP, in the
presence of energisation buffer, prior to fractionation into mitochondrial and
cytosolic components. The uptake of IBTP by the different fractions was assessed
by immunoblotting with an antibody directed against the triphenylphosphonium
moiety of the IBTP molecule (Figure 48). The efficiency of the fractionation was
assessed by blotting the membrane with an antibody against the mitochondrial
isoform of Sod2. (Figure 48B). Mitochondria were successfully isolated from
liver and retina samples, but some mitochondrial contamination was evident in the
cytosolic fraction obtained from the heart. This was attributed to the evident
difficulty when homogenising cardiac tissue, due to its high fibrous content.
Blotting of the membrane with the anti-IBTP antibody, revealed the presence of
IBTP solely in the cytosolic fractions of the tissues, and its absence from the
mitochondrial ones (Figure 48C). It was concluded that, under these specific
experimental conditions, IBTP was retained in the cytosol and not efficiently
taken up by mitochondria.
The uptake of IBTP by isolated mitochondria was then assessed. For this,
heart and liver mitochondrial preparations were treated with IBTP both in the






































Figure 48: Reaction of IBTP with thiol proteins in cell fractions
Heart, liver and retina homogenates from wild-type animals were treated
with IBTP prior to fractionation into cytosolic (Ct) and mitochondrial (Mt)
fractions. Equal amount of protein were loaded in a denaturing gel, as
confirmed by Ponceau staining (A). The efficiency of the fractionation was
confirmed by blotting with an anti-Sod2 antibody which detects the
mitochondria-specific 25 kDa Sod2 (red arrowhead) (B). The anti-IBTP
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samples were not treated with IBTP. The results from the two tissues were
comparable. No proteins were detected by anti-IBTP in samples that were not
treated with IBTP, confirming the specificity of the in detecting IBTP-bound
proteins. In the IBTP-treated samples however, an increased number ofproteins
were detected in the non-energised samples when compared to the energised
samples. Although this result confirmed the uptake of IBTP by isolated
mitochondria, it did not agree with the expectation that energisation should
increase IBTP uptake by mitochondria.
Having verified the uptake of IBTP by isolated mitochondria, it was
necessary to confirm that this was also the case upon oral administration of the
compound to animals. IBTP was administered orally, at a concentration of 500
pM, to a pair of C57BL/6 wild-type mice for two weeks. At the end of the two
weeks, the animals were culled and heart, brain, liver and retina samples were
collected, and mitochondrial samples were prepared. In the case of the retina, only
whole homogenates were used, rather than mitochondrial preparations, due to the
limited availability of the tissue. The control samples included in the experiment
were collected from mice not administered IBTP. The results from the
immunoblotting experiment using the anti-IBTP antibody are shown in Figure
50. A band of about 190 kDa was detected in the heart mitochondrial sample
treated with IBTP, but not in the control. Additional bands seen in IBTP-treated
samples were considered non-specific, as they were also seen in the control
samples that had not been treated with IBTP. It was concluded, firstly, that IBTP
was taken up by heart mitochondria following oral administration of the
compound, and secondly, that a comparison of control and IBTP-treated samples
should be carried out before deciding which are specific bands reflecting the
reaction of IBTP with thiol proteins in the mitochondrial fraction.
The efficiency of IBTP uptake by different tissues was further
investigated, by its administration to Sod2+/~ and atrdl/atrdl mutants. The former
was chosen because it is defective in a major antioxidant enzyme, so that signs of
oxidative stress should be evident in all tissues analyzed. The atrdl/atrdl mutants
were examined because it is one of the retinal degeneration
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Figure 50 : Reaction of IBTP with thiol proteins in mitochondrial fractions of various wild-type
mouse tissues
The uptake of IBTP was assessed in vivo using samples from wild-type animals. Liver, heart, brain and
retina were collected from animals administered either control drinking water (C) or IBTP (I) for two
weeks. Mitochondrial fractions were prepared from all the tissues, apart from retina, in which whole
homogenates were used. These samples were then used for the immunoblotting experiment. There is
only one band of about 190 kDa (circled) that is detected in the heart sample. This agrees with previous
reports of good IBTP uptake by heart.
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mutants that showed signs of oxidative damage, as reflected by decreased CI
activity. For this part of the study, mutant mice were again administered IBTP. for
2 weeks at a concentration of 500 pM. At the start of the 2-week treatment, the
atrdl/atrdl mice were 2 weeks old to ensure that retinal degeneration had not
progressed and that photoreceptor cells would still be present by the end of the
treatment. Although Sod2+l~ mice show no retinal degeneration up to the age of
one year, these mice were 2 months old at the start of the experiment to ensure the
presence ofpotentially detectable oxidative protein modifications. As before,
controls included mitochondrial samples prepared from age- and genotype-
matched animals. Samples from wild-type animals were also included in this
experiment. The results are shown in Figure 51. In the wild-type blot (Figure
51A) a-IBTP detected a protein at about 190 kDa in the IBTP-treated heart
mitochondrial sample. A band of equal size, observed in the non-IBTP-treated
sample, was substantially fainter. Non-specific bands were detected in control and
IBTP-treated brain and retina samples. In the Sod2+l" immunoblot (Figure 51B)
the antibody again detected a non-specific 40 kDa band in the heart, brain and
retina samples, but not in the IBTP-treated sample. In the atrdl/atrdl blot (Figure
51C), a non-specific 40 kDa band was again detected, but no specific IBTP bands
were present.
The control samples had not been treated with IBTP, and therefore the
detection of any bands by a-IBTP are likely to be false-positives. However, as our
purpose was to establish whether IBTP penetrates the tissues and accumulates in
mitochondria following a two-week oral administration, an additional approach is
to compare IBTP-treated wild-type and mutant samples. In this comparison
(colour-coordinated in Figure 52), the presence of a band in the wild-type sample
and its absence in the mutant samples would reflect the interaction of IBTP with
the corresponding protein in the wild-type sample, but the lack of it in the mutant,
due to oxidative protein modification. A strong band, at about 190 kDa, was again
present in the wild-type heart mitochondrial sample, but absent in both the Sod2+/'
and the atrdl/atrdl heart samples (Figure 52B). In the retina blots (Figure 52C),
there was an IBTP band ofhigh molecular weight (~ 190 kDa) in the Sod2+/~ blot
only. The strong signal in the atrdl/atrdl blot at above 190 kDa was not
considered genuine and possibly
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Figure52:Alternativeinterpretationofi 1 (A)TheresultsfromFigure51co ldbalternatively interpretedbycomparisontw enIBTP-t atedsampl s asindicatedbythcoloro-coordination.A lredolumns (B)correspondtIBTP-treateheartsam l sfr differentstrai sand,imilarly,lgreencolumn(C) correspondtIBTP-treateretinasamples.Tha ows indicateproteinsiz(kD ).
corresponded to proteins retained at the top of the protein gel. Also, there were
two bands in the wild-type retina sample, at 50 kDa and 40 kDa, which showed
different intensities in the two mutants. In the Sod2+/~ sample, the 50 kDa band is
stronger while the 40 kDa band is of the same, if not less, intensity. In the
atrd/atrdll sample the 50 kDa band had disappeared whereas the 40 kDa band
was a lot fainter
To summarise the results from the use of IBTP in vivo, it has been shown,
firstly that IBTP can successfully accumulate in mouse heart mitochondria
following oral administration for 2 weeks at a concentration of 500 p.M.
Secondly, there was no convincing reduction in the number of specific bands
detected by a-IBTP in the Sod2+l~ and atrdl/atrdl samples compared with wild-
type, which might have reflected increased oxidative damage in these mutants.
Thirdly, although the specificity of the anti-IBTP antibody was confirmed on
mitochondrial samples treated with the compound after fractionation (Figure 49),
it appears to detect many non-specific bands in mitochondrial samples prepared
after oral administrations of IBTP.
To obtain additional evidence for the uptake of MitoQ by retina, tritium-
labelled MitoQ (3H-MitoQ) was administered orally to wild-type C57BL/6 mice
(n=3) for 2 weeks at a concentration of 500 pM. Tissue samples (heart, brain,
liver, eye without retina, retina) were assayed in a scintillation counter and the
uptake of 3H-MitoQ was estimated on the basis of a standard curve. Control
samples were collected from animals administered with pure drinking water.
Uptake of 3H-MitoQ was significant in all the tissues assayed (all p<0.05) (Figure
53). Measurements were highest in the heart and liver samples, at over 3 nmol/g
wet weight. Uptake by the retina was about 1.3 nmol/g wet weight, while in the
remainder of the eye, uptake was at just under 0.5 nmol/g wet weight. The
experiment using 3H-MitoQ therefore verified the uptake of the drug by heart,
liver, brain and retina tissues.
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6.3.8. The effect ofMitoQ administration on the retinal
degeneration mutants
Having investigated the uptake ofMitoQ by different tissues after oral
administration, the aim of this chapter was to assess the effects ofMitoQ
administration on the rates ofphotoreceptor degeneration, mitochondrial enzyme
activities and the reduced glutathione concentrations of the retinal degeneration
mutants and wild-type controls.
6.3.8.1. Effects ofMitoQ on the rates of photoreceptor
degeneration
The rates of photoreceptor degeneration were measured by means ofONL
analysis and TUNEL assays, as previously described. Firstly, the methods were
applied on samples collected from 3-month-old wild-type animals (n=4)
administered MitoQ at a low (250 pM) or high (500 uM) dose since conception.
No photoreceptor degeneration was caused by MitoQ administration, as indicated
by both an unchanged ONL thickness and the absence ofTUNEL-positive
apoptotic cells in these samples (Figure 54).
MitoQ administration had no effect on the rate ofphotoreceptor
degeneration in the rdl/rdl mutant, as this was complete by the third week of life
(Figure 55). An increasing number of apoptotic photoreceptor cells were detected
by TUNEL assays with age and at no time-point were the percentages ofTUNEL-
positive cells significantly different between the untreated rdl/rdl mutants and
those administered MitoQ (all p>0.05; n=5).
Similarly, long-term oral administration ofMitoQ to atrdl/atrdl mutants
had no effect on the rate of photoreceptor degeneration (Figure 56). In agreement
with the ONL analysis results, TUNEL assays on MitoQ-treatedmutant samples
showed increasing percentages of apoptotic cells with age. At no time-point were
these results significantly different from those obtained in mutant samples that
were not treated with the antioxidant (all p>0.05; n=5).
In MitoQ-administered Rho'1' mutants, photoreceptor degeneration was
complete by 3 months of age (Figure 57). The rate of degeneration was not
significantly different between antioxidant-treated and untreated samples (all
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p>0.05; n=5). The same conclusion was reached for the TUNEL assays, in which
TUNEL-positive apoptotic cells were detected at an increasing percentage in the
first two months of age and at lower percentages in the following months. MitoQ
administration did not cause any significant changes in these measurements.
Finally, administration of the antioxidant to rds/rds mice again did not
affect the rates of retinal degeneration in these mutants (Figure 58). According to
the results from the ONL analysis, photoreceptor degeneration progressed at a
similar rate in the rds/rds mutants, irrespective of treatment. In both treated and
untreated samples, photoreceptor degeneration was complete by 6 months of age.
The TUNEL assay results confirmed the above observation. There was a
significant number of apoptotic cells detected in the rds/rds mutant retinas in the
first two months of age, and the percentages were unaffected by MitoQ
administration. At subsequent time-points of analysis, the percentage ofTUNEL-
positive cells in the retina dropped significantly and to the same extent in the
presence or absence of MitoQ.
To summarise, all four retinal degeneration mutants were administered
MitoQ until photoreceptor degeneration was complete. The results from both
ONL analysis and TUNEL assays showed that MitoQ administration had no
effect on the rates of photoreceptor degeneration in these mutants.
6.3.8.2. Effect ofMitoQ administration on
mitochondrial enzyme activities in retinal
degeneration mutants
The specific activities of citrate synthase (CS) and complex I (CI) were measured
in liver, brain, heart and retina mitochondrial samples collected from MitoQ-
treated retinal degeneration mutant mice. A comparison was made between these
results and those obtained from untreated mutant samples (Table 10, Figure 59).
Firstly, the specific activities of the enzymes were measured in wild-type
samples collected from animals treated with MitoQ. In no tissue was the activity
of either CS or CI either reduced or increased, when compared to samples from
non-treated wild-type animals (all p>0.05; n=3-6).
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LIVER
Citrate Synthase Complex I
Genotype n activity se Pw-value Pm-value activity se Pw-value pm-value
Wild type 4 1.6949 0.1893 0.5969 0.2011
MitoQ 4 1.7739 0.6605 0.9122 0.6069 0.0869 0.9649
rd1/rd1 4 2.4467 0.4353 0.1644 0.4743 0.0779 0.5904
rd1/rd1 MitoQ 4 2.0165 0.5010 0.5700 0.5409 0.5105 0.1363 0.7342 0.8254
atrd1/atrd1 5 1.7838 0.4554 0.8744 0.4807 0.0564 0.5559
atrd1/atrd1 MitoQ 3 2.3652 0.5033 0.2189 0.4441 0.4368 0.1903 0.6001 0.7903
Rho''' 4 2.3787 0.3408 0.1300 0.3215 0.1168 0.2812
Rho~'~ MitoQ 3 2.3346 0.0257 0.0877 0.9354 0.7838 0.2291 0.6042 0.1086
rds/rds 3 2.3260 0.3538 0.1499 0.4796 0.1843 0.6964
rds/rds MitoQ 3 2.1103 0.1029 0.2265 0.6732 0.4140 0.1005 0.5844 0.8095
BRAIN
Citrate Synthase Complex I
Genotype n activity se Pw-value pm-value activity se Pw-value pm-value
Wild type 5 3.7515 0.7808 0.2444 0.0518
MitoQ 4 4.8915 0.7694 0.3401 0.2191 0.0529 0.7452
rd1/rd1 4 5.3456 0.4538 0.1446 0.3236 0.0522 0.3235
rd1/rd1 MitoQ 2 4.0993 0.0478 0.8008 0.1413 0.3175 0.0683 0.4714 0.9491
atrd1/atrd1 4 4.3842 0.9078 0.6118 0.3758 0.0211 0.0704
atrd1/atrd1 MitoQ 2 7.0551 0.8787 0.0630 0.1422 0.4019 0.2170 0.3235 0.3291
Rho'' 3 4.0025 0.2766 0.8208 0.3001 0.0613 0.5236
Rho MitoQ 3 4.8652 0.7877 0.3852 0.3598 0.1876 0.0071 0.4437 0.1422
rds/rds 3 6.0147 0.6241 0.0935 0.3430 0.0513 0.2564
rds/rds MitoQ 3 3.4975 0.7695 0.8372 0.0639 0.3751 0.0372 0.1287 0.6388
HEART
Citrate Synthase Complex 1
Genotype n activity se p^value pm-value activity se Pw-value pm-value
Wild type 4 13.9632 2.3818 1.8227 0.3594
MitoQ 3 9.2230 1.5564 0.1873 1.1013 0.1562 0.1658
rd1/rd1 3 17.3775 6.5664 0.0794 1.3934 0.0998 0.3672
rd1/rd1 MitoQ 3 18.7647 4.8917 0.3783 0.3448 2.0418 0.4833 0.7242 0.2591
atrd1/atrd1 3 18.0613 5.9593 0.5063 1.3424 0.3161 0.3815
atrd1/atrd1 MitoQ 3 20.1814 5.9117 0.3245 0.8130 1.7980 0.4311 0.9663 0.4421
Rho 3 15.4951 5.4382 0.7862 2.5000 0.0325 0.1728
Rho '' MitoQ 3 10.7623 1.0155 0.3264 0.4405 1.6640 0.4003 0.7811 0.1059
rds/rds 3 14.3333 3.2423 0.9283 3.2235 0.8895 0.1631
rds/rds MitoQ 3 15.0110 1.3199 0.7890 0.8848 0.4140 0.1969 0.0633 0.0936
RETINA
Citrate Synthase Complex I
Genotype n activity se Pw-value Pm-value activity se Pw-value Pm-value
Wild type 6 1.1066 0.1144 0.7248 0.1651
MitoQ 6 1.0074 0.1905 0.6646 0.5118 0.0836 0.2765
rd1/rd1 6 1.0074 0.2115 0.6885 0.1541 0.0370 0.0071
rd1/rd1 MitoQ 6 0.8523 0.0855 0.1053 0.5122 0.0924 0.0244 0.0035 0.1951
atrd1/atrd1 4 1.3502 0.3817 0.4865 0.1969 0.0630 0.0377
atrd1/atrd1 MitoQ 5 0.8228 0.1447 0.1529 0.2005 0.1817 0.0589 0.0189 0.8652
Rho 6 0.8719 0.0632 0.1028 0.1058 0.0087 0.0038
Rho''' MitoQ 5 1.0224 0.1219 0.6134 0.2467 0.1294 0.0585 0.0115 0.6273
rds/rds 3 0.8983 0.1653 0.3309 0.0991 0.0107 0.0361
rds/rds MitoQ 3 1.2439 0.0808 0.4602 0.1336 0.2063 0.0256 0.0242 0.0180
Table 10: Enzyme activities in wild type and retinal degeneration mutants administered MitoQ
Citrate synthase and complex I activities (pmol/min/g tissue) were measured in liver, brain, heart and retina from
wild type, retinal degeneration mutants (rd1/rd1, atrd1/atrd1, Rho'1' and rds/rds) and retinal degeneration mutants
administered MitoQ (rd1/rd1 MitoQ, atrd1/atrd1 MitoQ, RhoMitoQ and rds/rds MitoQ. The standard errors (se)
and statistical significance compared with wild type (pw-value) and with single retinal degeneration mutants (pm-
value) are shown. Statistical significant values (pw or pm<0.05) are highlighted in red. 216
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Secondly, MitoQ administration had no effect on any of the CS or CI activities in
liver, brain or heart samples, irrespective of genotype (all p>0.05; n=2-5). The
same was the case for CS activities measured in retinal samples (p>0.05; n=3-6).
All MitoQ-administered retinal degeneration mutants had significantly decreased
CI activities in their retinas (p<0.05; n=3-6) when compared to wild-type. MitoQ
administration did however significantly increase the activity ofCI in the rds/rds
mutants (p=0.018; n=3), although it was not restored to wild-type levels.
6.3.8.3. Effect ofMitoQ administration on reduced
glutathione measurements in retinal degeneration
mutants
The GSH concentrations in the liver, brain, heart and retina ofMitoQ-
administered-retinal degeneration mutants were measured (Table 11, Figure 60).
Firstly, MitoQ administration had no significant effect on the GSH
concentrations in any of the wild-type tissues assayed, or in any of the mutant
liver samples (all p>0.05; all n=3). GSH concentrations in brain samples remained
at wild-type levels in all of the mutants administered with the drug. A significant
increase previously seen in the GSH concentration of rds/rds brain samples was
not present in the mice treated with the antioxidant. Similar results were obtained
for measurements in rdl/rdl and atrdl/atrdl heart samples. Upon MitoQ
administration, the GSH concentration ofRho'1' heart samples was significantly
increased from 0.47 (untreated) to 0.75 pmol/g protein (treated) (p=0.027; n=3).
Finally, although antioxidant treatment increased the GSH concentration ofRho'1'
mutant retinas from 0.041 pmol/g protein towards wild-type levels at 0.057
pmol/g protein, this was not statistically significant (p=0.215; n=3).
6.4. Summary and conclusions
In this chapter, the role of oxidative stress in photoreceptor degeneration was
investigated by administering a mitochondrially targeted antioxidant to mouse
models of RP. The retinal degeneration mutants rdl/rdl, atrdl/atrdl, Rho'1' and
218
LIVER
Genotype n concentration se pw-value Pm-value
Wild type 3 4.2027 0.1542
MitoQ 3 4.6227 0.3074 0.4986
rd1/rd1 3 3.8625 0.7369 0.7752
rd1/rd1 MitoQ 3 4.7126 0.1881 0.3138 0.5539
atrd1/atrd1 3 3.5817 0.1700 0.2250
atrd1/atrd1 MitoQ 3 5.5596 0.4625 0.1355 0.0525
Rho 3 5.1527 0.1507 0.0758
Rho MitoQ 3 4.7995 0.8185 0.5197 0.7284
rds/rds 3 4.2940 0.0485 0.8157
rds/rds MitoQ 3 4.3272 0.1667 0.7875 0.9175
BRAIN
Genotype n concentration se pw-value Pm-value
Wild type 3 0.9631 0.1082
MitoQ 3 1.3134 0.0461 0.2430
rd 1/rd 1 3 1.3998 0.0433 0.1586
rd1/rd1 MitoQ 3 1.4844 0.1013 0.1377 0.6804
atrd1/atrd1 3 1.3015 0.0751 0.3598
atrd1/atrd1 MitoQ 3 1.6533 0.0786 0.0571 0.1502
Rho''- 3 1.1672 0.0314 0.4683
Rho~'~ MitoQ 3 1.4844 0.1068 0.1975 0.0968
rds/rds 3 2.1092 0.2360 0.0437
rds/rds MitoQ 3 1.8954 0.1838 0.4004 0.1554
HEART
Genotype n concentration se pw-value Pm-value
Wild type 3 0.6642 0.0619
MitoQ 3 0.4675 0.0757 0.3316
rd1/rd1 3 0.2579 0.0274 0.0440
rd1/rd1 MitoQ 3 0.4632 0.1061 0.3875 0.3401
atrd1/atrd1 3 0.3288 0.0273 0.0480
atrd1/atrd1 MitoQ 3 0.4570 0.0840 0.3264 0.3951
Rho 3 0.4714 0.0718 0.3324
Rho''' MitoQ 3 0.7447 0.0417 0.6926 0.0270
rds/rds 3 0.9538 0.1623 0.3439
rds/rds MitoQ 3 0.7447 0.0417 0.7080 0.2862
RETINA
Genotype n concentration se pw-value Pm-value
Wild type 3 0.0841 0.0052
MitoQ 3 0.0729 0.0111 0.6630
rd1/rd1 3 0.0430 0.0029 0.0253
rd1/rd1 MitoQ 3 0.0413 0.0044 0.0274 0.8603
atrd1/atrd1 3 0.0747 0.0125 0.6852
atrd1/atrd1 MitoQ 3 0.0554 0.0076 0.1722 0.6186
Rho~'' 3 0.0411 0.0023 0.0235
Rho''' MitoQ 3 0.0568 0.0081 0.1863 0.2151
rds/rds 3 0.0778 0.0046 0.6741
rds/rds MitoQ 3 0.0809 0.0124 0.8735 0.8665
Table 11: Reduced glutathione
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rds/rds were treated with the ubiquinone analogue MitoQ, from conception until
photoreceptor degeneration was complete. This is the first study in which MitoQ
was orally administered to mice for a long period of time. In a previous in vivo
study by Smith et al. (2003), administration of the drug at a concentration of 500
pM for 26 days was shown to have no side-effects to the animals. In Chapter 4 it
was shown that retinal degeneration in the mutants is complete within between 3
weeks and 3 months of age, so it was necessary to confirm the safety of long-term
oral administration of the antioxidant. Adult wild-type mice were therefore treated
with a low (250 pM) or high (500 pM) dose ofMitoQ for 3 months, during which
period, the health of the animals was monitored daily. MitoQ administration, at
either dose, had no side effects and the food consumption, weight gain and
breeding capacity were unaffected by drug treatment. The possibility that neonatal
survival was affected by MitoQ was considered, since some of the litters on either
the low or high dose died shortly after birth. However, the absence of similar
cases in consecutive wild-type and mutant litters did not support this possibility. It
was therefore concluded that long-term oral administration of MitoQ at a 500 pM
concentration was safe for the animals.
The uptake ofMitoQ by whole retina and retinal mitochondria was
investigated. This was carried out by using two chemically similar compounds,
namely 4-iodobutyl-triphenylphosphonium (IBTP) and tritium-labelled MitoQ
(3H-MitoQ). Both compounds have been used for the same purpose by other
investigators, and their uptake by isolated mitochondria, cells and some tissues
has been shown (Kelso et al., 2001; Lin et al., 2002; Smith et al., 2003). The
IBTP results confirmed the uptake ofmitochondrially-targeted antioxidants firstly
by heart mitochondria after oral administration and secondly by isolated heart and
liver mitochondria treated with the compound post-fractionation. The anti-IBTP
antibody showed some non-specific binding, suggesting that different conditions
or antibodies may be necessary to show uptake of IBTP by retina mitochondria
after oral administration. Further experiments with 3H-MitoQ showed uptake by
several tissues, including retina. The mitochondrial uptake of 3H-MitoQ was not
investigated because this compound would not be retained in these organelles
upon tissue fractionation and dissipation of the membrane potential. In summary,
the mitochondrial uptake of MitoQ-like compounds was confirmed by use of
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IBTP and their retina uptake was confirmed by the use of H-MitoQ. These were
sufficient indications for uptake of MitoQ by retina mitochondria.
The effect ofMitoQ on wild-type and retinal degeneration mutants was assessed.
Firstly, it was confirmed that administration of the drug was not compromising
the structure or function of the retina, since no photoreceptor degeneration was
evident in wild-type samples after administration of the antioxidant. In addition,
the activity of complex I (CI) did not decrease and the GSH concentration
remained constant at wild-type levels in MitoQ-treated wild-type samples.
Although an increase in enzyme activity and GSH concentration would agree with
administration of an antioxidant, the absence of these observations is not
surprising. It is possible that in wild-type mice CI activity and GSH concentration
are a maximum level which does not increase further.
Secondly, the retinal degeneration rates of rdl/rdl, atrdl/atrdl, Rho" and
rds/rds mutants were assessed and MitoQ administration did not influence the
rates ofphotoreceptor degeneration in any of the mutant samples. The failure of
MitoQ to alter rates of retinal degeneration cannot be attributed to failure of the
antioxidant to reach the target tissue, as its uptake by the retina was confirmed.
Moreover, Adlam et al. (2005) demonstrated the antioxidant efficiency ofMitoQ
by orally administering the compound to rats and protecting heart function from
ischemia-reperfusion injury. There are therefore two possible explanations for the
failure to slow rates of degeneration. Firstly, the amount of administered MitoQ
might not have been sufficient to reduce the rate of degeneration in the mutants.
The results of the preliminary study, which confirmed the safety of long-term
administration of 500 pM MitoQ, suggest that increased doses might also be safe
to administer. Secondly, the fast degeneration rates, observed particularly in the
rdl/rdl and atrdl/atrdl mutants, suggest that the mutations confer pathology of
such severity that it is difficult to reverse.
At a biochemical level, MitoQ administration had some effect on enzyme
activities and reduced glutathione concentrations. As expected, treatment with the
antioxidant did not cause a change in any of the CS or CI activities in liver, brain
and heart mutant samples. These were at wild-type levels in the absence ofMitoQ
and remained at the same levels after its administration. Similarly, the activity of
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CS in all retina samples remained unchanged and similar to wild-type. MitoQ
administration did not restore the previously observed decrease in CI activities in
the retinal degeneration mutants, with one exception. In the rds/rdsmutant, the
activity ofCI was significantly increased upon MitoQ treatment (p=0.018; n=3).
The fact that MitoQ administration did not change the rates of
photoreceptor degeneration in the retinal degeneration mutants but ameliorated
the loss of CI activity in the slower degeneration of rds/rds mice supports the
possibility that the severity of the retinal degeneration mutation matters.
Therefore, the administration ofMitoQ to mutants in which the retinal
degeneration progressed even more slowly might prove to be more fruitful.
To summarise, although the long-term oral administration ofMitoQ at a
concentration of 500 pM was shown not to be toxic to mice and there was some
evidence of the uptake of the compound by retina mitochondria, it had no effect
on the rates ofphotoreceptor degeneration in retinal degeneration mutants. The
most promising result was the apparent partial rescue of the reduction in CI
activity in the slowest mutant rds/rds, suggesting that further experiments to





The main aim of this project was to determine the role of oxidative stress in
retinal degeneration. The hypothesis that oxidative stress influences rates of
degeneration was tested by crossing four mouse models for retinitis pigmentosa
(RP) (rdl/rdl, atrdl/atrdl, Rho~'~ and rds/rds) to heterozygous Sod2+' knockout
mice or by treating them with the mitochondrially targeted antioxidant, MitoQ.
The rates of photoreceptor degeneration and levels of oxidative damage in the
mouse models were assessed and changes in response to decreased Sod2
expression or treatment with an antioxidant were investigated.
The hypothesis underlying this project assigns a general role to oxidative
stress in retinal degeneration (Wright et al., 2004). ROS production may or may
not be directly implicated in either the generation or the pathology of retinal
degeneration resulting from genetic mutations, but it is proposed to be indirectly
implicated, regardless of the cause. Mutations in 40 genes have either been
mapped or identified in RP (Table 1), each of which imposes a cellular stress, not
always including oxidative stress, on photoreceptors and leads to apoptosis. The
cellular redox state, which is cell type- and species-specific, can however
influence the probability of cell death by apoptosis. The link between oxidative
stress and apoptosis is based primarily on the dual role ofmitochondria as both
the major generators of oxidative stress and the mediators of the intrinsic
apoptotic pathway, the principal mode of cell death in RP. The hypothesis
therefore postulates that a change in the steady state level of ROS production, by
experimentally altering the levels of antioxidant defences, would affect the
probability of cell death in any given retinal degeneration, regardless of whether
oxidative stress is primarily implicated in the disease.
The model supporting this hypothesis is diagrammatically presented in
Figure 61. Figure 61Ai shows that in a homogeneous population of cells, the
probability of apoptosis follows a normal bell-shaped distribution. A fixed cell
death threshold (red dotted line) determines the proportion of apoptotic cells (na).
The mean probability of apoptosis can vary between different cell types and/or
species, in such a way that the 'bell' shifts position along the x-axis and as a result
the proportion of apoptotic cells na changes (Figure 61Aii). External insults,
including genetic mutations and environmental effects may account for this shift.
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attributed to increased PUFA concentration, high oxygen tension and light
exposure, can result in an increased na in comparison to a population of liver cells
that are not exposed to these sources of oxidative stress. Figure 61 Bi shows the
single-cell situation. A cell has an apoptotic threshold (red dotted line), a
probability of survival (x), a probability of apoptosis (1-x) and a given steady
state ROS production. Mutations (peaks) of different severity (peak height) may
be present in the cell, and some may be severe enough to cross the apoptotic
threshold, and lead to cell death, whereas others are mild enough to go unnoticed.
There are different factors that can influence x, including environmental, genetic
and metabolic influences. One factor that has been shown to greatly influence cell
survival is the steady state production of ROS, which are constitutively generated
in mitochondria as a result of leaking electrons from the ETC. ROS formation has
been inversely correlated with lifespan (Wright et al., 2004), suggesting that
increased production of free radicals increases the probability of apoptosis. Both
the apoptotic threshold of a cell and its level of steady state mitochondrial ROS
production are dependent on the type of cell and the species. Different cell types
have a different susceptibility to 'external insults', which dictate their apoptotic
thresholds, as mentioned above. As a result, exactly the same mutation expressed
in two different cell types would not affect the survival of the two cells equally.
Also, ROS production differs between species, so that, for example, mice have
increased mitochondrial H2O2 production compared to cows (Sohal et al., 1989;
1990). A photoreceptor cell therefore in two different species would have the
same apoptotic threshold, as it is exposed to similar 'external insults', but the
level of species-specific ROS production would affect its probability of survival
when the same mutation or other cellular stress is present. The shift in the mean
apoptotic probability of a population of cells and in the level of the cell apoptotic
threshold, as determined by cell and species characteristics, are depicted in
Figure 61Aii and Bii, respectively.
All these factors are summarised in Figure 61Ci, in which the
probabilities of apoptosis and survival are overlaid on the y-axis, to illustrate
schematically how ROS production could influence the rate of degeneration of a
tissue.
A few points about the above model need to be clarified. Firstly, the cell
death thresholds depicted in both the population of cells and in single cells are
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virtually the same. The only difference lies in the fact that in the population of
cells the cell death threshold is fixed and na changes in response to shifting of the
mean apoptotic probability (the 'bell'). In contrast, in a single cell, the apoptotic
threshold can shift in a cell type- and/or species-dependent manner. When
however one focuses on a single cell type in a single species this apoptotic
threshold is also assumed to be fixed. Therefore, a decreased apoptotic threshold
implies both an increased single-cell probability of apoptosis and an increased
proportion of a population of cells of doing so as well.
Secondly, although the probability axes have been overlaid and are on the
same scale, from zero to one, they are used separately. A probability of apoptosis
is used when referring to a population of cells, whereas a probability of survival is
used when referring to a single cell.
Thirdly, steady state ROS production also influences the probability of
apoptosis. In a single cell, whether a mutation causes it to cross the apoptotic
threshold depends on the level of ROS production, which, if high enough, will
lower x sufficiently to do so. The severity of the mutation is reflected by the
height of the peak (s). In a population of cells, where the apoptotic threshold is
fixed, ROS production may shift the mean probability of apoptosis. The rate at
which a population of cells degenerates depends both on the mean probability of
apoptosis, which determines na, and on the severity of the cell mutation, which
determines s. In summary, the rate of degeneration of a homogeneous population
of cells is a function of na and 5, both ofwhich are influenced by ROS levels. As
shown in Figure 61Cii, increased ROS production can both shift the mean cell
population probability of apoptosis and increase na or decrease the probability of
cell survival x by 'elevating' the baseline of the mutation, which increases s.
In this project, the aim was to test the above hypothesis using a single
species (mouse), a single cell type (photoreceptor cell) and four distinct genetic
mutations (Pde6brdI, Pde6batrdl, Rho and Prph2rds). All mouse photoreceptors are
assumed to have the same apoptotic threshold and equal levels of steady state
ROS production (Figure 62A-2E). What differs is the severity of the mutations
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The rate at which a population of photoreceptor cells degenerate in each mutant is
a function of the proportion of apoptotic cells in the population (na) and of the
severity of the genetic mutation (s) present in the cell. It follows that, with fixed
thresholds and probabilities of apoptosis, that are specific to mouse photoreceptor
cells, it is the mutation severities that determine degeneration rates in the mutants.
The steady state ROS production was modified by either decreased Sod2
expression (Figure 62Ai-2Ei) or MitoQ treatment (Figure 62Aii-2Eii).
According to the model, increased oxidative stress in the mutants should increase
the probability of apoptosis and speed up the rates at which photoreceptor cells
degenerate. Similarly, exposure to the antioxidant MitoQ should reduce ROS
production, and depending on the severity of the causal mutations, reduce the
proportion of cells that cross the apoptotic threshold.
The results of the project are summarised in Figures 63 and 64. Briefly, rates of
degeneration were estimated in each of the four mutants by both ONL analysis
and TUNEL assays, and a comparison was made between the single retinal
degeneration mutants, mutants crossed to Sod2 heterozygous knockout mice and
mutants treated with the antioxidant MitoQ. The genetic heterogeneity of retinal
degeneration, discussed by Rivolta et al. (2002), was confirmed by the distinct
degeneration rates observed in each of the mutants. Neither the rates of retinal
degeneration nor the percentages of TUNEL-positive cells were altered in
response to modified cellular redox states. Additionally, the levels of oxidative
damage were assessed both by spectrophotometric enzyme assays and by reduced
glutathione measurements. Signs of oxidative damage were detected in all four
mutants, but their levels were not universally altered by modifying steady state
ROS production. The decreased Sod2 expression further compromised complex I
activity in the homozygous atrdl mutant, while treatment with MitoQ ameliorated
this enzyme's activity in the rds/rds mutant.
Distinct degeneration rates in the mutants
The rates at which the retinal degenerations proceeded in the four mutants were
quite distinct, taking 3 weeks, 6 weeks, 3 months and 3 months to be completed in
the rdl/rdl, atrdl/atrdl, Rho" and rds/rds mutants, respectively (Figure 63, left











Figure 63: Summary results - Photoreceptor degeneration in retinal degeneration mutants
Photoreceptor degeneration was measured in (A, E) rd1/rd1, (B, F) atrd1/atrd1 (B, F), (C, G) Rho'1'
and (D, H) rds/rds mutants by (A-D) ONL analysis (ONL: solid lines,, INL: dotted lines) and (E-H)
TUNEL assays. A comparison was made between wild-type samples (blue), single retinal
degeneration mutants (green), mutants with decreased sod2 expression (red) and mutants treated
with MitoQ (yellow).
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Figure 64: Summary results - Oxidative damage in retinal degeneration mutants
Oxidative damage was assessed in (A, E) rd1/rd1, (B, F) atrd1/atrd1 (B, F), (C, G) Rho"1' and (D,
H) rds/rds mutants by (A-D) spectrophotometric enzyme assays and (E-H) by measurements of
reduced GSH contents. A comparison was made between wild type samples (blue), single retinal
degeneration mutants (green), mutants with decreased sod2 expression (red) and mutants treated
with MitoQ (yellow).
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Farber & Lolley (1974), Hart et al. (2005), Humphries et al. (1997) and Travis et
al. (1991) for these muatnts. The results from the TUNEL assays (Figure 63,
right column) were consistent with the ONL analysis results, confirming the
estimated rates of degeneration. However, Portera-Cailliau et al. (1994)
previously reported that in the rdl/rdl mouse the number of TUNEL-positive
cells peaked at PI4, compared with P21 in this study, while that in the rds/rds
mouse did so at PI8 and P30, compared with P14 here. Failure to observe exactly
the same peaks of apoptosis in this project can be attributed to the time intervals
over which samples were analyzed. These were probably not sufficiently tight to
allow the detection of the precise peaks of apoptotic cell death. Nevertheless, the
results were broadly very similar to those published by others.
Sod2 effects on retinal degeneration
Prior to analyzing the retinal degeneration double mutants, in which Sod2
expression was halved, the retinal phenotype in the Sod2 heterozygous null
mutant was analyzed. An abnormal retinal phenotype was previously reported in
Sod2~'~ null mice at P20, but this did not include photoreceptor degeneration,
possibly due to the early lethality of these animals (Sandbach et al., 2001). In this
project, Sod2+/~ heterozygotes showed no signs ofphotoreceptor degeneration. As
expected, all of the tissues assayed had decreased complex I activity (all p<0.05),
and the GSH concentration was significantly reduced (p<0.05) by approximately
60% in the retina, brain and liver of these mice. Published studies have also
reported reduced complex I activity and reduced GSH concentration in Sod2+,~
mutants mutants (van Remmen et al. 1999). Although these results show a
ubiquitous increase in oxidative stress in Sod2+'~ mice, this was not sufficient to
trigger photoreceptor apoptosis in these mutants. A direct effect of oxidative
stress, caused by decreased Sod2 expression on photoreceptor apoptosis was
therefore excluded, arguing against the proposed model. In contrast to these
results in the retina, a similar decrease in Sod2 expression has been shown to
increase apoptosis in other tissues. For example, the mitochondrial dysfunction
observed in the heart of Sod2+,~ heterozygotes is accompanied by an increased
incidence of cardiomyocyte apoptosis (van Remmen et al., 2001). This might
suggest that basal steady state ROS production is higher in cardiomyocytes than
in photoreceptor cells, so that the survival probability (x in Figure 61) is lower in
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these cells. Steady state mitochondrial H2O2 formation is high in heart relative to
other tissues (Wright et al., 2004), although the corresponding value for retina has
not been published.
The retinal degeneration phenotype includes oxidative damage
The involvement of oxidative stress in the pathology of the retinal degeneration
mutants analysed in this project has not previously been reported, except in the
cases of rdl/rdl and rds/rds, where up-regulation of clusterin and ceruloplamsin,
which are markers of oxidative stress, have been detected (Lohr et al., 2006). In
the present study, signs of oxidative damage were detected in all four mutants
(Figure 64, left column). The observation that complex I activity was reduced
only in the retinas of these models, and not in other tissues or in wild-type
samples, while citrate synthase activity remained unchanged in all tissues, shows
a direct effect of each mutation on increasing oxidative stress. Additionally, the
retinal GSH concentration of rdl/rdl and Rho~' mutants was significantly reduced
compared to the wild-type (p<0.05) (Figure 64, right column).
A role for oxidative stress in retinal degeneration has been suggested
before. The increased oxygen tension imposed by the choroidal blood flow, the
high metabolic rate of the retina compared to other tissues which is shown by its
elevated consumption of oxygen, and the high concentration of PUFAs, are three
of the factors that render the wild-type retina prone to oxidative damage (Travis,
1998). It is therefore conceivable that the damaging effect of oxidative stress,
even in wild-type photoreceptor cells, would be magnified in retinal degeneration
mutants. Indeed, it has been suggested that the failure of rds/rds and Rho
knockout mutants to form OS results in the proximity of the mitochondria to an
increased p02, and hence to a possible increase in free radical production (Travis,
1998). Finally, although RP-type retinal degenerations primarily affect the
survival of rod photoreceptors, cone photoreceptors also degenerate as a
consequence and this has been shown to involve oxidative damage (Shen et al.,
2005). One possibility is that the decreased complex I activities reported in the
mutants analysed are reflecting cone oxidative damage rather than rod damage.
However, this is excluded, since the mouse retina is richer in rods and sample
collection took place before complete retinal degeneration. If in the samples
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assayed rods were oxidative damage-free their present majority should mask the
cone damage.
Although oxidative damage has been previously reported in photoreceptor
degeneration attributed to light exposure (Donovan et al., 2001) and increased
expression of genes implicated in oxidative stress has been detected in the rdl/rdl
and rds/rds mutants (Lohr et al., 2006), this is the first time that oxidative damage
to complex I activity has been reported in these four retinal degeneration mutants.
This implies post-translational damage to complex I subunits, perhaps including
oxidation of thiols, nitration, nitrosylation and other changes, which could be
investigated further by mass spectrometry.
Decreased Sod2 expression and complex I activity
Decreasing the level of the antioxidant superoxide dismutase in the retinal
degeneration mutants increased the level of oxidative damage only in the
atrdl/atrdl mutant (p=0.048; n=5). This result was particularly unexpected given
that complex I activity was already severly compromised in all the assayed tissues
of the Sod2 heterozygous knockout mouse. The difference in mutation severity
between the rdl/rdl and atrdl/atrdl mutants, which is shown by their distinct
rates of photoreceptor degeneration, may explain why only the slower (atrdl)
degeneration shows a further change in complex I activity. The pathology of the
atrdl/atrdl mutant has not been investigated in detail, since it was only recently
generated by ENU mutagenesis (Thaung et al., 2002). The causal mutation is in
the Pde6b gene, which is the same as in the rdl mouse, suggesting that in the
atrdl homozygous mouse there may also be an increase in cGMP levels, causing
opening of cGMP-gated cation channels and an increase in the influx of cations,
2+ . . 2+ •
including Ca . There is evidence that increases in Ca~ can act as a trigger for
cell death (Olshevskaya et al., 2004). High outer segment Ca2+ has also been
implicated as a causal factor in apoptosis in other retinal degenerations (Yuan et
al., 2003, Fain 2006). It seems however that in the homozygous atrdl mutant and
not in the rdl mutant, despite the genetic mutation, additional oxidative damage is
possible. If the proposed retinal degeneration model (Figure 61) is correct, it is
not clear why decreased Sod2 expression had no effect on photoreceptor
degeneration in the Rho~' mice and it would be interesting to know whether
reducing Sod2 activity affects the rds/rds mutant. It was not however possible to
235
create an rds/rds Sod2+/~ double mutant due to close linkage of Sod2 and Prph2 on
mouse chromosome 17. If there is some residual activity of complex I, further
change is only possible if it does not lead to massive cell death. The slower
degeneration rate in Rho" compared to rdl/rdl and atrdl/atrdl, implies a milder
mutation that could be more readily modified. The lack of a Sod2 effect on
complex I activity in this mutant suggests that the additional oxidative stress is
insufficient to influence the rate of degeneration.
Decreased Sod2 expression and rates of photoreceptor degeneration.
Decreased Sod2 expression had no effect on any of the rates of degeneration.
There may be different explanations in each mutant. The rdl/rdl mutant is the
fastest degenerating mutant, in which photoreceptors begin to degenerate before
they are fully differentiated. The mutation seems to be of such a severity that it
may not be possible to increase the rate of degeneration further. There may be a
maximum for the function (na x s) that is consistent with some cell survival. The
mutational damage may mask any additional stress introduced into the cell.
Increased ROS however could result in a transition from apoptosis to necrosis, as
the latter is associated with severe and acute insults. Future work using markers
specific for necrosis would be interesting. In the atrdl/atrdl mouse, the retina
also degenerates rapidly, although this mutant is not as severe as the rdl/rdl
mutant. Despite the decrease in complex I activity in atrdl homozygotes, the
decrease in Sod2 is not sufficient to affect the degeneration rate of this mutant.
The lack of a further decrease in complex I activity in Rho'~ mice is consistent
with the failure to change the degeneration rate in this mutant.
MitoQ administration and complex I activity
MitoQ had a positive effect on the rds/rds mutant by ameliorating its complex I
activity (p=0.018; n=3). This both confirms the retinal uptake of the antioxidant
and indicates that MitoQ is more likely to have a beneficial effect in mutants with
slower rates of degeneration. The rds/rds mutant is the least severe mutant
analyzed in this project, implying that there is a possibility for improvement of
slower mutants such as rds/+. In contrast, homozygous rdl and atrdl mutants
may be too severe and rapid for MitoQ to have an effect on oxidative damage.
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The major question remains as to whether the rate of degeneration slows if
targeted antioxidants completely restore complex I activity.
The beneficial effects of oral MitoQ administration at a concentration of
500 pM have previously been shown to decrease heart dysfunction, cell death
and mitochondrial damage in ischemia-reperfusion (Adlam et al., 2005). In
particular, complex I activity was significantly ameliorated in heart samples
treated with MitoQ in comparison to non-treated samples. It would therefore be
expected that MitoQ administration at the same dose would have similarly
beneficial effects in the retinal degeneration mutants assayed. Nevertheless, the
issues of bioavailability and mitochondrial steady state concentration in the retina
remain to be answered.
MitoQ administration and photoreceptor degeneration
There was no effect ofMitoQ on rates ofphotoreceptor degeneration. In the cases
of the rdl/rdl and atrdl/atrdl mutants, one explanation is again based on the
severity of the mutations. In these mutants, in which photoreceptors start to
degenerate shortly after birth, the achieved decrease in ROS production may not
have been enough to influence the rate ofphotoreceptor cell death. This
possibility is supported by the lack of a MitoQ effect on complex I activities. In
the Rho ' and rds/rds mice, the rates of degeneration were neither slowed nor
reversed in response to MitoQ administration. The experimental set-up might
account for the failure to detect any change in rates of degeneration. Samples
were analyzed at monthly intervals until the degeneration was complete. Tighter
time-points might have allowed the detection of subtle or short-lived changes in
degeneration rates.
Modification of the redox state of the retina, by decreased Sod2 expression
or MitoQ administration, in general failed to alter levels of oxidative damage or
degeneration rates. A number of questions are raised by this finding and their
answers provide future directions for the project.
An issue that needs to be considered when analysing the numerical data collected
in this study is that of statistical significance. Wacholder et al. (2004), in referring
to molecular epidemiology studies, discussed the occurrence of false-positive
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statistical findings and the limitations of declaring statistical significance based on
a p-value alone. In addition to p-values, one has to ensure that the statistical
power of an experiment, defined as the probability that one can detect an effect if
there is really one, is sufficient and that multiple testing is also taken into
consideration (Falconer & Mackay, 1996).
With respect to power, in this study, in most experiments we had
appropriate sample sizes and sufficient power (0.80) to detect significant
differences between wild-type and mutants at a false-positive rate of 0.05.
However, what was not accounted for in this study was multiple testing, as
different tissues and mutants were examined. As a result, it is possible that some
of the significant findings are false-positives due to multiple testing. This could
explain the presence of some unexpected statistically significant findings. For
example, altered enzyme activities in retinal degeneration mutant heart, brain and
liver samples were unexpected, given that the disease phenotype is confined to the
retina. To determine whether these are true findings, future projects should
include verifying the observed results.
Experimental design - number of oxidative stress markers
ROS are able to attack DNA, proteins and lipids and there are different markers
for assessing the level of oxidative damage to each of these classes ofmolecules.
As discussed in Chapter 3, various immunohistochemical methods were attempted
but oxidative damage was eventually assessed only by two markers: the activity
of the oxidative stress-sensitive complex I and the levels ofGSH. It is possible
that genetically decreasing Sod2 to 50% of wild-type level and oral administration
ofMitoQ at a concentration of 500 pM are indeed effective in altering the redox
state of the retina. Failure to see more evidence of these effects could be attributed
to an insufficient number ofmarkers of oxidative damage in this project.
Therefore, before reaching a conclusion as to the efficiency of these experimental
approaches in modifying oxidative damage, using additional markers may be
essential.
Mitochondrial DNA is prone to oxidative damage and there are different
methods for detecting and assessing the extent of this damage. One way that was
attempted was to perform cytochemical COX/SDH assays, as discussed in
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Chapter 3. Although COX deficient photoreceptors have been detected in aged
human samples (Barron et al., 2001), COX-negative photoreceptor cells were not
detected in any mouse mutants analysed in this project. This could be attributed to
either the inefficiency of this method to detect mtDNA damage in photoreceptor
cells or the absence of COX-deficient photoreceptors in the particular samples.
An additional and more robust method for detecting oxidative mtDNA damage is
screening for mtDNA mutations. Recently, Bender et al. (2006) showed that in
substantia nigra neurons from both aged controls and patients with Parkinson's
disease there was an increased incidence of somatic mtDNA deletions, often
associated with respiratory chain deficiency. It would therefore be interesting to
investigate the levels of oxidative damage-induced mutations in mtDNA in retinal
degeneration models by sequencing. However, the increased mutation rate of
mtDNA and its multiple heteroplasmic copies in the cell, render this approach
experimentally challenging. Whether decreased Sod2 expression in models of
retinal degeneration or treatment with MitoQ would have an effect on the levels
of detected mtDNA mutations is uncertain.
Since cone degeneration has been shown to involve oxidative damage
(Shen et al., 2005), it would also be interesting to measure cone function in retinal
degeneration models and to try to modify them by experimentally altering the
redox status of the cells. Cone degeneration is a secondary feature of the RP
phenotype and takes significantly longer than rod degeneration to be completed.
Using cone-specific markers, like wheat germ agglutinin, in conjunction with
ONL analysis and/or TUNEL assays, one could follow the rate of cone
degeneration. However, measuring enzyme activities and GSH contents in cone
cells would be extremely challenging given the reduced number of these
photoreceptor cells in mouse retinas.
Finally, in war it is always beneficial to know one's enemy, in this case
the exact nature and levels of the ROS generated. The high reactivity of ROS with
their target molecules complicates experimental methods for measuring ROS
levels in a cell, which is the reason why the levels of oxidative stress are
indirectly estimated. Although the various types of free radical species give rise to
different types of cell damage, knowing the main damaging ROS in the retina and
the nature this damage, would improve attempts at preventing it. Therefore, it
would be useful to measure ROS in the retina. The markers 2'-7'-
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dichlorofluorescein diacetate (DCFDA) and dihydroethedium have been used in
vitro to assess production of hydrogen peroxide and superoxide anion respectively
(Qi et al., 2005). Also, attempts to measure HNE and MDA adducts in lipids and
indicators of nitrosature stress were unsuccessful but warrant further
investigation. Application of such markers to retinal samples from both wild-type
and retinal degeneration mutants would shed further light on the level and type of
oxidative stress we have attempted to modify.
Experimental design - choice of retinal degeneration mutants
Another reason for not finding a general effect of redox state modification on
levels of oxidative damage and rates of degeneration could be the choice of
mutants analyzed.
It is possible that the decreased expression of Sod2 and the oral
administration ofMitoQ, at the levels applied in this project, would have an effect
on mutants with slower rates of degeneration. None of the treatments had any
effect on the fast degenerating rdl mutant, implying that the mutation in this
mouse line is so severe that detrimental or beneficial changes in redox state are
masked so that this is an inappropriate model to test the proposed hypothesis. The
observation that MitoQ administration ameliorated the activity of complex I in the
rds/rds mutant might be an indication that this antioxidant would be beneficial to
slower degenerating mutants. The Prph2+/rds (Kedzierski et al., 2001) and retinitis
pigmentosa GTPase regulator (Rpgr) knockout (Hong et al., 2004) mutants, in
which photoreceptor degeneration takes a year to be completed, are examples of
retinal degeneration mutants in which reduced Sod2 levels and/or Mito Q
treatment may have an effect. The results from these experiments will shed more
light on the efficiency of the experimental approaches in altering levels of
oxidative damage and rates of degeneration.
The hypothesis tested supports the proposal that, irrespective of a direct
causal role for oxidative stress in photoreceptor cell death, constitutive ROS
production influences the probability of cell death. The complex I data suggests
that oxidative stress directly influences the disease phenotype in all four models,
which makes it difficult to dissociate this direct effect from an indirect one on
rates of apoptotic cell death. Attempts to modify constitutive mitochondrial ROS
production in a cell might be masked by an increase in ROS production caused by
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the disease itself. If a substantial increase in oxidative stress is part of the disease
pathology, it could overwhelm attempts to increase or decrease ROS production
by genetic or pharmacological means. This could explain why none of the four
mutants responded to the experimental treatments. In order to influence rates of
degeneration, it may be necessary to modify the redox state in mutants causing
little or no signs of direct oxidative damage.
Experimental design - dosage effects
The lack of a universal effect of either increased or decreased oxidative stress on
rates ofphotoreceptor degeneration or detectable oxidative damage may be
explicable in quantitative terms. The level of Sod2 in the mutants might not have
been sufficiently low to increase steady state ROS production. The expression of
Sod2 however could not be genetically decreased by more than 50% as complete
loss of Sod2 activity confers a lethal phenotype (Li et al., 1995). It would
therefore be interesting to repeat the experiments using mice where the Sod2 null
genotype is confined to the retina. Generation of a conditional retina-specific
Sod2 knockout mouse would ensure a long enough lifespan to allow a more
significant increase in constitutive ROS production.
Similarly, the lack of an effect ofMitoQ on rates of degeneration might be
attributed to its administered dosage. Previous in vitro and in vivo work has
demonstrated the antioxidant capacity ofMitoQ. Smith et al. (2002) compared
various methods of drug administration at different doses and showed that oral
administration ofMitoQ at a 1 mM concentration had no toxic effects on the
animals for at least 26 days. This was not the case however for concentrations
above 2 mM. In this project, where MitoQ was orally administered for a period of
several months, the maximum concentration assessed was 500 p.M. A preliminary
study confirmed that oral administration ofMitoQ at a concentration of 500 pM
was efficiently taken up by different tissues. This confirmed the suitability of the
method of administration and showed that intra-venous or intra-peritoneal
injection was unnecessary. The preliminary study also demonstrated that the
administered 500 pM concentration ofMitoQ for a period of at least 3 months
was not toxic to the animals. This suggests that higher concentrations of the
antioxidant could be orally administered, in the expectation of exerting a more
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efficient effect on rates of degeneration. Further analysis of 3H-MitoQ would
clarify the metabolic fate of this drug.
The complexity of both ROS production and the cellular antioxidant
machinery highlights the multifactorial nature of oxidative stress. Although there
are differences in the reactivity of different free radicals, oxidative damage cannot
be attributed to a single reactive molecule. Hydroxyl radicals are the most reactive
ROS whose generation follows that of superoxide anions and hydrogen peroxide.
Similarly, the importance of cellular antioxidant mechanisms and enzymes varies,
and the antioxidant status of a cell depends on the concerted action of different
antioxidants. It is conceivable therefore that to efficiently affect the redox state of
a cell, one might need to modify the level ofmore than one antioxidant system.
Although published data suggests that either a 50% Sod2 decrease or treatment
with MitoQ are effective on their own in vivo, it is possible that they should be
coupled with modifications in other participants of the antioxidant machinery.
Decreased Sod2 expression in the heterozygous null mouse could be accompanied
by a decrease in the levels of catalase and/or glutathione peroxidase, both of
which detoxify the Sod2-generated superoxide anions. Alternatively, the joint
over-expression of Sod2 and catalase, as carried out by Schriner et al. (1999) to
extend lifespan in mice, with or without MitoQ supplementation, might be
required to reduce constitutive ROS production sufficiently to slow rates of
degeneration. In this way, a more effective increase or decrease in ROS
production would be evident. Similarly, the protective effect ofMitoQ in terms of
protein oxidation might be more efficient if it were coupled with increased levels
of an antioxidant that was working at the level ofmitochondrial DNA or lipid
peroxidation damage. For example, MitoVitamin E has been shown to scavenge
endogenous oxidants (Siler-Marsiglio et al., 2005) and to prevent cell death in
FRDA cells treated with the glutathione-synthesis inhibitor BSO (Jauslin et al.,
2003) and so might provide a complementary strategy.
To conclude, in the rdl/rdl, atrdl/atrdl, Rho~ and rds/rdsmouse models of RP,
photoreceptor degeneration occurs at different rates. Although a direct causative
role of oxidative stress in RP was excluded, evidence for oxidative damage,
reflected in decreased CI activity, was present in all of the mutants. The rates of
photoreceptor degeneration however were not affected by changed antioxidant
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levels, but CI activity was further reduced in atrdl/atrdl Sod2+l~ double mutants
with decreased Sod2 expression, and ameliorated in the rds/rds mutant upon
MitoQ administration. The results obtained in this project do not fully support the
predictions based on the proposed hypothesis. Future work on slower
degenerating mutants will be required to further elucidate the role of oxidative
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